{"matching_results": 30460, "aggregations": [{"type": "term", "field": "host", "results": [{"key": "americanbankingnews.com", "matching_results": 881, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 637}, {"key": "negative", "matching_results": 232}, {"key": "neutral", "matching_results": 12}]}]}, {"key": "freelancer.com.co", "matching_results": 667, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 623}, {"key": "negative", "matching_results": 42}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "thelincolnianonline.com", "matching_results": 637, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 451}, {"key": "negative", "matching_results": 186}]}]}, {"key": "tickerreport.com", "matching_results": 625, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 530}, {"key": "negative", "matching_results": 94}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "zolmax.com", "matching_results": 620, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 460}, {"key": "negative", "matching_results": 160}]}]}, {"key": "watchlistnews.com", "matching_results": 612, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 435}, {"key": "negative", "matching_results": 177}]}]}, {"key": "wkrb13.com", "matching_results": 598, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 439}, {"key": "negative", "matching_results": 159}]}]}, {"key": "dailypolitical.com", "matching_results": 558, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 434}, {"key": "negative", "matching_results": 123}, {"key": "neutral", "matching_results": 1}]}]}, {"key": "marketscreener.com", "matching_results": 551, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 424}, {"key": "negative", "matching_results": 125}, {"key": "neutral", "matching_results": 2}]}]}, {"key": "prnewswire.com", "matching_results": 479, "aggregations": [{"type": "term", "field": "enriched_text.sentiment.document.label", "results": [{"key": "positive", "matching_results": 433}, {"key": "negative", "matching_results": 46}]}]}]}], "results": [{"id": "_uF793rEd5lanYxx7ydjj7AtK8ap4Tj_Ri349yQroUfcqIGU-GdjgW4I4IlEH29v", "result_metadata": {"score": 37.05241}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nodularis Treatment Market", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Prurigo", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.8%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Prurigo nodularis", "relevance": 0.932431, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}], "categories": [{"score": 0.935158, "label": "/health and fitness/therapy"}, {"score": 0.700743, "label": "/health and fitness/disorders"}, {"score": 0.693262, "label": "/real estate/buying and selling homes"}], "relations": [], "keywords": [{"text": "Prurigo Nodularis Treatment Market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.992417, "count": 1}, {"text": "steady CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.007583, "count": 1}]}, "crawl_date": "2018-11-27T15:15:01Z", "url": "https://www.wesrch.com/medical/paper-details/press-paper-ME1LYY000HTQR-prurigo-nodularis-treatment-market-to-expand-at-a-steady-cagr-of-4-8-by-2028", "host": "wesrch.com", "text": "., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co.", "main_image_url": "https://www.wesrch.com/assets/images/logo.png", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T14:39:00Z", "enriched_text": {"entities": [{"count": 10, "sentiment": {"score": 0.0633362, "label": "positive"}, "text": "Prurigo", "relevance": 0.853897, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Nodularis Treatment Market", "relevance": 0.604318, "type": "Company"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.162096, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Swapna Supekar", "relevance": 0.125143, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Segmental Insights", "relevance": 0.122996, "type": "PrintMedia"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "\u2018Prurigo", "relevance": 0.120755, "type": "HealthCondition"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Europe", "relevance": 0.10987, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.1093, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "China", "relevance": 0.107178, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Africa", "relevance": 0.106786, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "Africa", "dbpedia_resource": "http://dbpedia.org/resource/Africa"}}, {"count": 1, "sentiment": {"score": 0.702921, "label": "positive"}, "text": "Asia Pacific", "relevance": 0.105857, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.358157, "label": "negative"}, "text": "Takeda Pharmaceutical Company Limited", "relevance": 0.10582, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.105335, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bayer AG", "relevance": 0.104395, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.104245, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "U.S.A", "relevance": 0.0945649, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline", "relevance": 0.0918001, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.0917706, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceutical Industries Ltd", "relevance": 0.0912935, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.0911684, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.0902926, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson Services Inc.", "relevance": 0.0887305, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Canada", "relevance": 0.0870401, "type": "Location", "disambiguation": {"subtype": ["GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}, {"count": 1, "sentiment": {"score": -0.449951, "label": "negative"}, "text": "Sanofi SA", "relevance": 0.0856803, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "4.8%", "relevance": 0.0856803, "type": "Quantity"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.0856803, "type": "TwitterHandle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "3.4%", "relevance": 0.0856803, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "40%", "relevance": 0.0856803, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "45%", "relevance": 0.0856803, "type": "Quantity"}], "sentiment": {"document": {"score": 0.60889, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "You"}, "sentence": "You have Already saved this Press Release to your Library.", "action": {"verb": {"text": "have", "tense": "present"}, "text": "have", "normalized": "have"}}, {"subject": {"text": "You"}, "sentence": "You have Already saved this Press Release to your Library.", "object": {"text": "this Press Release", "keywords": [{"text": "Press Release"}], "entities": []}, "action": {"verb": {"text": "save", "tense": "past"}, "text": "saved", "normalized": "save"}}, {"subject": {"text": "by Future Market Insights titled \u2018Prurigo Nodularis Treatment Market", "keywords": [{"text": "\u2018Prurigo Nodularis Treatment"}, {"text": "Future Market Insights"}], "entities": [{"type": "HealthCondition", "text": "\u2018Prurigo"}]}, "sentence": " According to the latest report published by Future Market Insights titled \u2018Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028\u2019 , the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "the latest report", "keywords": [{"text": "latest report"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "Future Market Insights", "keywords": [{"text": "Future Market Insights"}]}, "sentence": " According to the latest report published by Future Market Insights titled \u2018Prurigo Nodularis Treatment Market: Global Industry Analysis 2013 \u2013 2017 and Opportunity Assessment 2018 \u2013 2028\u2019 , the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018\u20132028.", "object": {"text": "\u2018Prurigo Nodularis Treatment Market", "keywords": [{"text": "\u2018Prurigo Nodularis Treatment"}], "entities": [{"type": "HealthCondition", "text": "\u2018Prurigo"}]}, "action": {"verb": {"text": "title", "tense": "past"}, "text": "titled", "normalized": "title"}}, {"subject": {"text": "The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018\u20132028.", "object": {"text": "a valuation of US$ 697.9 Mn", "keywords": [{"text": "valuation"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is expected to reach", "normalized": "be expect to reach"}}, {"subject": {"text": "Factors", "keywords": [{"text": "Factors"}]}, "sentence": " Global Prurigo Nodularis Treatment Market: Factors Influencing Growth", "object": {"text": "Growth", "keywords": [{"text": "Growth"}]}, "action": {"verb": {"text": "Influencing", "tense": "present"}, "text": "Influencing", "normalized": "Influencing"}}, {"subject": {"text": "awareness programmes", "keywords": [{"text": "awareness programmes"}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "action": {"verb": {"text": "increase", "tense": "present"}, "text": "increasing", "normalized": "increase"}}, {"subject": {"text": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China", "keywords": [{"text": "highly populated regions"}, {"text": "rapidly developing healthcare"}, {"text": "awareness programmes"}, {"text": "Asia Pacific"}], "entities": [{"type": "Company", "text": "Asia Pacific"}, {"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}]}, "sentence": " The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "object": {"text": "an important role", "keywords": [{"text": "important role"}]}, "action": {"verb": {"text": "play", "tense": "future"}, "text": "is expected to play", "normalized": "be expect to play"}}, {"subject": {"text": "https://www.futuremarketinsights.com/reports/sample/rep-gb-3339"}, "sentence": " To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3339", "object": {"text": "key findings Request Sample Report", "keywords": [{"text": "key findings Request"}, {"text": "Sample Report"}]}, "action": {"verb": {"text": "know", "tense": "future"}, "text": "To know", "normalized": "To know"}}, {"subject": {"text": "The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": []}, "sentence": " The global prurigo nodularis treatment market has been segmented on the basis of product type, distribution channel and region.", "object": {"text": "on the basis of product type, distribution channel and region", "keywords": [{"text": "product type"}, {"text": "distribution channel"}, {"text": "basis"}, {"text": "region"}]}, "action": {"verb": {"text": "segment", "tense": "past"}, "text": "has been segmented", "normalized": "have be segment"}}, {"subject": {"text": "Prurigo", "keywords": [{"text": "Prurigo"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "treatment product types"}, {"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}]}, "action": {"verb": {"text": "nodularis", "tense": "present"}, "text": "nodularis", "normalized": "nodularis"}}, {"subject": {"text": "corticosteroids, emollients, capsacin cream, antihistamines and others", "keywords": [{"text": "capsacin cream"}, {"text": "corticosteroids"}, {"text": "antihistamines"}, {"text": "emollients"}]}, "sentence": " Prurigo nodularis treatment product types include corticosteroids, emollients, capsacin cream, antihistamines and others.", "object": {"text": "Prurigo nodularis treatment product types", "keywords": [{"text": "Prurigo"}, {"text": "treatment product types"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "capsacin cream under the product type segment", "keywords": [{"text": "product type segment"}, {"text": "capsacin cream"}]}, "sentence": " Globally, capsacin cream under the product type segment stands the most attractive product form amongst the different product types.", "object": {"text": "the most attractive product form amongst the different product types", "keywords": [{"text": "attractive product form"}, {"text": "different product types"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "action": {"verb": {"text": "anticipate", "tense": "past"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "retail pharmacies", "keywords": [{"text": "retail pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are anticipated to be", "normalized": "be anticipate to be"}}, {"subject": {"text": "by hospital pharmacies", "keywords": [{"text": "hospital pharmacies"}]}, "sentence": " Among all distribution channels of prurigo nodularis treatment, retail pharmacies are anticipated to be the most lucrative distribution channel followed by hospital pharmacies.", "object": {"text": "the most lucrative distribution channel", "keywords": [{"text": "lucrative distribution channel"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Western Europe", "keywords": [{"text": "Western Europe"}], "entities": [{"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "the global prurigo nodularis treatment Market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment Market"}], "entities": []}, "action": {"verb": {"text": "dominate", "tense": "past"}, "text": "dominated", "normalized": "dominate"}}, {"subject": {"text": "by governments", "keywords": [{"text": "governments"}]}, "sentence": " With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "object": {"text": "key research and development initiatives", "keywords": [{"text": "development initiatives"}, {"text": "key research"}]}, "action": {"verb": {"text": "take", "tense": "past"}, "text": "taken", "normalized": "take"}}, {"subject": {"text": "advanced medical facilities", "keywords": [{"text": "advanced medical facilities"}]}, "sentence": " Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "object": {"text": "the region cope with the current healthcare crisis", "keywords": [{"text": "current healthcare crisis"}, {"text": "region cope"}]}, "action": {"verb": {"text": "help", "tense": "present"}, "text": "are helping", "normalized": "be help"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "the second largest regional market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "largest regional market"}, {"text": "treatment"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Country"]}}, {"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the markets in U.S.A and Canada", "keywords": [{"text": "U.S.A"}, {"text": "markets"}, {"text": "Canada"}], "entities": [{"type": "Location", "text": "U.S.A", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Location", "text": "Canada", "disambiguation": {"subtype": ["Country", "GovernmentalJurisdiction", "Kingdom", "AwardDiscipline", "FilmScreeningVenue", "Country"], "name": "Canada", "dbpedia_resource": "http://dbpedia.org/resource/Canada"}}]}, "sentence": " North America is the second largest regional market for prurigo nodularis treatment and is expected to be valued at US$ 75.6 Mn by 2028, with the markets in U.S.A and Canada growing at a faster rate.", "object": {"text": "at a faster rate", "keywords": [{"text": "faster rate"}]}, "action": {"verb": {"text": "grow", "tense": "present"}, "text": "growing", "normalized": "grow"}}, {"subject": {"text": "Eastern Europe", "keywords": [{"text": "Eastern Europe"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}]}, "sentence": " Eastern Europe is projected to be the third largest market for prurigo nodularis treatment.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": []}, "sentence": " The global prurigo nodularis treatment market is expected to create incremental opportunity of US$ 197.9 Mn between 2018 and 2028", "object": {"text": "incremental opportunity of US$ 197.9 Mn between 2018 and 2028", "keywords": [{"text": "incremental opportunity"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "create", "tense": "future"}, "text": "is expected to create", "normalized": "be expect to create"}}, {"subject": {"text": "The prurigo", "keywords": [{"text": "prurigo"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "treatment market", "keywords": [{"text": "treatment market"}]}, "action": {"verb": {"text": "nodularis", "tense": "present"}, "text": "nodularis", "normalized": "nodularis"}}, {"subject": {"text": "The prurigo nodularis treatment market", "keywords": [{"text": "prurigo"}, {"text": "treatment market"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The prurigo nodularis treatment market is expected to witness fast and steady growth, partly due to the rising government support across various regions and increasing demand for prurigo nodularis treatment across the world.", "object": {"text": "steady growth", "keywords": [{"text": "steady growth"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "is expected to witness", "normalized": "be expect to witness"}}, {"subject": {"text": "The global market for prurigo nodularis treatment", "keywords": [{"text": "prurigo nodularis"}, {"text": "global market"}, {"text": "treatment"}], "entities": [{"type": "HealthCondition", "text": "Prurigo", "disambiguation": {"subtype": ["Disease"], "name": "Prurigo", "dbpedia_resource": "http://dbpedia.org/resource/Prurigo"}}]}, "sentence": " The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "object": {"text": "highly competitive"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "many players", "keywords": [{"text": "players"}]}, "sentence": " The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Some of the companies", "keywords": [{"text": "companies"}]}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "Some of the companies identified in global prurigo nodularis treatment market", "keywords": [{"text": "global prurigo nodularis"}, {"text": "treatment market"}], "entities": []}, "sentence": " Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "object": {"text": "Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others", "keywords": [{"text": "Teva Pharmaceutical Industries"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "GlaxoSmithKline plc"}, {"text": "Sanofi SA"}], "entities": [{"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "GlaxoSmithKline", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Teva Pharmaceutical Industries Ltd"}, {"type": "Company", "text": "Johnson & Johnson Services Inc."}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Sanofi SA"}, {"type": "Company", "text": "Takeda Pharmaceutical Company Limited", "disambiguation": {"subtype": ["Company"], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "companies", "keywords": [{"text": "companies"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "object": {"text": "close collaborations", "keywords": [{"text": "close collaborations"}]}, "action": {"verb": {"text": "build", "tense": "future"}, "text": "building", "normalized": "build"}}, {"subject": {"text": "these partnerships", "keywords": [{"text": "partnerships"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "object": {"text": "firms to grow and expand in the global market", "keywords": [{"text": "global market"}, {"text": "firms"}], "entities": []}, "action": {"verb": {"text": "allow", "tense": "present"}, "text": "allow", "normalized": "allow"}}, {"subject": {"text": "firms", "keywords": [{"text": "firms"}]}, "sentence": " In order to increase market coverage, companies are focussing on building close collaborations with local distributers as these partnerships allow firms to grow and expand in the global market.", "action": {"verb": {"text": "expand", "tense": "present"}, "text": "expand", "normalized": "expand"}}], "concepts": [{"text": "Marketing", "relevance": 0.983556, "dbpedia_resource": "http://dbpedia.org/resource/Marketing"}, {"text": "Teva Pharmaceutical Industries", "relevance": 0.888358, "dbpedia_resource": "http://dbpedia.org/resource/Teva_Pharmaceutical_Industries"}, {"text": "Prurigo nodularis", "relevance": 0.718918, "dbpedia_resource": "http://dbpedia.org/resource/Prurigo_nodularis"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.662492, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Distribution", "relevance": 0.651395, "dbpedia_resource": "http://dbpedia.org/resource/Distribution_(business)"}, {"text": "Pharmacy", "relevance": 0.62003, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical industry", "relevance": 0.589242, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Region", "relevance": 0.556793, "dbpedia_resource": "http://dbpedia.org/resource/Region"}, {"text": "Pfizer", "relevance": 0.53078, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "GlaxoSmithKline", "relevance": 0.526715, "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}, {"text": "Economics", "relevance": 0.491559, "dbpedia_resource": "http://dbpedia.org/resource/Economics"}], "categories": [{"score": 0.778574, "label": "/finance/financial news"}, {"score": 0.758716, "label": "/finance/investing"}, {"score": 0.758716, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "partOf", "sentence": "Prurigo Nodularis Treatment Market to expand at a steady CAGR of 4.8% by 2028 Swapna Supekar 27th-Nov-2018 26 According to the latest report published by Future Market Insights titled \u02bbPrurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028' , the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.387339, "arguments": [{"text": "published", "location": [200, 209], "entities": [{"type": "EventCommunication", "text": "published"}]}, {"text": "report", "location": [193, 199], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.647654, "arguments": [{"text": "regions", "location": [1053, 1060], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "China", "location": [1081, 1086], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.614891, "arguments": [{"text": "Asia", "location": [1064, 1068], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "Pacific", "location": [1069, 1076], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.875969, "arguments": [{"text": "Western", "location": [2032, 2039], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [2040, 2046], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Global Prurigo Nodularis Treatment Market: Regional Highlights With nearly 40% - 45% market share, Western Europe dominated the global prurigo nodularis treatment Market in 2017, partly due to the presence of leading market players and key research and development initiatives taken by governments in the region.", "score": 0.457949, "arguments": [{"text": "governments", "location": [2219, 2230], "entities": [{"type": "GeopoliticalEntity", "text": "Regional Highlights\nWith nearly"}]}, {"text": "region", "location": [2238, 2244], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.82137, "arguments": [{"text": "regions", "location": [2270, 2277], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Latin America", "location": [2286, 2299], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "Moreover, in developing regions such as Latin America, advanced medical facilities are helping the region cope with the current healthcare crisis.", "score": 0.667622, "arguments": [{"text": "facilities", "location": [2318, 2328], "entities": [{"type": "Facility", "text": "facilities"}]}, {"text": "region", "location": [2345, 2351], "entities": [{"type": "GeopoliticalEntity", "text": "regions"}]}]}, {"type": "agentOf", "sentence": "Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3339 Global Prurigo Nodularis Treatment Market: Vendor Insights The global market for prurigo nodularis treatment is highly competitive with many players operating in the global market.", "score": 0.494528, "arguments": [{"text": "Global Prurigo Nodularis Treatment Market", "location": [3171, 3212], "entities": [{"type": "Organization", "text": "Global Prurigo Nodularis Treatment Market", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Report", "location": [3074, 3080], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.473218, "arguments": [{"text": "Bayer AG", "location": [3434, 3442], "entities": [{"type": "Organization", "text": "Bayer AG", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3364, 3373], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.671821, "arguments": [{"text": "Pfizer Inc.", "location": [3444, 3455], "entities": [{"type": "Organization", "text": "Pfizer Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3364, 3373], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.607119, "arguments": [{"text": "GlaxoSmithKline plc", "location": [3457, 3476], "entities": [{"type": "Organization", "text": "GlaxoSmithKline plc", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3364, 3373], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Prurigo Nodularis Treatment Market to expand at a steady CAGR of 4.8% by 2028 Swapna Supekar 27th-Nov-2018 26 According to the latest report published by Future Market Insights titled \u02bbPrurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028' , the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.61155, "arguments": [{"text": "Future Market Insights", "location": [213, 235], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "report", "location": [193, 199], "entities": [{"type": "EventCommunication", "text": "report"}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.598112, "arguments": [{"text": "Johnson & Johnson Services Inc.", "location": [3514, 3545], "entities": [{"type": "Organization", "text": "Johnson & Johnson Services Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3364, 3373], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.507685, "arguments": [{"text": "Merck & Co. Inc.", "location": [3547, 3563], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3364, 3373], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "Some of the companies identified in global prurigo nodularis treatment market are Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and others.", "score": 0.577551, "arguments": [{"text": "Sanofi SA", "location": [3565, 3574], "entities": [{"type": "Organization", "text": "Sanofi SA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3364, 3373], "entities": [{"type": "Organization", "text": "companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Prurigo Nodularis Treatment Market to expand at a steady CAGR of 4.8% by 2028 Swapna Supekar 27th-Nov-2018 26 According to the latest report published by Future Market Insights titled \u02bbPrurigo Nodularis Treatment Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028' , the global prurigo nodularis treatment market is poised to expand at 3.4% CAGR over the forecast period of 2018-2028.", "score": 0.899785, "arguments": [{"text": "Future Market Insights", "location": [213, 235], "entities": [{"type": "Organization", "text": "Future Market Insights"}]}, {"text": "published", "location": [200, 209], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "populationOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.577512, "arguments": [{"text": "697.9", "location": [567, 572], "entities": [{"type": "Cardinal", "text": "697.9"}]}, {"text": "US$", "location": [563, 566], "entities": [{"type": "GeopoliticalEntity", "text": "US$"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.516048, "arguments": [{"text": "Mn", "location": [573, 575], "entities": [{"type": "Person", "text": "Mn"}]}, {"text": "attesting", "location": [589, 598], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "agentOf", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.42228, "arguments": [{"text": "& Africa", "location": [638, 646], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "attesting", "location": [589, 598], "entities": [{"type": "EventCommunication", "text": "attesting"}]}]}, {"type": "basedIn", "sentence": "The global market for prurigo nodularis treatment is expected to reach a valuation of US$ 697.9 Mn by 2028 end, attesting the highest growth rate by Middle East & Africa, which is expected to expand at 4.8% CAGR over 2018-2028.", "score": 0.611012, "arguments": [{"text": "& Africa", "location": [638, 646], "entities": [{"type": "Organization", "text": "& Africa"}]}, {"text": "Middle East", "location": [626, 637], "entities": [{"type": "GeopoliticalEntity", "text": "Middle East", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.891549, "arguments": [{"text": "regions", "location": [1053, 1060], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Asia", "location": [1064, 1068], "entities": [{"type": "GeopoliticalEntity", "text": "Asia", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "locatedAt", "sentence": "The rapidly developing healthcare infrastructure and increasing awareness programmes in the highly populated regions of Asia Pacific and China is expected to play an important role in driving revenue growth of the global prurigo nodularis treatment market.", "score": 0.848801, "arguments": [{"text": "regions", "location": [1053, 1060], "entities": [{"type": "Location", "text": "regions"}]}, {"text": "Pacific", "location": [1069, 1076], "entities": [{"type": "GeographicFeature", "text": "Pacific"}]}]}], "keywords": [{"text": "Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.863415, "label": "positive"}, "relevance": 0.930999, "count": 2}, {"text": "Global Industry Analysis", "sentiment": {"score": 0.863415, "label": "positive"}, "relevance": 0.700259, "count": 1}, {"text": "global prurigo nodularis treatment market", "sentiment": {"score": 0.340999, "mixed": "1", "label": "positive"}, "relevance": 0.688221, "count": 4}, {"text": "Future Market Insights", "sentiment": {"score": 0.863415, "label": "positive"}, "relevance": 0.654572, "count": 1}, {"text": "various regions", "sentiment": {"score": 0.772514, "label": "positive"}, "relevance": 0.648716, "count": 2}, {"text": "global market", "sentiment": {"score": 0.768755, "label": "positive"}, "relevance": 0.617947, "count": 4}, {"text": "Global Prurigo Nodularis Treatment Market", "sentiment": {"score": 0.515314, "mixed": "1", "label": "positive"}, "relevance": 0.593256, "count": 4}, {"text": "prurigo nodularis treatment", "sentiment": {"score": 0.729189, "label": "positive"}, "relevance": 0.587019, "count": 6}, {"text": "Western Europe", "sentiment": {"score": 0.649314, "label": "positive"}, "relevance": 0.576418, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568705, "count": 1}, {"text": "market", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.559629, "count": 1}, {"text": "basis of product type", "sentiment": {"score": -0.965726, "label": "negative"}, "relevance": 0.557575, "count": 1}, {"text": "market share", "sentiment": {"score": 0.649314, "label": "positive"}, "relevance": 0.557467, "count": 1}, {"text": "Eastern Europe", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.556641, "count": 1}, {"text": "region", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.547868, "count": 2}, {"text": "North America", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.547746, "count": 1}, {"text": "important role", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.547345, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54277, "count": 2}, {"text": "Pfizer Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539993, "count": 1}, {"text": "Growth", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.535363, "count": 1}, {"text": "regions of Asia Pacific", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.533464, "count": 1}, {"text": "faster rate", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532252, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.531965, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.531532, "count": 1}, {"text": "regions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528777, "count": 1}, {"text": "steady growth", "sentiment": {"score": 0.62988, "label": "positive"}, "relevance": 0.526505, "count": 1}, {"text": "players", "sentiment": {"score": 0.836049, "label": "positive"}, "relevance": 0.526269, "count": 1}, {"text": "markets", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.526188, "count": 1}, {"text": "US", "sentiment": {"score": 0.522431, "label": "positive"}, "relevance": 0.525843, "count": 1}, {"text": "highest growth rate", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.525791, "count": 1}, {"text": "Prurigo nodularis treatment product types", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524856, "count": 1}, {"text": "initiatives", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.52302, "count": 1}, {"text": "order", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520933, "count": 1}, {"text": "key findings Request Sample Report", "sentiment": {"score": -0.965726, "label": "negative"}, "relevance": 0.520065, "count": 1}, {"text": "Teva Pharmaceutical Industries Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520009, "count": 1}, {"text": "governments", "sentiment": {"score": 0.649314, "label": "positive"}, "relevance": 0.519959, "count": 1}, {"text": "Press Release", "sentiment": {"score": 0.415497, "label": "positive"}, "relevance": 0.518375, "count": 1}, {"text": "presence", "sentiment": {"score": 0.649314, "label": "positive"}, "relevance": 0.517619, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517458, "count": 1}, {"text": "near future", "sentiment": {"score": 0.825717, "label": "positive"}, "relevance": 0.517135, "count": 1}, {"text": "China", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.517135, "count": 1}, {"text": "Favourable regulations", "sentiment": {"score": 0.879527, "label": "positive"}, "relevance": 0.514009, "count": 1}, {"text": "Request", "sentiment": {"score": 0.836049, "label": "positive"}, "relevance": 0.513776, "count": 1}, {"text": "corticosteroids", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513651, "count": 1}, {"text": "firms", "sentiment": {"score": 0.590495, "label": "positive"}, "relevance": 0.513201, "count": 1}, {"text": "partnerships", "sentiment": {"score": 0.590495, "label": "positive"}, "relevance": 0.512703, "count": 1}, {"text": "end", "sentiment": {"score": 0.69688, "label": "positive"}, "relevance": 0.512593, "count": 1}, {"text": "demand", "sentiment": {"score": 0.62988, "label": "positive"}, "relevance": 0.512227, "count": 1}, {"text": "healthcare infrastructure", "sentiment": {"score": 0.771773, "label": "positive"}, "relevance": 0.511544, "count": 1}, {"text": "Johnson Services Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510686, "count": 1}]}, "extracted_metadata": {"sha1": "79dd0e77b8f68edd6e313b8a50e37fa30a56742b", "filename": "1543331701529.zip-b8bc9862abf72e297e0294ae6641f297.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/prurigo-nodularis-treatment-and-management-market", "https://www.futuremarketinsights.com/customization-available/rep-gb-3339", "https://www.futuremarketinsights.com/reports/sample/rep-gb-3339"], "title": "Prurigo Nodularis Treatment Market to expand at a steady CAGR of 4.8% by 2028", "forum_title": "WeSRCH.com: Latest Press Release"}, {"id": "-ZAMzDgoJmayf2UhGABBZGKzh7gSUBQ4xJ5AVfmzJ6TGd6f5WNPSFdPxyGp0rz3A", "result_metadata": {"score": 36.74121}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments LP", "relevance": 0.33, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.896398, "label": "/finance/investing"}, {"score": 0.896398, "label": "/finance/investing/beginning investing"}, {"score": 0.88517, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "HBK Investments LP", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997108, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.660062, "count": 1}, {"text": "Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.248164, "count": 1}]}, "crawl_date": "2018-11-28T14:36:57Z", "url": "https://www.finanznachrichten.de/nachrichten-2018-11/45390024-hbk-investments-lp-form-8-3-takeda-pharmaceutical-co-ltd-008.htm", "host": "finanznachrichten.de", "text": "N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening", "main_image_url": "https://fns1.de/g/fb.png", "country": "DE", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-28T14:25:00Z", "enriched_text": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "HBK Investments", "relevance": 0.988692, "type": "Company", "disambiguation": {"subtype": [], "name": "HBK Investments", "dbpedia_resource": "http://dbpedia.org/resource/HBK_Investments"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.910266, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc", "relevance": 0.83781, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.749921, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.679365, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.679365, "type": "Quantity"}], "sentiment": {"document": {"score": -0.418973, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state \"N/A\" YES : Shire Plc 2.", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the offeror or offeree", "keywords": [{"text": "offeror"}, {"text": "offeree"}]}, "sentence": " POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security:", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}], "concepts": [{"text": "Offer and acceptance", "relevance": 0.945303, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Uniform Commercial Code", "relevance": 0.805651, "dbpedia_resource": "http://dbpedia.org/resource/Uniform_Commercial_Code"}, {"text": "Hedge fund", "relevance": 0.778056, "dbpedia_resource": "http://dbpedia.org/resource/Hedge_fund"}, {"text": "Investment", "relevance": 0.727384, "dbpedia_resource": "http://dbpedia.org/resource/Investment"}, {"text": "Collective investment scheme", "relevance": 0.687831, "dbpedia_resource": "http://dbpedia.org/resource/Collective_investment_scheme"}, {"text": "Security", "relevance": 0.670192, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Mutual fund", "relevance": 0.64546, "dbpedia_resource": "http://dbpedia.org/resource/Mutual_fund"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.643202, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Name", "relevance": 0.641726, "dbpedia_resource": "http://dbpedia.org/resource/Name"}], "categories": [{"score": 0.810546, "label": "/finance/investing/funds"}, {"score": 0.803437, "label": "/real estate/buying and selling homes"}, {"score": 0.79765, "label": "/finance/investing/beginning investing"}], "relations": [{"type": "employedBy", "sentence": "KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient.", "score": 0.40878, "arguments": [{"text": "Owner", "location": [302, 307], "entities": [{"type": "Person", "text": "controller"}]}, {"text": "its", "location": [280, 283], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}], "keywords": [{"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.836882, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.710942, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.661949, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.650582, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.638611, "count": 1}, {"text": "offeree Takeda Pharmaceutical Co Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.630726, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.74856, "label": "negative"}, "relevance": 0.610741, "count": 2}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.604915, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.591141, "count": 1}, {"text": "KEY INFORMATION", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.587397, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.584722, "count": 1}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.569999, "count": 1}, {"text": "HBK Investments L.P.", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.558284, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.547794, "count": 1}, {"text": "latest practicable date", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.538369, "count": 1}, {"text": "offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.536107, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530624, "count": 1}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528867, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.526285, "count": 2}, {"text": "funds", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.524728, "count": 1}, {"text": "form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524176, "count": 1}, {"text": "identity of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.520619, "count": 1}, {"text": "PERSON", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.520018, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.518707, "count": 1}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516895, "count": 1}, {"text": "disclosure", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.516571, "count": 3}, {"text": "controller of interests", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.515788, "count": 1}, {"text": "behalf", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.51522, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.514845, "count": 1}, {"text": "disclosures", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513259, "count": 1}, {"text": "addition", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512792, "count": 1}, {"text": "November", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51275, "count": 1}, {"text": "separate form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51168, "count": 1}, {"text": "positions", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.511087, "count": 1}, {"text": "relation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510316, "count": 1}, {"text": "respect", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509669, "count": 1}, {"text": "trustee", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509135, "count": 1}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.508722, "count": 1}, {"text": "company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507066, "count": 1}, {"text": "party", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.506578, "count": 1}, {"text": "beneficiaries", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.504995, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.504835, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.504747, "count": 1}, {"text": "Code", "sentiment": {"score": -0.466321, "label": "negative"}, "relevance": 0.50177, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.501304, "count": 1}, {"text": "vehicle companies", "sentiment": {"score": -0.879358, "label": "negative"}, "relevance": 0.497103, "count": 1}, {"text": "relevant securities of the offeror", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.491446, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.484997, "count": 1}, {"text": "offeree", "sentiment": {"score": 0.450809, "mixed": "1", "label": "positive"}, "relevance": 0.482571, "count": 5}, {"text": "Class of relevant security", "sentiment": {"score": -0.588915, "label": "negative"}, "relevance": 0.46976, "count": 1}]}, "extracted_metadata": {"sha1": "89f0393e66508b3b8503b013131b3b108d96407a", "filename": "1543415817733.zip-490cd87ff9d0450763dd2ec6bceda8eb.xml", "file_type": "json"}, "title": "HBK Investments LP - Form 8.3 - Takeda Pharmaceutical Co Ltd", "forum_title": "FinanzNachrichten.de: News"}, {"id": "m5ru5ppjP5tlAfOCJ6onAib5o4qjsPj_WyAv7QBCrlvA2X0uvHbXxYGeOIsaD9j5", "result_metadata": {"score": 36.44342}, "author": "Shashii Pawar", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0.683173, "label": "positive"}}, "semantic_roles": [], "concepts": [{"text": "Pharmaceutical formulation", "relevance": 0.895888, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_formulation"}], "categories": [{"score": 0.94317, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.768738, "label": "/health and fitness"}], "relations": [], "keywords": [{"text": "Oral Solid Dosage Pharmaceutical Formulation", "sentiment": {"score": 0.683173, "label": "positive"}, "relevance": 0.993628, "count": 1}, {"text": "Maximum Share US", "sentiment": {"score": 0.683173, "label": "positive"}, "relevance": 0.264303, "count": 1}, {"text": "Bn", "sentiment": {"score": 0.683173, "label": "positive"}, "relevance": 0.017538, "count": 1}]}, "crawl_date": "2018-11-28T04:00:53Z", "url": "https://www.findmarketresearch.org/2018/11/oral-solid-dosage-pharmaceutical-formulation-market-will-hold-maximum-share-us-926-3-bn-by-2027/", "host": "findmarketresearch.org", "text": "Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T10:42:00+05:00", "enriched_text": {"entities": [{"count": 14, "sentiment": {"score": -0.254085, "label": "negative"}, "text": "Market", "relevance": 0.890677, "type": "Company"}, {"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mn", "relevance": 0.409573, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 5, "sentiment": {"score": 0.0984138, "label": "positive"}, "text": "North America", "relevance": 0.290873, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 5, "sentiment": {"score": 0.566872, "label": "positive"}, "text": "Latin America", "relevance": 0.28518, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "FMI", "relevance": 0.254282, "type": "Organization", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}, {"count": 3, "sentiment": {"score": -0.625144, "label": "negative"}, "text": "APEJ", "relevance": 0.241942, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 2, "sentiment": {"score": -0.548104, "label": "negative"}, "text": "Japan", "relevance": 0.21719, "type": "Location", "disambiguation": {"subtype": ["Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Otsuka Pharmaceutical Co.", "relevance": 0.186119, "type": "Company", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"count": 1, "sentiment": {"score": -0.522212, "label": "negative"}, "text": "Hospital pharmacy", "relevance": 0.18216, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eli Lilly", "relevance": 0.180258, "type": "Person", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"count": 1, "sentiment": {"score": -0.530235, "label": "negative"}, "text": "diabetes", "relevance": 0.175494, "type": "HealthCondition", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Western Europe", "relevance": 0.170379, "type": "Location", "disambiguation": {"subtype": ["Region"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Company Ltd.", "relevance": 0.167862, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Bristol-Myers Squibb Company", "relevance": 0.166052, "type": "Company", "disambiguation": {"subtype": ["AwardWinner"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Gilead Sciences", "relevance": 0.161513, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.160377, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.156405, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "China", "relevance": 0.153568, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis AG", "relevance": 0.153324, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.1525, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": -0.206781, "label": "negative"}, "text": "Bayer AG", "relevance": 0.152086, "type": "Company", "disambiguation": {"subtype": ["Brand"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Astellas Pharma Inc", "relevance": 0.151295, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Biogen Inc.", "relevance": 0.146166, "type": "Company", "disambiguation": {"subtype": [], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AstraZeneca Plc.", "relevance": 0.144297, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.249578, "label": "positive"}, "text": "Amgen Inc.", "relevance": 0.144229, "type": "Company", "disambiguation": {"subtype": [], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.143209, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Celgene Corporation", "relevance": 0.142318, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.141684, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0.571628, "label": "positive"}, "text": "Korea", "relevance": 0.140825, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "Country"], "name": "Korea", "dbpedia_resource": "http://dbpedia.org/resource/Korea"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Teva Pharmaceticals", "relevance": 0.134928, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "AbbVie Inc.", "relevance": 0.126195, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Hoffman-La-Roche Ltd.", "relevance": 0.126052, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire Plc.", "relevance": 0.124704, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Ltd.", "relevance": 0.120041, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.571628, "label": "positive"}, "text": "India", "relevance": 0.116975, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.1%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.4%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "6.5%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "7.4%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "9.2%", "relevance": 0.116975, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.116975, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.550399, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "oral solid dosage forms", "keywords": [{"text": "oral solid dosage"}]}, "sentence": "Instead of increasing pipeline productivity for biologics and patent cliff challenges, oral solid dosage forms hold substantial opportunity in extending product lifecycle and leveraging growth potential.", "object": {"text": "substantial opportunity", "keywords": [{"text": "substantial opportunity"}]}, "action": {"verb": {"text": "hold", "tense": "present"}, "text": "hold", "normalized": "hold"}}, {"subject": {"text": "Manufacturers", "keywords": [{"text": "Manufacturers"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations", "keywords": [{"text": "rapid release formulations"}, {"text": "new drug formulations"}, {"text": "various life cycle"}, {"text": "management patent strategies"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Manufacturers", "keywords": [{"text": "Manufacturers"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "various life cycle management patent strategies", "keywords": [{"text": "various life cycle"}, {"text": "management patent strategies"}]}, "action": {"verb": {"text": "employ", "tense": "present"}, "text": "are employing", "normalized": "be employ"}}, {"subject": {"text": "obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations", "keywords": [{"text": "rapid release formulations"}, {"text": "new drug formulations"}, {"text": "isomers"}, {"text": "prodrugs"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "cycle management patent strategies", "keywords": [{"text": "cycle management patent"}, {"text": "strategies"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "patents", "keywords": [{"text": "patents"}]}, "sentence": " Manufacturers are employing various life cycle management patent strategies which include obtaining patents on isomers, metabolites, prodrugs, and new drug formulations such as extended, controlled, or rapid release formulations.", "object": {"text": "on isomers", "keywords": [{"text": "isomers"}]}, "action": {"verb": {"text": "obtain", "tense": "present"}, "text": "include obtaining", "normalized": "include obtain"}}, {"subject": {"text": "Future Market Insights (FMI), in its report,", "keywords": [{"text": "Future Market Insights"}, {"text": "FMI"}, {"text": "report"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "sentence": " Future Market Insights (FMI), in its report, projects the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027.", "object": {"text": "the global oral solid dosage pharmaceutical formulation market to register 6.5% CAGR during the forecast period 2017 to 2027", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "forecast period"}, {"text": "market"}, {"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "6.5"}]}, "action": {"verb": {"text": "project", "tense": "present"}, "text": "projects", "normalized": "project"}}, {"subject": {"text": "the market", "keywords": [{"text": "market"}], "entities": [{"type": "Company", "text": "Market"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "$ 500,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 500,000"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "will reach", "normalized": "will reach"}}, {"subject": {"text": "2027"}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "further estimated to surpass US$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 900,000"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "to surpass US"}, "action": {"verb": {"text": "estimate", "tense": "past"}, "text": "estimated", "normalized": "estimate"}}, {"subject": {"text": "$ 900,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 900,000"}]}, "sentence": " In terms of revenue, the market will reach nearly US$ 500,000 Mn in 2017; by 2027 is further estimated to surpass US$ 900,000 Mn.", "object": {"text": "US"}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "is further estimated to surpass", "normalized": "be far estimate to surpass"}}, {"subject": {"text": "by Asia Pacific Excluding Japan (APEJ) and Western Europe", "keywords": [{"text": "Asia Pacific Excluding"}, {"text": "Western Europe"}, {"text": "Japan"}, {"text": "APEJ"}], "entities": [{"type": "Organization", "text": "Asia Pacific"}, {"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}, {"type": "Location", "text": "Western Europe", "disambiguation": {"subtype": ["Region"]}}]}, "sentence": " North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation: North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "object": {"text": "oral solid dosage pharmaceutical formulation,", "keywords": [{"text": "dosage pharmaceutical formulation"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Revenue from the market in North America", "keywords": [{"text": "Revenue"}, {"text": "North America"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " Revenue from the market in North America is expected to surpass US$ 300,000 Mn by 2027-end.", "object": {"text": "$ 300,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 300,000"}]}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "is expected to surpass", "normalized": "be expect to surpass"}}, {"subject": {"text": "APEJ", "keywords": [{"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027.", "object": {"text": "projected"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "APEJ", "keywords": [{"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " In addition, APEJ is projected to reach revenue worth US$ 294,750.4 Mn in the market by 2027.", "object": {"text": "revenue worth US$ 294,750.4 Mn in the market", "keywords": [{"text": "revenue worth"}, {"text": "Mn"}, {"text": "market"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "reach", "tense": "future"}, "text": "is projected to reach", "normalized": "be project to reach"}}, {"subject": {"text": "Latin America", "keywords": [{"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Latin America is expected to be the fastest growth region in the market, expanding at 9.2% CAGR through 2027.", "object": {"text": "the fastest growth region", "keywords": [{"text": "fastest growth region"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Japan", "keywords": [{"text": "Japan"}], "entities": [{"type": "Location", "text": "Japan", "disambiguation": {"subtype": ["Country", "Kingdom", "Country"], "name": "Empire of Japan", "dbpedia_resource": "http://dbpedia.org/resource/Empire_of_Japan"}}]}, "sentence": " In contrast, Japan will witness a sluggish growth in the market.", "object": {"text": "a sluggish growth in the market", "keywords": [{"text": "sluggish growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "witness", "tense": "future"}, "text": "will witness", "normalized": "will witness"}}, {"subject": {"text": "US"}, "sentence": " By dosage form, tablets will continue to remain preferred in the market, with sales estimated to surpass US$ 500,000 Mn by 2027-end.", "object": {"text": "$ 500,000 Mn", "keywords": [{"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"type": "Quantity", "text": "$ 500,000"}]}, "action": {"verb": {"text": "surpass", "tense": "future"}, "text": "estimated to surpass", "normalized": "estimate to surpass"}}, {"subject": {"text": "Sales of tablets", "keywords": [{"text": "tablets"}, {"text": "Sales"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "anticipated"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Sales of tablets", "keywords": [{"text": "tablets"}, {"text": "Sales"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "the highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "are anticipated to exhibit", "normalized": "be anticipate to exhibit"}}, {"subject": {"text": "the highest CAGR in the market", "keywords": [{"text": "highest CAGR"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}]}, "sentence": " Sales of tablets are anticipated to exhibit the highest CAGR in the market, followed by capsules.", "object": {"text": "by capsules", "keywords": [{"text": "capsules"}]}, "action": {"verb": {"text": "follow", "tense": "past"}, "text": "followed", "normalized": "follow"}}, {"subject": {"text": "Capsules", "keywords": [{"text": "Capsules"}]}, "sentence": " Capsules are expected to be the second most lucrative dosage form in the market, expanding at 6.1% CAGR through 2027.", "object": {"text": "the second most lucrative dosage form in the market", "keywords": [{"text": "lucrative dosage form"}], "entities": [{"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "are expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Immediate release", "keywords": [{"text": "Immediate release"}]}, "sentence": " Immediate release is expected to generate revenue over US$ 400,000 Mn by 2027-end.", "object": {"text": "revenue over US$ 400,000 Mn by 2027-end", "keywords": [{"text": "revenue"}, {"text": "Mn"}], "entities": [{"type": "Location", "text": "Mn", "disambiguation": {"subtype": ["StateOrCounty"]}}]}, "action": {"verb": {"text": "generate", "tense": "future"}, "text": "is expected to generate", "normalized": "be expect to generate"}}, {"subject": {"text": "7.4% CAGR", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "7.4"}]}, "sentence": " Controlled release under extended release segment, is expected to register 7.4% CAGR through 2027.", "action": {"verb": {"text": "register", "tense": "future"}, "text": "is expected to register", "normalized": "be expect to register"}}, {"subject": {"text": "Retail pharmacy", "keywords": [{"text": "Retail pharmacy"}]}, "sentence": " Retail pharmacy is expected to be the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end.", "object": {"text": "the largest end-user of oral solid dosage pharmaceutical formulation market by 2027-end", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "largest end-user"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is expected to be", "normalized": "be expect to be"}}, {"subject": {"text": "Retail pharmacy", "keywords": [{"text": "Retail pharmacy"}]}, "sentence": " Retail pharmacy is expected to exhibit highest CAGR in the market through 2027.", "object": {"text": "highest CAGR", "keywords": [{"text": "highest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "Hospital pharmacy", "keywords": [{"text": "Hospital pharmacy"}], "entities": [{"type": "Facility", "text": "Hospital pharmacy"}]}, "sentence": " In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.", "object": {"text": "lowest CAGR", "keywords": [{"text": "lowest CAGR"}]}, "action": {"verb": {"text": "exhibit", "tense": "future"}, "text": "is expected to exhibit", "normalized": "be expect to exhibit"}}, {"subject": {"text": "it"}, "sentence": " In contrast, Hospital pharmacy is expected to exhibit lowest CAGR, even though it stands as second largest end-user in the market during the forecast period.", "object": {"text": "as second largest end-user", "keywords": [{"text": "largest end-user"}]}, "action": {"verb": {"text": "stand", "tense": "present"}, "text": "stands", "normalized": "stand"}}, {"subject": {"text": "Presence of MNCs", "keywords": [{"text": "Presence"}, {"text": "MNCs"}]}, "sentence": " Increasing Presence of MNCs to Drive Market Growth in Latin America: Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "object": {"text": "to Drive Market Growth in Latin America", "keywords": [{"text": "Drive Market Growth"}, {"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "action": {"verb": {"text": "Increasing", "tense": "present"}, "text": "Increasing", "normalized": "Increasing"}}, {"subject": {"text": "Latin America", "keywords": [{"text": "Latin America"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}]}, "sentence": " Increasing Presence of MNCs to Drive Market Growth in Latin America: Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "object": {"text": "emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources", "keywords": [{"text": "oral solid dosage"}, {"text": "manufacturing hub"}, {"text": "low-cost resources"}, {"text": "availability"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Multinational companies", "keywords": [{"text": "Multinational companies"}]}, "sentence": " Multinational companies are focusing on expanding their presence in this region.", "object": {"text": "focusing on expanding their presence in this region", "keywords": [{"text": "presence"}, {"text": "region"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Multinational companies", "keywords": [{"text": "Multinational companies"}]}, "sentence": " Multinational companies are focusing on expanding their presence in this region.", "object": {"text": "their presence", "keywords": [{"text": "presence"}]}, "action": {"verb": {"text": "expand", "tense": "future"}, "text": "expanding", "normalized": "expand"}}, {"subject": {"text": "These factors", "keywords": [{"text": "factors"}]}, "sentence": " These factors are expected to propel market growth in Latin America.", "object": {"text": "market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "propel", "tense": "future"}, "text": "are expected to propel", "normalized": "be expect to propel"}}, {"subject": {"text": "They"}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region", "keywords": [{"text": "commonly used pharmaceuticals"}, {"text": "various disease conditions"}, {"text": "North America"}, {"text": "turn"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "pharmaceuticals", "keywords": [{"text": "pharmaceuticals"}]}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "for treating various disease conditions in North America, which in turn is driving growth of the market in this region", "keywords": [{"text": "various disease conditions"}, {"text": "North America"}, {"text": "turn"}, {"text": "growth"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "use", "tense": "past"}, "text": "used", "normalized": "use"}}, {"subject": {"text": "North America", "keywords": [{"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " They are most commonly used pharmaceuticals for treating various disease conditions in North America, which in turn is driving growth of the market in this region.", "object": {"text": "growth of the market in this region", "keywords": [{"text": "growth"}, {"text": "market"}, {"text": "region"}], "entities": [{"type": "Company", "text": "Market"}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "is driving", "normalized": "be drive"}}, {"subject": {"text": "Growing effluent consumers in APEJ countries such as China, India and Korea", "keywords": [{"text": "effluent consumers"}, {"text": "APEJ countries"}, {"text": "Korea"}, {"text": "China"}], "entities": [{"type": "Location", "text": "China", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "Kingdom", "FilmScreeningVenue", "Country"], "name": "China", "dbpedia_resource": "http://dbpedia.org/resource/China"}}, {"type": "Location", "text": "India", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "Korea", "disambiguation": {"subtype": ["AdministrativeDivision", "Country", "Country"], "name": "Korea", "dbpedia_resource": "http://dbpedia.org/resource/Korea"}}]}, "sentence": " Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "object": {"text": "growth of the oral solid dosage pharmaceutical formulation market in this region", "keywords": [{"text": "dosage pharmaceutical formulation"}, {"text": "growth"}, {"text": "market"}, {"text": "region"}]}, "action": {"verb": {"text": "boost", "tense": "present"}, "text": "are boosting", "normalized": "be boost"}}, {"subject": {"text": "Consumers here", "keywords": [{"text": "Consumers"}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity", "keywords": [{"text": "western lifestyle-related diseases"}, {"text": "wealthy-life-fast-paced western lifestyle"}, {"text": "obesity"}, {"text": "diabetes"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "Consumers here", "keywords": [{"text": "Consumers"}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "wealthy-life-fast-paced western lifestyle", "keywords": [{"text": "wealthy-life-fast-paced western lifestyle"}]}, "action": {"verb": {"text": "adopt", "tense": "present"}, "text": "are adopting", "normalized": "be adopt"}}, {"subject": {"text": "diabetes, cancer, and obesity", "keywords": [{"text": "obesity"}, {"text": "cancer"}], "entities": [{"type": "HealthCondition", "text": "diabetes", "disambiguation": {"subtype": ["Disease"], "name": "Diabetes mellitus", "dbpedia_resource": "http://dbpedia.org/resource/Diabetes_mellitus"}}]}, "sentence": " Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "object": {"text": "western lifestyle-related diseases", "keywords": [{"text": "western lifestyle-related diseases"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "This"}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "them"}, "action": {"verb": {"text": "compel", "tense": "present"}, "text": "compels", "normalized": "compel"}}, {"subject": {"text": "them"}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "action": {"verb": {"text": "seek", "tense": "present"}, "text": "seeking", "normalized": "seek"}}, {"subject": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "expected to fuel market growth in APEJ", "keywords": [{"text": "market growth"}, {"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "market growth in APEJ", "keywords": [{"text": "market growth"}, {"text": "APEJ"}], "entities": [{"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "sentence": " This compels them in seeking innovative drug treatments, which in turn is expected to fuel market growth in APEJ.", "object": {"text": "innovative drug treatments", "keywords": [{"text": "innovative drug treatments"}]}, "action": {"verb": {"text": "fuel", "tense": "future"}, "text": "is expected to fuel", "normalized": "be expect to fuel"}}, {"subject": {"text": "factors", "keywords": [{"text": "factors"}]}, "sentence": " However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "object": {"text": "productivity of Asian manufacturers and containment issues", "keywords": [{"text": "containment issues"}, {"text": "productivity"}, {"text": "Asian manufacturers"}]}, "action": {"verb": {"text": "decrease", "tense": "present"}, "text": "decreasing", "normalized": "decrease"}}, {"subject": {"text": "low R&D expenditure", "keywords": [{"text": "low R&D expenditure"}]}, "sentence": " However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "object": {"text": "with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ", "keywords": [{"text": "USFDA compliance"}, {"text": "challenges"}, {"text": "growth"}, {"text": "market"}], "entities": [{"type": "Company", "text": "Market"}, {"type": "Location", "text": "APEJ", "disambiguation": {"subtype": ["City"]}}]}, "action": {"verb": {"text": "couple", "tense": "past"}, "text": "coupled", "normalized": "couple"}}, {"subject": {"text": "Key players", "keywords": [{"text": "Key players"}]}, "sentence": " Key players identified in FMI\u2019s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "action": {"verb": {"text": "identify", "tense": "past"}, "text": "identified", "normalized": "identify"}}, {"subject": {"text": "AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc", "keywords": [{"text": "Boehringer Ingelheim GmbH"}, {"text": "Bristol-Myers Squibb Company"}, {"text": "Takeda Pharmaceutical Company"}, {"text": "Bayer AG"}], "entities": [{"type": "Company", "text": "AstraZeneca Plc."}, {"type": "Company", "text": "Bristol-Myers Squibb Company", "disambiguation": {"subtype": ["AwardWinner", "Company"], "name": "Bristol-Myers Squibb", "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}}, {"type": "Person", "text": "Eli Lilly", "disambiguation": {"subtype": ["MilitaryPerson"], "name": "Eli Lilly", "dbpedia_resource": "http://dbpedia.org/resource/Eli_Lilly"}}, {"type": "Company", "text": "Gilead Sciences", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Gilead Sciences", "dbpedia_resource": "http://dbpedia.org/resource/Gilead_Sciences"}}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Novartis AG", "disambiguation": {"subtype": ["Company"], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "AbbVie Inc."}, {"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Hoffman-La-Roche Ltd."}, {"type": "Company", "text": "Johnson & Johnson", "disambiguation": {"subtype": ["Organization", "AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"type": "Company", "text": "Biogen Inc.", "disambiguation": {"subtype": ["Company"], "name": "Biogen Idec", "dbpedia_resource": "http://dbpedia.org/resource/Biogen_Idec"}}, {"type": "Company", "text": "Bayer AG", "disambiguation": {"subtype": ["Organization", "Brand", "Company"], "name": "Bayer", "dbpedia_resource": "http://dbpedia.org/resource/Bayer"}}, {"type": "Company", "text": "Teva Pharmaceticals"}, {"type": "Company", "text": "Amgen Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Amgen", "dbpedia_resource": "http://dbpedia.org/resource/Amgen"}}, {"type": "Company", "text": "Takeda Pharmaceutical Company Ltd."}, {"type": "Company", "text": "Otsuka Pharmaceutical Co.", "disambiguation": {"subtype": [], "name": "Otsuka Pharmaceutical", "dbpedia_resource": "http://dbpedia.org/resource/Otsuka_Pharmaceutical"}}, {"type": "Company", "text": "Ltd."}, {"type": "Company", "text": "Shire Plc."}, {"type": "Company", "text": "Celgene Corporation", "disambiguation": {"subtype": ["Organization", "VentureFundedCompany"], "name": "Celgene", "dbpedia_resource": "http://dbpedia.org/resource/Celgene"}}, {"type": "Company", "text": "Astellas Pharma Inc"}]}, "sentence": " Key players identified in FMI\u2019s report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc.", "object": {"text": "Key players identified in FMI\u2019s report", "keywords": [{"text": "FMI\u2019s report"}, {"text": "Key players"}], "entities": [{"type": "Organization", "text": "FMI", "disambiguation": {"subtype": [], "name": "Investment company", "dbpedia_resource": "http://dbpedia.org/resource/Investment_company"}}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "A Sample of this Report", "keywords": [{"text": "Sample"}, {"text": "Report"}]}, "sentence": " A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "object": {"text": "Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "keywords": [{"text": "Request  https://www.futuremarketinsights.com/reports/sample/rep-gb-2782"}], "entities": [{"type": "TwitterHandle", "text": "@"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}], "concepts": [{"text": "Pharmacology", "relevance": 0.982685, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "North America", "relevance": 0.898337, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacy", "relevance": 0.897225, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"}, {"text": "Pharmaceutical formulation", "relevance": 0.804676, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_formulation"}, {"text": "Bristol-Myers Squibb", "relevance": 0.758359, "dbpedia_resource": "http://dbpedia.org/resource/Bristol-Myers_Squibb"}, {"text": "Multinational companies", "relevance": 0.602286, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "United States", "relevance": 0.599382, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Pharmaceutical companies of Japan", "relevance": 0.572255, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_Japan"}, {"text": "Boehringer Ingelheim", "relevance": 0.570354, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Biotechnology companies", "relevance": 0.560896, "dbpedia_resource": "http://dbpedia.org/resource/Biotechnology_companies"}, {"text": "Americas", "relevance": 0.542542, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Americas", "relevance": 0.514023, "dbpedia_resource": "http://dbpedia.org/resource/Americas_(terminology)"}, {"text": "Takeda Pharmaceutical Company", "relevance": 0.506005, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}, {"text": "Pharmaceutical industry", "relevance": 0.483771, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Pfizer", "relevance": 0.47511, "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}, {"text": "Novartis", "relevance": 0.473654, "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}, {"text": "Ingelheim am Rhein", "relevance": 0.464848, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "Latin America", "relevance": 0.463666, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "AstraZeneca", "relevance": 0.46108, "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.450094, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Clopidogrel", "relevance": 0.434296, "dbpedia_resource": "http://dbpedia.org/resource/Clopidogrel"}, {"text": "Dosage forms", "relevance": 0.420102, "dbpedia_resource": "http://dbpedia.org/resource/Dosage_forms"}, {"text": "Pharmaceutical drug", "relevance": 0.410939, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Indigenous peoples of the Americas", "relevance": 0.403027, "dbpedia_resource": "http://dbpedia.org/resource/Indigenous_peoples_of_the_Americas"}], "categories": [{"score": 0.945123, "label": "/business and industrial/pharmaceutical industry"}, {"score": 0.859266, "label": "/business and industrial/manufacturing"}, {"score": 0.781923, "label": "/health and fitness/drugs"}], "relations": [{"type": "hasAttribute", "sentence": "North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation: North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "score": 0.96908, "arguments": [{"text": "Asia Pacific Excluding Japan", "location": [940, 968], "entities": [{"type": "Organization", "text": "Asia Pacific Excluding Japan", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "APEJ", "location": [970, 974], "entities": [{"type": "Ticker", "text": "APEJ"}]}]}, {"type": "locatedAt", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.459042, "arguments": [{"text": "players", "location": [3738, 3745], "entities": [{"type": "Person", "text": "players"}]}, {"text": "FMI", "location": [3760, 3763], "entities": [{"type": "GeopoliticalEntity", "text": "FMI"}]}]}, {"type": "agentOf", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.774054, "arguments": [{"text": "FMI", "location": [3760, 3763], "entities": [{"type": "GeopoliticalEntity", "text": "FMI"}]}, {"text": "report", "location": [3766, 3772], "entities": [{"type": "EventCommunication", "text": "Request"}]}]}, {"type": "residesIn", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.474656, "arguments": [{"text": "Hoffman", "location": [3953, 3960], "entities": [{"type": "Person", "text": "Hoffman"}]}, {"text": "La", "location": [3961, 3963], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "employedBy", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.498404, "arguments": [{"text": "Hoffman", "location": [3953, 3960], "entities": [{"type": "Person", "text": "Hoffman"}]}, {"text": "Roche Ltd.", "location": [3964, 3974], "entities": [{"type": "Organization", "text": "Roche Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "hasAttribute", "sentence": "Key players identified in FMI's report include AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., Boehringer Ingelheim GmbH, Hoffman-La-Roche Ltd., Johnson & Johnson, Biogen Inc., Bayer AG, Teva Pharmaceticals, Amgen Inc., Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co., Ltd., Shire Plc., Celgene Corporation, Astellas Pharma Inc. A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2782", "score": 0.71673, "arguments": [{"text": "Astellas Pharma Inc.", "location": [4153, 4173], "entities": [{"type": "Organization", "text": "Astellas Pharma Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "@", "location": [4224, 4225], "entities": [{"type": "Money", "text": "@", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "locatedAt", "sentence": "North America to Remain Largest Market for Oral Solid Dosage Pharmaceutical Formulation: North America will remain the largest market for oral solid dosage pharmaceutical formulation, followed by Asia Pacific Excluding Japan (APEJ) and Western Europe.", "score": 0.891566, "arguments": [{"text": "Western", "location": [980, 987], "entities": [{"type": "Location", "text": "Western"}]}, {"text": "Europe", "location": [988, 994], "entities": [{"type": "GeopoliticalEntity", "text": "Europe", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "basedIn", "sentence": "Increasing Presence of MNCs to Drive Market Growth in Latin America: Latin America is emerging as a manufacturing hub for oral solid dosage forms on the back of availability of low-cost resources.", "score": 0.586785, "arguments": [{"text": "Market Growth", "location": [2474, 2487], "entities": [{"type": "Organization", "text": "Market for Oral Solid Dosage Pharmaceutical Formulation"}]}, {"text": "Latin America", "location": [2491, 2504], "entities": [{"type": "GeopoliticalEntity", "text": "Latin America"}]}]}, {"type": "locatedAt", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.620649, "arguments": [{"text": "consumers", "location": [3071, 3080], "entities": [{"type": "Person", "text": "Consumers"}]}, {"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.915942, "arguments": [{"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "APEJ", "location": [3084, 3088], "entities": [{"type": "GeopoliticalEntity", "text": "APEJ"}]}]}, {"type": "partOfMany", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.233982, "arguments": [{"text": "China", "location": [3107, 3112], "entities": [{"type": "GeopoliticalEntity", "text": "China", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "Growing effluent consumers in APEJ countries such as China, India and Korea are boosting growth of the oral solid dosage pharmaceutical formulation market in this region.", "score": 0.353547, "arguments": [{"text": "India", "location": [3114, 3119], "entities": [{"type": "GeopoliticalEntity", "text": "India", "disambiguation": {"subtype": ["Country"]}}]}, {"text": "countries", "location": [3089, 3098], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Consumers here are adopting wealthy-life-fast-paced western lifestyle, leading them to suffer western lifestyle-related diseases including diabetes, cancer, and obesity.", "score": 0.669607, "arguments": [{"text": "them", "location": [3304, 3308], "entities": [{"type": "Person", "text": "their"}]}, {"text": "diseases", "location": [3345, 3353], "entities": [{"type": "HealthCondition", "text": "diseases"}]}]}, {"type": "basedIn", "sentence": "However factors such as decreasing productivity of Asian manufacturers and containment issues, and low R&D expenditure coupled with challenges incurred in USFDA compliance are expected to impede growth of the market in APEJ.", "score": 0.771607, "arguments": [{"text": "manufacturers", "location": [3566, 3579], "entities": [{"type": "Organization", "text": "manufacturers", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Asian", "location": [3560, 3565], "entities": [{"type": "GeopoliticalEntity", "text": "Asian", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "oral solid dosage forms", "sentiment": {"score": 0.914972, "label": "positive"}, "relevance": 0.679649, "count": 3}, {"text": "Future Market Insights", "sentiment": {"score": 0.86537, "label": "positive"}, "relevance": 0.639962, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.619002, "count": 1}, {"text": "Multinational companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.601332, "count": 1}, {"text": "North America", "sentiment": {"score": 0.73753, "mixed": "1", "label": "positive"}, "relevance": 0.600193, "count": 4}, {"text": "Oral Solid Dosage Pharmaceutical Formulation", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.583026, "count": 1}, {"text": "Immediate Release", "sentiment": {"score": -0.545022, "label": "negative"}, "relevance": 0.570973, "count": 3}, {"text": "effluent consumers", "sentiment": {"score": 0.889941, "label": "positive"}, "relevance": 0.568598, "count": 1}, {"text": "rapid release formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.56849, "count": 1}, {"text": "Largest Market", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.563968, "count": 2}, {"text": "pharmaceutical formulation market", "sentiment": {"score": 0.679277, "mixed": "1", "label": "positive"}, "relevance": 0.562, "count": 3}, {"text": "Latin America", "sentiment": {"score": 0.882643, "label": "positive"}, "relevance": 0.55887, "count": 4}, {"text": "growth potential", "sentiment": {"score": 0.979025, "label": "positive"}, "relevance": 0.558341, "count": 1}, {"text": "new drug formulations", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.554196, "count": 1}, {"text": "solid dosage", "sentiment": {"score": 0.878234, "label": "positive"}, "relevance": 0.551734, "count": 2}, {"text": "patent cliff challenges", "sentiment": {"score": 0.979025, "label": "positive"}, "relevance": 0.546994, "count": 1}, {"text": "Western Europe", "sentiment": {"score": 0.566327, "mixed": "1", "label": "positive"}, "relevance": 0.545547, "count": 1}, {"text": "Pfizer Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.544245, "count": 1}, {"text": "Bristol-Myers Squibb Company", "sentiment": {"score": 0.547526, "label": "positive"}, "relevance": 0.544099, "count": 1}, {"text": "Key players", "sentiment": {"score": 0.547526, "label": "positive"}, "relevance": 0.542173, "count": 1}, {"text": "pipeline productivity", "sentiment": {"score": 0.979025, "label": "positive"}, "relevance": 0.538289, "count": 1}, {"text": "Novartis AG", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.532292, "count": 1}, {"text": "productivity of Asian manufacturers", "sentiment": {"score": -0.878136, "label": "negative"}, "relevance": 0.528952, "count": 1}, {"text": "Takeda Pharmaceutical Company Ltd", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.528335, "count": 1}, {"text": "AstraZeneca Plc", "sentiment": {"score": 0.547526, "label": "positive"}, "relevance": 0.528062, "count": 1}, {"text": "Boehringer Ingelheim GmbH", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.526462, "count": 1}, {"text": "AbbVie Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.524184, "count": 1}, {"text": "global oral", "sentiment": {"score": 0.86537, "label": "positive"}, "relevance": 0.520112, "count": 1}, {"text": "Manufacturers", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.516431, "count": 1}, {"text": "Retail pharmacy", "sentiment": {"score": 0.630785, "label": "positive"}, "relevance": 0.516087, "count": 2}, {"text": "oral solid dosage", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.514762, "count": 1}, {"text": "factors", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514728, "count": 1}, {"text": "Eli Lilly", "sentiment": {"score": 0.637948, "label": "positive"}, "relevance": 0.513612, "count": 1}, {"text": "dosage form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513569, "count": 1}, {"text": "Biogen Inc.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.513339, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.512306, "count": 2}, {"text": "report", "sentiment": {"score": 0.86537, "label": "positive"}, "relevance": 0.511957, "count": 1}, {"text": "market", "sentiment": {"score": 0.284889, "mixed": "1", "label": "positive"}, "relevance": 0.511687, "count": 12}, {"text": "contrast", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511642, "count": 2}, {"text": "Otsuka Pharmaceutical Co.", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.511347, "count": 1}, {"text": "Asia Pacific Excluding Japan", "sentiment": {"score": 0.965383, "label": "positive"}, "relevance": 0.511277, "count": 1}, {"text": "Teva Pharmaceticals", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.51085, "count": 1}, {"text": "Gilead Sciences", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.510001, "count": 1}, {"text": "pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509748, "count": 1}, {"text": "western lifestyle", "sentiment": {"score": -0.569076, "label": "negative"}, "relevance": 0.509613, "count": 1}, {"text": "Bayer AG", "sentiment": {"score": 0.725654, "label": "positive"}, "relevance": 0.509567, "count": 1}, {"text": "various disease conditions", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50857, "count": 1}, {"text": "Consumers", "sentiment": {"score": -0.569076, "label": "negative"}, "relevance": 0.508542, "count": 1}, {"text": "release mechanism", "sentiment": {"score": -0.545022, "label": "negative"}, "relevance": 0.50789, "count": 1}, {"text": "tablets", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507528, "count": 1}]}, "extracted_metadata": {"sha1": "7d2de15010043cf38a7d3a38689912309eef9bf5", "filename": "1543377653502.zip-449c33b738d17d155fbe962c8c1970a5.xml", "file_type": "json"}, "external_links": ["https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market", "https://www.futuremarketinsights.com/reports/sample/rep-gb-2782"], "title": "Oral Solid Dosage Pharmaceutical Formulation will Hold Maximum Share US$ 926.3 Bn by 2027", "forum_title": "Research Insights | Find Market Research - Part 27"}, {"id": "mN93HnwrjszwZqIqJxCWbwXWqeFTrhmA2W-rqADz8bXpyjIEvYb4qqg9wKG50zxY", "result_metadata": {"score": 36.312023}, "author": "Ram", "enriched_title": {"entities": [], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Supply and demand", "relevance": 0.915043, "dbpedia_resource": "http://dbpedia.org/resource/Supply_and_demand"}], "categories": [{"score": 0.941689, "label": "/health and fitness"}, {"score": 0.771299, "label": "/business and industrial/energy/electricity"}, {"score": 0.747468, "label": "/health and fitness/drugs"}], "relations": [], "keywords": [{"text": "Anti-Obesity Drugs Dynamics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.998312, "count": 1}, {"text": "Segments", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.797087, "count": 1}, {"text": "Supply Demand", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.082209, "count": 1}]}, "crawl_date": "2018-11-27T15:01:19Z", "url": "https://www.findmarketresearch.org/2017/09/anti-obesity-drugs-market-dynamics-segments-and-supply-demand-2016-2024/", "host": "findmarketresearch.org", "text": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co.", "country": "IN", "source_type": "mainstream", "language": "en", "publication_date": "2017-09-13T12:24:00+05:00", "enriched_text": {"entities": [{"count": 4, "sentiment": {"score": -0.429801, "label": "negative"}, "text": "obesity", "relevance": 0.459881, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"count": 2, "sentiment": {"score": -0.23485, "label": "negative"}, "text": "North America", "relevance": 0.265989, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 2, "sentiment": {"score": 0.772965, "label": "positive"}, "text": "U.S.", "relevance": 0.255382, "type": "Location", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "World Health Organization", "relevance": 0.249489, "type": "Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}, {"count": 1, "sentiment": {"score": -0.511131, "label": "negative"}, "text": "Centers for Disease Control and Prevention", "relevance": 0.233762, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boehringer Ingelheim GmbH", "relevance": 0.21415, "type": "Company", "disambiguation": {"subtype": [], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"count": 1, "sentiment": {"score": -0.437578, "label": "negative"}, "text": "underweight", "relevance": 0.203406, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia Pacific", "relevance": 0.195081, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.772965, "label": "positive"}, "text": "FDA", "relevance": 0.191908, "type": "Organization", "disambiguation": {"subtype": ["GovernmentAgency"], "name": "Food and Drug Administration", "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}}, {"count": 1, "sentiment": {"score": -0.220423, "label": "negative"}, "text": "Zydus Cadila", "relevance": 0.187799, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.484587, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.185499, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.455695, "label": "negative"}, "text": "Rhythm Pharmaceuticals", "relevance": 0.18362, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novo Nordisk A/S", "relevance": 0.181441, "type": "Company", "disambiguation": {"subtype": [], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Roche AG", "relevance": 0.176553, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer Inc.", "relevance": 0.173095, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "GlaxoSmithKline PLC", "relevance": 0.169467, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.573217, "label": "negative"}, "text": "Arena Pharmaceuticals Inc.", "relevance": 0.164026, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Merck & Co. Inc.", "relevance": 0.162933, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Orexigen Therapeutics Inc.", "relevance": 0.151261, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Co. Ltd.", "relevance": 0.145122, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Zafgen", "relevance": 0.144862, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Norgine B.V.", "relevance": 0.144754, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "68.8%", "relevance": 0.144754, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "13%", "relevance": 0.144754, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "39%", "relevance": 0.144754, "type": "Quantity"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "@", "relevance": 0.144754, "type": "TwitterHandle"}], "sentiment": {"document": {"score": 0.366083, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "The World Health Organization", "keywords": [{"text": "World Health Organization"}], "entities": [{"type": "Organization", "text": "World Health Organization", "disambiguation": {"subtype": [], "name": "World Health Organization", "dbpedia_resource": "http://dbpedia.org/resource/World_Health_Organization"}}]}, "sentence": " The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "object": {"text": "that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese", "keywords": [{"text": "global obesity"}, {"text": "obese"}, {"text": "adults"}]}, "action": {"verb": {"text": "reveal", "tense": "present"}, "text": "reveals", "normalized": "reveal"}}, {"subject": {"text": "global obesity", "keywords": [{"text": "global obesity"}]}, "sentence": " The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "action": {"verb": {"text": "double", "tense": "past"}, "text": "has more than doubled", "normalized": "have more than double"}}, {"subject": {"text": "an estimated 39% of adults", "keywords": [{"text": "adults"}], "entities": [{"type": "Quantity", "text": "39"}]}, "sentence": " Percentage-wise, an estimated 39% of adults were overweight and 13% were obese in 2014.", "object": {"text": "overweight", "keywords": [{"text": "overweight"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "an estimated 39% of adults were overweight and 13%", "keywords": [{"text": "overweight"}, {"text": "adults"}], "entities": [{"type": "Quantity", "text": "13"}, {"type": "Quantity", "text": "39"}]}, "sentence": " Percentage-wise, an estimated 39% of adults were overweight and 13% were obese in 2014.", "object": {"text": "obese", "keywords": [{"text": "obese"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were", "normalized": "be"}}, {"subject": {"text": "An additional 42 million children below the age of five", "keywords": [{"text": "children"}, {"text": "age"}]}, "sentence": " An additional 42 million children below the age of five were found to be overweight or obese in 2013.", "object": {"text": "overweight or obese", "keywords": [{"text": "overweight"}, {"text": "obese"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "were found to be", "normalized": "be find to be"}}, {"subject": {"text": "by the Centers for Disease Control and Prevention", "keywords": [{"text": "Disease Control"}, {"text": "Centers"}, {"text": "Prevention"}], "entities": [{"type": "Organization", "text": "Centers for Disease Control and Prevention", "disambiguation": {"subtype": ["GovernmentAgency", "GovernmentalBody"], "name": "Centers for Disease Control and Prevention", "dbpedia_resource": "http://dbpedia.org/resource/Centers_for_Disease_Control_and_Prevention"}}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "two surveys", "keywords": [{"text": "surveys"}]}, "action": {"verb": {"text": "conduct", "tense": "past"}, "text": "conducted", "normalized": "conduct"}}, {"subject": {"text": "an astounding 68.8% of the U.S. adult population", "keywords": [{"text": "U.S. adult population"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "68.8"}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "considered to be overweight or obese", "keywords": [{"text": "obese"}, {"text": "overweight"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an astounding 68.8% of the U.S. adult population", "keywords": [{"text": "U.S. adult population"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "68.8"}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "to be overweight or obese", "keywords": [{"text": "obese"}, {"text": "overweight"}]}, "action": {"verb": {"text": "consider", "tense": "past"}, "text": "considered", "normalized": "consider"}}, {"subject": {"text": "an astounding 68.8% of the U.S. adult population", "keywords": [{"text": "U.S. adult population"}], "entities": [{"type": "Location", "text": "U.S.", "disambiguation": {"subtype": ["Region", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "FilmEditor", "Country"], "name": "United States", "dbpedia_resource": "http://dbpedia.org/resource/United_States"}}, {"type": "Quantity", "text": "68.8"}]}, "sentence": " Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "object": {"text": "overweight or obese", "keywords": [{"text": "overweight"}, {"text": "obese"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "is considered to be", "normalized": "be consider to be"}}, {"subject": {"text": "It"}, "sentence": " It is no surprise, then, that today, most of the world\u2019s population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.", "object": {"text": "no surprise, then, that today, most of the world\u2019s population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition", "keywords": [{"text": "population lives"}, {"text": "underweight"}, {"text": "malnutrition"}, {"text": "overweight"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "HealthCondition", "text": "underweight"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "This"}, "sentence": " This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market .", "object": {"text": "rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "alarm", "tense": "present"}, "text": "alarming", "normalized": "alarm"}}, {"subject": {"text": "This alarming rise in the prevalence of obesity, particularly in the developed region of North America,", "keywords": [{"text": "developed region"}, {"text": "North America"}, {"text": "prevalence"}, {"text": "obesity"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market .", "object": {"text": "the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has been single-handedly propelling", "normalized": "have be single-handedly propel"}}, {"subject": {"text": "This alarming rise in the prevalence of obesity, particularly in the developed region of North America,", "keywords": [{"text": "developed region"}, {"text": "North America"}, {"text": "prevalence"}, {"text": "obesity"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market .", "object": {"text": "single-handedly propelling the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "This alarming rise in the prevalence of obesity, particularly in the developed region of North America,", "keywords": [{"text": "developed region"}, {"text": "North America"}, {"text": "prevalence"}, {"text": "obesity"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market .", "object": {"text": "the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "propel", "tense": "present"}, "text": "propelling", "normalized": "propel"}}, {"subject": {"text": "These"}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite", "keywords": [{"text": "pharmacological agents"}, {"text": "calories"}, {"text": "appetite"}, {"text": "absorption"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contain", "normalized": "contain"}}, {"subject": {"text": "a host of pharmacological agents", "keywords": [{"text": "pharmacological agents"}, {"text": "host"}]}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "weight", "keywords": [{"text": "weight"}]}, "action": {"verb": {"text": "control", "tense": "present"}, "text": "control", "normalized": "control"}}, {"subject": {"text": "pharmacological agents", "keywords": [{"text": "pharmacological agents"}]}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "weight", "keywords": [{"text": "weight"}]}, "action": {"verb": {"text": "reduce", "tense": "present"}, "text": "reduce", "normalized": "reduce"}}, {"subject": {"text": "a host of pharmacological agents", "keywords": [{"text": "pharmacological agents"}, {"text": "host"}]}, "sentence": " These contain a host of pharmacological agents that control or reduce weight by altering either the absorption of calories or regulating appetite.", "object": {"text": "either the absorption of calories", "keywords": [{"text": "calories"}, {"text": "absorption"}]}, "action": {"verb": {"text": "alter", "tense": "present"}, "text": "altering", "normalized": "alter"}}, {"subject": {"text": "This comprehensive research publication", "keywords": [{"text": "comprehensive research publication"}]}, "sentence": " This comprehensive research publication offers clients an exhaustive database of accurate, authentic, objective, and the most recent information on the global anti-obesity drugs market.", "object": {"text": "an exhaustive database of accurate, authentic, objective, and the most recent information on the global anti-obesity drugs market", "keywords": [{"text": "global anti-obesity drugs"}, {"text": "exhaustive database"}, {"text": "recent information"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "The overall market", "keywords": [{"text": "overall market"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "segmented based on several key criteria", "keywords": [{"text": "key criteria"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "each segment", "keywords": [{"text": "segment"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "thoroughly evaluated to identify the leading and weakest categories", "keywords": [{"text": "weakest categories"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "each segment", "keywords": [{"text": "segment"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "to identify the leading and weakest categories", "keywords": [{"text": "weakest categories"}]}, "action": {"verb": {"text": "evaluate", "tense": "past"}, "text": "evaluated", "normalized": "evaluate"}}, {"subject": {"text": "each segment", "keywords": [{"text": "segment"}]}, "sentence": " The overall market is segmented based on several key criteria and each segment is thoroughly evaluated to identify the leading and weakest categories.", "object": {"text": "the leading and weakest categories", "keywords": [{"text": "weakest categories"}]}, "action": {"verb": {"text": "identify", "tense": "future"}, "text": "is thoroughly evaluated to identify", "normalized": "be thoroughly evaluate to identify"}}, {"subject": {"text": "Statistical data and inputs from industry experts", "keywords": [{"text": "inputs"}, {"text": "Statistical data"}, {"text": "industry experts"}]}, "sentence": " Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.", "object": {"text": "the qualitative data offered in the report", "keywords": [{"text": "qualitative data"}, {"text": "report"}]}, "action": {"verb": {"text": "support", "tense": "present"}, "text": "support", "normalized": "support"}}, {"subject": {"text": "the qualitative data", "keywords": [{"text": "qualitative data"}]}, "sentence": " Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.", "action": {"verb": {"text": "offer", "tense": "past"}, "text": "offered", "normalized": "offer"}}, {"subject": {"text": "clients", "keywords": [{"text": "clients"}]}, "sentence": " Statistical data and inputs from industry experts support the qualitative data offered in the report and help clients devise actionable and profitable decisions for the future.", "object": {"text": "actionable and profitable decisions", "keywords": [{"text": "decisions"}]}, "action": {"verb": {"text": "devise", "tense": "present"}, "text": "devise", "normalized": "devise"}}, {"subject": {"text": "The global market for anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}, {"text": "global market"}], "entities": []}, "sentence": " The global market for anti-obesity drugs has been expanding at a significant pace in recent years.", "object": {"text": "expanding at a significant pace", "keywords": [{"text": "significant pace"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The global market for anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}, {"text": "global market"}], "entities": []}, "sentence": " The global market for anti-obesity drugs has been expanding at a significant pace in recent years.", "action": {"verb": {"text": "expand", "tense": "past"}, "text": "has been expanding", "normalized": "have be expand"}}, {"subject": {"text": "the obvious driving factor", "keywords": [{"text": "obvious driving factor"}]}, "sentence": " With the obvious driving factor being the surge in obesity levels around the globe, this market is also propelled by the strong pipeline of anti-obesity drugs.", "object": {"text": "the surge in obesity levels around the globe", "keywords": [{"text": "obesity levels"}, {"text": "surge"}, {"text": "globe"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "being", "normalized": "be"}}, {"subject": {"text": "by the strong pipeline of anti-obesity drugs", "keywords": [{"text": "strong pipeline"}, {"text": "anti-obesity drugs"}]}, "sentence": " With the obvious driving factor being the surge in obesity levels around the globe, this market is also propelled by the strong pipeline of anti-obesity drugs.", "object": {"text": "this market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "propel", "tense": "past"}, "text": "is also propelled", "normalized": "be also propel"}}, {"subject": {"text": "The anti-obesity drugs market in North America", "keywords": [{"text": "anti-obesity drugs market"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "object": {"text": "been flourishing"}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "The anti-obesity drugs market in North America", "keywords": [{"text": "anti-obesity drugs market"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "object": {"text": "flourishing"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The anti-obesity drugs market in North America", "keywords": [{"text": "anti-obesity drugs market"}, {"text": "North America"}], "entities": [{"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}]}, "sentence": " The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "action": {"verb": {"text": "flourish", "tense": "past"}, "text": "has been flourishing", "normalized": "have be flourish"}}, {"subject": {"text": "the various risks", "keywords": [{"text": "various risks"}]}, "sentence": " The anti-obesity drugs market in North America has been flourishing over the years owing to the high level of awareness among the population about obesity and the various risks arising from the medical condition, increased healthcare expenditure, the presence of favorable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.", "object": {"text": "from the medical condition", "keywords": [{"text": "medical condition"}]}, "action": {"verb": {"text": "arise", "tense": "present"}, "text": "arising", "normalized": "arise"}}, {"subject": {"text": "The Asia Pacific market for anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}, {"text": "Asia Pacific market"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "object": {"text": "anticipated to gain momentum in the coming years", "keywords": [{"text": "momentum"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Asia Pacific market for anti-obesity drugs", "keywords": [{"text": "anti-obesity drugs"}, {"text": "Asia Pacific market"}], "entities": [{"type": "Company", "text": "Asia Pacific"}]}, "sentence": " The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "object": {"text": "momentum", "keywords": [{"text": "momentum"}]}, "action": {"verb": {"text": "gain", "tense": "future"}, "text": "is anticipated to gain", "normalized": "be anticipate to gain"}}, {"subject": {"text": "from increased spending on processed and packaged foods", "keywords": [{"text": "spending"}, {"text": "foods"}]}, "sentence": " The Asia Pacific market for anti-obesity drugs is anticipated to gain momentum in the coming years thanks to the rise in obese population, resulting from increased spending on processed and packaged foods and the growing consumption of sugar-sweetened beverages.", "object": {"text": "obese population", "keywords": [{"text": "obese population"}]}, "action": {"verb": {"text": "result", "tense": "present"}, "text": "resulting", "normalized": "result"}}, {"subject": {"text": "Improving healthcare infrastructure and mounting healthcare expenditure", "keywords": [{"text": "healthcare expenditure"}, {"text": "healthcare infrastructure"}]}, "sentence": " Improving healthcare infrastructure and mounting healthcare expenditure is also expected to drive the market for anti-obesity drugs in APAC.", "object": {"text": "the market", "keywords": [{"text": "market"}], "entities": []}, "action": {"verb": {"text": "drive", "tense": "future"}, "text": "is also expected to drive", "normalized": "be also expect to drive"}}, {"subject": {"text": "The leading companies", "keywords": [{"text": "companies"}]}, "sentence": " The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "action": {"verb": {"text": "operate", "tense": "present"}, "text": "operating", "normalized": "operate"}}, {"subject": {"text": "Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG", "keywords": [{"text": "Takeda Pharmaceuticals Company"}, {"text": "Arena Pharmaceuticals Inc."}, {"text": "Boehringer Ingelheim GmbH"}, {"text": "Novo Nordisk A/S"}], "entities": [{"type": "Company", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Boehringer Ingelheim", "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}}, {"type": "Company", "text": "Arena Pharmaceuticals Inc."}, {"type": "Company", "text": "Takeda Pharmaceuticals Company Limited"}, {"type": "Person", "text": "Zydus Cadila"}, {"type": "Company", "text": "Rhythm Pharmaceuticals"}, {"type": "Company", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Organization", "Company"], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"type": "Company", "text": "Eisai Co. Ltd."}, {"type": "Company", "text": "Novo Nordisk A/S", "disambiguation": {"subtype": ["Company"], "name": "Novo Nordisk", "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}}, {"type": "Company", "text": "Orexigen Therapeutics Inc."}, {"type": "Company", "text": "Zafgen"}, {"type": "Company", "text": "GlaxoSmithKline PLC", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"type": "Company", "text": "Norgine B.V."}, {"type": "Company", "text": "Pfizer Inc.", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"type": "Company", "text": "Roche AG"}]}, "sentence": " The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "object": {"text": "The leading companies operating in the global anti-obesity drugs market", "keywords": [{"text": "global anti-obesity drugs"}, {"text": "companies"}, {"text": "market"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "include", "normalized": "include"}}, {"subject": {"text": "to the increasing prevalence of obesity in several parts of the world", "keywords": [{"text": "prevalence"}, {"text": "obesity"}, {"text": "parts"}, {"text": "world"}], "entities": [{"type": "HealthCondition", "text": "obesity", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom"], "name": "Obesity", "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}}]}, "sentence": " Owing to the increasing prevalence of obesity in several parts of the world, the degree of competition among players in the anti-obesity drugs market has been on the rise.", "object": {"text": "the degree of competition among players in the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "degree"}, {"text": "competition"}, {"text": "players"}]}, "action": {"verb": {"text": "Owing", "tense": "present"}, "text": "Owing", "normalized": "Owing"}}, {"subject": {"text": "the degree of competition among players in the anti-obesity drugs market", "keywords": [{"text": "anti-obesity drugs"}, {"text": "degree"}, {"text": "competition"}, {"text": "players"}]}, "sentence": " Owing to the increasing prevalence of obesity in several parts of the world, the degree of competition among players in the anti-obesity drugs market has been on the rise.", "object": {"text": "on the rise", "keywords": [{"text": "rise"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "has been", "normalized": "have be"}}, {"subject": {"text": "Companies around the globe", "keywords": [{"text": "globe"}, {"text": "Companies"}]}, "sentence": " Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are also focused", "normalized": "be also focus"}}, {"subject": {"text": "successful commercialization of anti-obesity drugs", "keywords": [{"text": "successful commercialization"}, {"text": "anti-obesity drugs"}]}, "sentence": " Companies around the globe are also focused on the development as well as successful commercialization of anti-obesity drugs that are both clinically effective and safe in the long run and also have the potential to generate massive sales and reach blockbuster status.", "object": {"text": "both clinically effective and safe"}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The current portfolio of prescription weight-loss drugs and emerging anti-obesity drugs in pre-clinical or clinical trials", "keywords": [{"text": "prescription weight-loss drugs"}, {"text": "anti-obesity drugs"}, {"text": "current portfolio"}, {"text": "clinical trials"}]}, "sentence": " The current portfolio of prescription weight-loss drugs and emerging anti-obesity drugs in pre-clinical or clinical trials acts as a significant force driving the global anti-obesity drugs market.", "object": {"text": "as a significant force driving the global anti-obesity drugs market", "keywords": [{"text": "global anti-obesity drugs"}, {"text": "significant force"}, {"text": "market"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acts", "normalized": "act"}}, {"subject": {"text": "The report", "keywords": [{"text": "report"}]}, "sentence": " The report offers a comprehensive evaluation of the market.", "object": {"text": "a comprehensive evaluation of the market", "keywords": [{"text": "comprehensive evaluation"}, {"text": "market"}], "entities": []}, "action": {"verb": {"text": "offer", "tense": "present"}, "text": "offers", "normalized": "offer"}}, {"subject": {"text": "It"}, "sentence": " It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.", "object": {"text": "so"}, "action": {"verb": {"text": "do", "tense": "present"}, "text": "does", "normalized": "do"}}, {"subject": {"text": "The projections", "keywords": [{"text": "projections"}]}, "sentence": " The projections featured in the report have been derived using proven research methodologies and assumptions.", "object": {"text": "in the report", "keywords": [{"text": "report"}]}, "action": {"verb": {"text": "feature", "tense": "past"}, "text": "featured", "normalized": "feature"}}, {"subject": {"text": "The projections featured in the report", "keywords": [{"text": "projections"}, {"text": "report"}]}, "sentence": " The projections featured in the report have been derived using proven research methodologies and assumptions.", "object": {"text": "using proven research methodologies and assumptions", "keywords": [{"text": "proven research methodologies"}, {"text": "assumptions"}]}, "action": {"verb": {"text": "derive", "tense": "past"}, "text": "derived", "normalized": "derive"}}, {"subject": {"text": "the research report", "keywords": [{"text": "research report"}]}, "sentence": " By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.", "object": {"text": "as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications", "keywords": [{"text": "Regional markets"}, {"text": "facet"}, {"text": "repository"}, {"text": "analysis"}], "entities": []}, "action": {"verb": {"text": "serve", "tense": "present"}, "text": "serves", "normalized": "serve"}}], "concepts": [{"text": "Obesity", "relevance": 0.95305, "dbpedia_resource": "http://dbpedia.org/resource/Obesity"}, {"text": "Cancer", "relevance": 0.693069, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Weight loss", "relevance": 0.647781, "dbpedia_resource": "http://dbpedia.org/resource/Weight_loss"}, {"text": "Nutrition", "relevance": 0.62382, "dbpedia_resource": "http://dbpedia.org/resource/Nutrition"}, {"text": "Body shape", "relevance": 0.594214, "dbpedia_resource": "http://dbpedia.org/resource/Body_shape"}, {"text": "Boehringer Ingelheim", "relevance": 0.569633, "dbpedia_resource": "http://dbpedia.org/resource/Boehringer_Ingelheim"}, {"text": "Overweight", "relevance": 0.552087, "dbpedia_resource": "http://dbpedia.org/resource/Overweight"}, {"text": "Adipose tissue", "relevance": 0.544077, "dbpedia_resource": "http://dbpedia.org/resource/Adipose_tissue"}, {"text": "Dieting", "relevance": 0.505974, "dbpedia_resource": "http://dbpedia.org/resource/Dieting"}, {"text": "Physical exercise", "relevance": 0.480823, "dbpedia_resource": "http://dbpedia.org/resource/Physical_exercise"}, {"text": "Malnutrition", "relevance": 0.470342, "dbpedia_resource": "http://dbpedia.org/resource/Malnutrition"}, {"text": "Ingelheim am Rhein", "relevance": 0.464411, "dbpedia_resource": "http://dbpedia.org/resource/Ingelheim_am_Rhein"}, {"text": "Appetite", "relevance": 0.455206, "dbpedia_resource": "http://dbpedia.org/resource/Appetite"}, {"text": "Bariatrics", "relevance": 0.452258, "dbpedia_resource": "http://dbpedia.org/resource/Bariatrics"}, {"text": "Hoffmann\u2013La Roche", "relevance": 0.450803, "dbpedia_resource": "http://dbpedia.org/resource/Hoffmann\u2013La_Roche"}, {"text": "Pharmacology", "relevance": 0.449588, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Sedentary lifestyle", "relevance": 0.448945, "dbpedia_resource": "http://dbpedia.org/resource/Sedentary_lifestyle"}, {"text": "Body mass index", "relevance": 0.444508, "dbpedia_resource": "http://dbpedia.org/resource/Body_mass_index"}, {"text": "Medicine", "relevance": 0.441795, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Binge eating disorder", "relevance": 0.426806, "dbpedia_resource": "http://dbpedia.org/resource/Binge_eating_disorder"}, {"text": "Novo Nordisk", "relevance": 0.388789, "dbpedia_resource": "http://dbpedia.org/resource/Novo_Nordisk"}, {"text": "Bariatric surgery", "relevance": 0.374106, "dbpedia_resource": "http://dbpedia.org/resource/Bariatric_surgery"}, {"text": "Childhood obesity", "relevance": 0.370397, "dbpedia_resource": "http://dbpedia.org/resource/Childhood_obesity"}, {"text": "Pharmaceutical drug", "relevance": 0.364505, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Research and development", "relevance": 0.35368, "dbpedia_resource": "http://dbpedia.org/resource/Research_and_development"}], "categories": [{"score": 0.966812, "label": "/health and fitness/weight loss"}, {"score": 0.884127, "label": "/health and fitness/disease/diabetes"}, {"score": 0.79033, "label": "/health and fitness/disease/heart disease"}], "relations": [{"type": "agentOf", "sentence": "Global Anti-Obesity Drugs Market: Overview, Key Trends and Regional Outlook and Competitive Landscape Snapshot The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "score": 0.982886, "arguments": [{"text": "Regional Outlook and Competitive Landscape Snapshot\nThe World Health Organization", "location": [59, 140], "entities": [{"type": "Organization", "text": "Regional Outlook and Competitive Landscape Snapshot\nThe World Health Organization"}]}, {"text": "reveals", "location": [141, 148], "entities": [{"type": "EventCommunication", "text": "reveals"}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.616998, "arguments": [{"text": "Arena Pharmaceuticals Inc.", "location": [3256, 3282], "entities": [{"type": "Organization", "text": "Arena Pharmaceuticals Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.698257, "arguments": [{"text": "Takeda Pharmaceuticals Company Limited", "location": [3284, 3322], "entities": [{"type": "Organization", "text": "Takeda Pharmaceuticals Company Limited", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.650902, "arguments": [{"text": "Zydus Cadila", "location": [3324, 3336], "entities": [{"type": "Organization", "text": "Zydus Cadila", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.536111, "arguments": [{"text": "Rhythm Pharmaceuticals", "location": [3338, 3360], "entities": [{"type": "Organization", "text": "Rhythm Pharmaceuticals", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.575669, "arguments": [{"text": "Merck & Co. Inc.", "location": [3362, 3378], "entities": [{"type": "Organization", "text": "Merck & Co. Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.593886, "arguments": [{"text": "Eisai Co. Ltd.", "location": [3380, 3394], "entities": [{"type": "Organization", "text": "Eisai Co. Ltd.", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "This gives players a greater chance of approval from regulatory bodies such as the US FDA.", "score": 0.789031, "arguments": [{"text": "bodies", "location": [3895, 3901], "entities": [{"type": "Person", "text": "players"}]}, {"text": "FDA", "location": [3917, 3920], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}]}, {"type": "partOf", "sentence": "This gives players a greater chance of approval from regulatory bodies such as the US FDA.", "score": 0.978447, "arguments": [{"text": "FDA", "location": [3917, 3920], "entities": [{"type": "Organization", "text": "FDA", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "US", "location": [3914, 3916], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "hasAttribute", "sentence": "Global Anti-Obesity Drugs Market: Overview, Key Trends and Regional Outlook and Competitive Landscape Snapshot The World Health Organization reveals that global obesity has more than doubled since 1980, with over 1.9 billion adults overweight in 2014, of which, more than 600 million were obese.", "score": 0.319923, "arguments": [{"text": "adults", "location": [225, 231], "entities": [{"type": "Person", "text": "adults"}]}, {"text": "1.9 billion", "location": [213, 224], "entities": [{"type": "Money", "text": "1.9 billion", "disambiguation": {"subtype": ["Gainloss"]}}]}]}, {"type": "partOfMany", "sentence": "An additional 42 million children below the age of five were found to be overweight or obese in 2013.", "score": 0.790442, "arguments": [{"text": "children", "location": [409, 417], "entities": [{"type": "Person", "text": "children"}]}, {"text": "five", "location": [435, 439], "entities": [{"type": "Cardinal", "text": "five"}]}]}, {"type": "residesIn", "sentence": "Based on two surveys conducted by the Centers for Disease Control and Prevention, an astounding 68.8% of the U.S. adult population is considered to be overweight or obese.", "score": 0.854872, "arguments": [{"text": "population", "location": [606, 616], "entities": [{"type": "Person", "text": "population"}]}, {"text": "U.S.", "location": [595, 599], "entities": [{"type": "GeopoliticalEntity", "text": "U.S.", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "residesIn", "sentence": "It is no surprise, then, that today, most of the world's population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.", "score": 0.663248, "arguments": [{"text": "population", "location": [715, 725], "entities": [{"type": "Person", "text": "population"}]}, {"text": "world", "location": [707, 712], "entities": [{"type": "GeopoliticalEntity", "text": "world", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "agentOf", "sentence": "It is no surprise, then, that today, most of the world's population lives in countries where obesity and overweight are claiming more lives than underweight and malnutrition.", "score": 0.666608, "arguments": [{"text": "countries", "location": [735, 744], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "claiming", "location": [778, 786], "entities": [{"type": "EventCommunication", "text": "claiming"}]}]}, {"type": "locatedAt", "sentence": "This alarming rise in the prevalence of obesity, particularly in the developed region of North America, has been single-handedly propelling the anti-obesity drugs market .", "score": 0.518882, "arguments": [{"text": "region", "location": [912, 918], "entities": [{"type": "GeopoliticalEntity", "text": "region"}]}, {"text": "North America", "location": [922, 935], "entities": [{"type": "GeopoliticalEntity", "text": "North America", "disambiguation": {"subtype": ["Area"]}}]}]}, {"type": "partOf", "sentence": "Advanced medical research by drug-manufacturing companies, medical universities and institutes, and government agencies has also substantially contributed toward the growth of the anti-obesity drugs market.", "score": 0.974634, "arguments": [{"text": "agencies", "location": [2162, 2170], "entities": [{"type": "Organization", "text": "agencies", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "government", "location": [2151, 2161], "entities": [{"type": "GeopoliticalEntity", "text": "US", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "partOfMany", "sentence": "The leading companies operating in the global anti-obesity drugs market include Boehringer Ingelheim GmbH, Arena Pharmaceuticals Inc., Takeda Pharmaceuticals Company Limited, Zydus Cadila, Rhythm Pharmaceuticals, Merck & Co. Inc., Eisai Co. Ltd., Novo Nordisk A/S, Orexigen Therapeutics Inc., Zafgen, GlaxoSmithKline PLC, Norgine B.V., Pfizer Inc., and F. Hoffmann-La Roche AG.", "score": 0.577725, "arguments": [{"text": "Boehringer Ingelheim GmbH", "location": [3229, 3254], "entities": [{"type": "Organization", "text": "Boehringer Ingelheim GmbH", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [3161, 3170], "entities": [{"type": "Organization", "text": "Companies", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Global Anti-Obesity Drugs Market", "sentiment": {"score": -0.843118, "label": "negative"}, "relevance": 0.805504, "count": 1}, {"text": "anti-obesity drugs market", "sentiment": {"score": -0.611864, "mixed": "1", "label": "negative"}, "relevance": 0.617311, "count": 3}, {"text": "Statistical data", "sentiment": {"score": 0.960632, "label": "positive"}, "relevance": 0.594564, "count": 1}, {"text": "global obesity", "sentiment": {"score": -0.843118, "label": "negative"}, "relevance": 0.591464, "count": 1}, {"text": "drug-manufacturing companies", "sentiment": {"score": 0.794426, "label": "positive"}, "relevance": 0.589787, "count": 1}, {"text": "Arena Pharmaceuticals Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.589163, "count": 1}, {"text": "medical research", "sentiment": {"score": 0.794426, "label": "positive"}, "relevance": 0.585106, "count": 1}, {"text": "obesity", "sentiment": {"score": 0.355337, "mixed": "1", "label": "positive"}, "relevance": 0.581926, "count": 2}, {"text": "World Health Organization", "sentiment": {"score": -0.843118, "label": "negative"}, "relevance": 0.577592, "count": 1}, {"text": "comprehensive research publication", "sentiment": {"score": 0.994265, "label": "positive"}, "relevance": 0.571842, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.560041, "count": 1}, {"text": "Anti-obesity drugs", "sentiment": {"score": -0.857427, "label": "negative"}, "relevance": 0.555678, "count": 1}, {"text": "development activities", "sentiment": {"score": 0.757542, "label": "positive"}, "relevance": 0.555057, "count": 1}, {"text": "healthcare expenditure", "sentiment": {"score": 0.430151, "mixed": "1", "label": "positive"}, "relevance": 0.551296, "count": 2}, {"text": "industry experts", "sentiment": {"score": 0.960632, "label": "positive"}, "relevance": 0.550274, "count": 1}, {"text": "global anti-obesity drugs market", "sentiment": {"score": 0.632032, "mixed": "1", "label": "positive"}, "relevance": 0.548921, "count": 3}, {"text": "drugs", "sentiment": {"score": -0.857427, "label": "negative"}, "relevance": 0.546957, "count": 2}, {"text": "Zydus Cadila", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542416, "count": 1}, {"text": "Takeda Pharmaceuticals Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542292, "count": 1}, {"text": "extensive research", "sentiment": {"score": 0.757542, "label": "positive"}, "relevance": 0.541653, "count": 1}, {"text": "recent years", "sentiment": {"score": -0.60248, "label": "negative"}, "relevance": 0.541417, "count": 1}, {"text": "prevalence of obesity", "sentiment": {"score": -0.93389, "label": "negative"}, "relevance": 0.540699, "count": 1}, {"text": "historical data", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54033, "count": 1}, {"text": "government agencies", "sentiment": {"score": 0.794426, "label": "positive"}, "relevance": 0.539764, "count": 1}, {"text": "report", "sentiment": {"score": 0.897161, "label": "positive"}, "relevance": 0.539628, "count": 3}, {"text": "clinical trials", "sentiment": {"score": -0.772822, "label": "negative"}, "relevance": 0.539069, "count": 1}, {"text": "global market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53652, "count": 1}, {"text": "medical condition", "sentiment": {"score": 0.757542, "label": "positive"}, "relevance": 0.536072, "count": 1}, {"text": "qualitative data", "sentiment": {"score": 0.960632, "label": "positive"}, "relevance": 0.533955, "count": 1}, {"text": "Disease Control", "sentiment": {"score": -0.694232, "label": "negative"}, "relevance": 0.532988, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.532534, "count": 1}, {"text": "North America", "sentiment": {"score": 0.757542, "label": "positive"}, "relevance": 0.531404, "count": 1}, {"text": "region of North America", "sentiment": {"score": -0.93389, "label": "negative"}, "relevance": 0.530539, "count": 1}, {"text": "Companies", "sentiment": {"score": 0.526672, "mixed": "1", "label": "positive"}, "relevance": 0.53013, "count": 2}, {"text": "obvious driving factor", "sentiment": {"score": -0.60248, "label": "negative"}, "relevance": 0.529825, "count": 1}, {"text": "funding research", "sentiment": {"score": 0.599729, "label": "positive"}, "relevance": 0.527211, "count": 1}, {"text": "market", "sentiment": {"score": -0.546618, "label": "negative"}, "relevance": 0.526975, "count": 2}, {"text": "significant force", "sentiment": {"score": -0.772822, "label": "negative"}, "relevance": 0.525285, "count": 1}, {"text": "segment", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522478, "count": 1}, {"text": "years thanks", "sentiment": {"score": 0.599729, "label": "positive"}, "relevance": 0.522367, "count": 1}, {"text": "projections", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.522125, "count": 1}, {"text": "main types", "sentiment": {"score": -0.857427, "label": "negative"}, "relevance": 0.521645, "count": 1}, {"text": "U.S. adult population", "sentiment": {"score": -0.694232, "label": "negative"}, "relevance": 0.521155, "count": 1}, {"text": "globe", "sentiment": {"score": 0.640051, "mixed": "1", "label": "positive"}, "relevance": 0.519715, "count": 2}, {"text": "overall market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519483, "count": 1}, {"text": "inputs", "sentiment": {"score": 0.960632, "label": "positive"}, "relevance": 0.519379, "count": 1}, {"text": "depth", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518742, "count": 1}, {"text": "presence of favorable reimbursement policies", "sentiment": {"score": 0.757542, "label": "positive"}, "relevance": 0.518719, "count": 1}, {"text": "population", "sentiment": {"score": 0.757542, "label": "positive"}, "relevance": 0.518498, "count": 1}, {"text": "surprise", "sentiment": {"score": -0.587609, "label": "negative"}, "relevance": 0.518461, "count": 1}]}, "extracted_metadata": {"sha1": "bdc622e19c1f211818b66fdb0a77e498e8334efb", "filename": "1543330879840.zip-d5cda78cac2565904eae4a587107b74e.xml", "file_type": "json"}, "external_links": ["http://www.transparencymarketresearch.com/anti-obesity-drugs-market.html", "http://www.transparencymarketresearch.com/sample/sample.php?flag=B&#038;rep_id=12461"], "title": "Anti-Obesity Drugs Dynamics, Segments and Supply Demand 2016 \u2013 2024", "forum_title": "Research Insights | Find Market Research - Part 67"}, {"id": "Z1r85FZ7geFiERtXyaMLJmwV7MDwycP8knqCEubLr9VJaVhBtGil4_LHHSd68jCC", "result_metadata": {"score": 35.981857}, "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dr. David Kerstein", "relevance": 0.33, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer", "relevance": 0.33, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics", "relevance": 0.33, "type": "Company"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Medicine", "relevance": 0.909247, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Physician", "relevance": 0.615714, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}], "categories": [{"score": 0.772817, "label": "/science/medicine/pharmacology"}, {"score": 0.692055, "label": "/science/medicine/oncology"}, {"score": 0.570508, "label": "/health and fitness/disease/cancer"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "score": 0.617534, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New", "disambiguation": {"subtype": ["Commercial"]}}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.955242, "count": 1}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.399959, "count": 1}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.065678, "count": 1}]}, "crawl_date": "2018-11-28T03:31:28Z", "url": "https://www.tmcnet.com/usubmit/2018/11/26/8857122.htm", "host": "tmcnet.com", "text": "Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-26T13:30:00Z", "enriched_text": {"entities": [{"count": 16, "sentiment": {"score": 0.098835, "label": "positive"}, "text": "Dr. David Kerstein", "relevance": 0.891536, "type": "Person"}, {"count": 3, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano Therapeutics Ltd.", "relevance": 0.369934, "type": "Company"}, {"count": 3, "sentiment": {"score": -0.468284, "label": "negative"}, "text": "Anchiano Therapeutics", "relevance": 0.350162, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.370547, "label": "negative"}, "text": "Anchiano Therapeutics Anchiano Therapeutics", "relevance": 0.348475, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "New Chief Medical Officer CAMBRIDGE", "relevance": 0.305009, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Oncology Clinical Research", "relevance": 0.292293, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.433481, "label": "positive"}, "text": "New Chief Medical Officer", "relevance": 0.284173, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Senior Medical Director of Clinical Research", "relevance": 0.239049, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "President and Chief Executive Officer", "relevance": 0.213288, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Clinical Research Associate", "relevance": 0.199842, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Anchiano", "relevance": 0.195958, "type": "Location", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"count": 1, "sentiment": {"score": -0.241901, "label": "negative"}, "text": "President and Chief Executive Officerinfo", "relevance": 0.19568, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Medical Director", "relevance": 0.180693, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Dainippon Sumitomo Pharma Global Oncology", "relevance": 0.172694, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.370547, "label": "negative"}, "text": "Tufts University School of Medicine", "relevance": 0.166163, "type": "Organization", "disambiguation": {"subtype": ["CollegeUniversity"], "name": "Tufts University School of Medicine", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University_School_of_Medicine"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "bladder cancer.", "relevance": 0.165452, "type": "HealthCondition"}, {"count": 1, "sentiment": {"score": 0.333462, "label": "positive"}, "text": "urinary bladder", "relevance": 0.163366, "type": "Anatomy"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mass.", "relevance": 0.158946, "type": "Location", "disambiguation": {"subtype": ["PoliticalDistrict", "AdministrativeDivision", "GovernmentalJurisdiction", "USState", "StateOrCounty"], "name": "Massachusetts", "dbpedia_resource": "http://dbpedia.org/resource/Massachusetts"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda", "relevance": 0.158776, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Tufts University", "relevance": 0.154748, "type": "Organization", "disambiguation": {"subtype": ["Location", "CollegeUniversity", "University"], "name": "Tufts University", "dbpedia_resource": "http://dbpedia.org/resource/Tufts_University"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Frank Haluska", "relevance": 0.148759, "type": "Person"}, {"count": 1, "sentiment": {"score": -0.286249, "label": "negative"}, "text": "Takeda Pharmaceuticals International Co.", "relevance": 0.147499, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ARIAD Pharmaceuticals, Inc.", "relevance": 0.144097, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.370547, "label": "negative"}, "text": "Boston Biomedical", "relevance": 0.136888, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Jerusalem", "relevance": 0.135359, "type": "Location", "disambiguation": {"subtype": ["AdministrativeDivision", "City"], "name": "Jerusalem", "dbpedia_resource": "http://dbpedia.org/resource/Jerusalem"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Israel", "relevance": 0.127434, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cambridge", "relevance": 0.12624, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "MA", "relevance": 0.121369, "type": "Location", "disambiguation": {"subtype": ["StateOrCounty"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Officerinfo@anchiano.com", "relevance": 0.121369, "type": "EmailAddress"}], "sentiment": {"document": {"score": 0.394961, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "the appointment of David Kerstein", "keywords": [{"text": "David Kerstein"}, {"text": "appointment"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "action": {"verb": {"text": "announce", "tense": "past"}, "text": "announced", "normalized": "announce"}}, {"subject": {"text": "the Company", "keywords": [{"text": "Company"}]}, "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company\u2019s new Chief Medical Officer.", "object": {"text": "new Chief Medical Officer", "keywords": [{"text": "Chief Medical Officer"}], "entities": [{"type": "JobTitle", "text": "New Chief Medical Officer CAMBRIDGE"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "an accomplished physician experienced in leading clinical drug development programs for oncology therapies", "keywords": [{"text": "oncology therapies"}, {"text": "clinical drug development"}, {"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "action": {"verb": {"text": "experience", "tense": "past"}, "text": "experienced", "normalized": "experience"}}, {"subject": {"text": "an accomplished physician", "keywords": [{"text": "accomplished physician"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein is an accomplished physician experienced in leading clinical drug development programs for oncology therapies.", "object": {"text": "clinical drug development programs", "keywords": [{"text": "clinical drug development"}, {"text": "programs"}]}, "action": {"verb": {"text": "lead", "tense": "present"}, "text": "leading", "normalized": "lead"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "David, a skilled medical lead and accomplished clinical drug strategist,", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "have", "tense": "future"}, "text": "are thrilled to have", "normalized": "be thrill to have"}}, {"subject": {"text": "Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics", "keywords": [{"text": "Chief Executive Officer"}, {"text": "Frank Haluska"}, {"text": "Anchiano Therapeutics"}, {"text": "President"}], "entities": [{"type": "Person", "text": "Frank Haluska"}, {"type": "JobTitle", "text": "President and Chief Executive Officer"}, {"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "sentence": " \u201cWe are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\u201d said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "object": {"text": "We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano", "keywords": [{"text": "clinical drug strategist"}, {"text": "skilled medical lead"}, {"text": "David"}, {"text": "team"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "We"}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "medical leadership."}, {"text": "Anchiano\u2019s mission"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "look", "tense": "present"}, "text": "look", "normalized": "look"}}, {"subject": {"text": "Anchiano\u2019s", "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}]}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "a DNA-based cancer therapy for the treatment of malignancies", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "malignancies"}, {"text": "treatment"}]}, "action": {"verb": {"text": "develop", "tense": "future"}, "text": "to develop", "normalized": "to develop"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " \u201cWe look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\u201d said Dr. Kerstein.", "object": {"text": "We look forward to his medical leadership.\u201d \u201cI am eager to contribute to Anchiano\u2019s mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder", "keywords": [{"text": "DNA-based cancer therapy"}, {"text": "urinary bladder"}, {"text": "medical leadership."}, {"text": "Anchiano\u2019s mission"}], "entities": [{"type": "Location", "text": "Anchiano", "disambiguation": {"subtype": ["City"], "name": "Vinci, Tuscany", "dbpedia_resource": "http://dbpedia.org/resource/Vinci,_Tuscany"}}, {"type": "Anatomy", "text": "urinary bladder"}]}, "action": {"verb": {"text": "say", "tense": "past"}, "text": "said", "normalized": "say"}}, {"subject": {"text": "About David Kerstein, M.D. Dr. Kerstein", "keywords": [{"text": "David Kerstein"}, {"text": "M.D."}, {"text": "Dr."}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}, {"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Ltd."}]}, "action": {"verb": {"text": "join", "tense": "present"}, "text": "joins", "normalized": "join"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "object": {"text": "as Senior Medical Director of Oncology Clinical Research", "keywords": [{"text": "Oncology Clinical Research"}, {"text": "Senior Medical Director"}], "entities": [{"type": "JobTitle", "text": "Senior Medical Director of Oncology Clinical Research"}]}, "action": {"verb": {"text": "serve", "tense": "past"}, "text": "served", "normalized": "serve"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "object": {"text": "the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib", "keywords": [{"text": "cancer clinical portfolio"}, {"text": "global clinical lead"}, {"text": "strategy lead"}, {"text": "lung"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for iitial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc.,", "keywords": [{"text": "ARIAD Pharmaceuticals"}, {"text": "Senior Medical Director"}, {"text": "Clinical Research"}], "entities": [{"type": "JobTitle", "text": "Medical Director"}, {"type": "JobTitle", "text": "Senior Medical Director of Clinical Research"}, {"type": "Company", "text": "ARIAD Pharmaceuticals, Inc."}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "he", "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for iitial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "object": {"text": "the medical lead for the brigatinib clinical development program and the medical lead for iitial New Drug Application submission and Marketing Authorization Application submission for brigatinib", "keywords": [{"text": "Marketing Authorization Application"}, {"text": "clinical development program"}, {"text": "iitial New Drug"}, {"text": "medical lead"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "was", "normalized": "be"}}, {"subject": {"text": "Dr. Kerstein", "keywords": [{"text": "Dr. Kerstein"}], "entities": [{"type": "Person", "text": "Dr. David Kerstein"}]}, "sentence": " Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "object": {"text": "his career", "keywords": [{"text": "career"}]}, "action": {"verb": {"text": "begin", "tense": "past"}, "text": "began", "normalized": "begin"}}, {"subject": {"text": "He"}, "sentence": " He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "object": {"text": "his M.D.", "keywords": [{"text": "M.D"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "About Anchiano Therapeutics Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics Anchiano Therapeutics"}]}, "sentence": " About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "object": {"text": "a clinical-stage biopharmaceutical company", "keywords": [{"text": "clinical-stage biopharmaceutical company"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Company", "keywords": [{"text": "Company"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "BC-819"}]}, "action": {"verb": {"text": "has", "tense": "present"}, "text": "s", "normalized": "s"}}, {"subject": {"text": "The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819),", "keywords": [{"text": "advanced product candidate"}, {"text": "inodiftagene vixteplasmid"}, {"text": "Company"}, {"text": "BC-819"}]}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "in development", "keywords": [{"text": "development"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Statements This press release", "keywords": [{"text": "press release"}, {"text": "Statements"}], "entities": []}, "sentence": " The Company\u2019s most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. www.anchiano.com Forward Looking Statements This press release contains \u201cforward-looking statements\u201d that are subject to risks and uncertainties.", "object": {"text": "forward-looking statements\u201d that are subject to risks and uncertainties", "keywords": [{"text": "forward-looking statements"}, {"text": "uncertainties"}, {"text": "risks"}]}, "action": {"verb": {"text": "contain", "tense": "present"}, "text": "contains", "normalized": "contain"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "action": {"verb": {"text": "be", "tense": "present"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "These forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "on information Anchiano Therapeutics", "keywords": [{"text": "information Anchiano Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "action": {"verb": {"text": "base", "tense": "past"}, "text": "are based", "normalized": "be base"}}, {"subject": {"text": "Anchiano Therapeutics", "keywords": [{"text": "Therapeutics"}], "entities": [{"type": "Company", "text": "Anchiano Therapeutics"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "information", "keywords": [{"text": "information"}]}, "action": {"verb": {"text": "have", "tense": "present"}, "text": "has", "normalized": "have"}}, {"subject": {"text": "uncertainties", "keywords": [{"text": "uncertainties"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "actual performance or results", "keywords": [{"text": "actual performance"}, {"text": "results"}]}, "action": {"verb": {"text": "cause", "tense": "future"}, "text": "could cause", "normalized": "could cause"}}, {"subject": {"text": "by the forward-looking statements", "keywords": [{"text": "forward-looking statements"}]}, "sentence": " These forward-looking statements are based on information Anchiano Therapeutics has when those statements are made or its management\u2019s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.", "object": {"text": "those"}, "action": {"verb": {"text": "suggest", "tense": "past"}, "text": "in or suggested", "normalized": "in or suggest"}}], "concepts": [{"text": "Medicine", "relevance": 0.947846, "dbpedia_resource": "http://dbpedia.org/resource/Medicine"}, {"text": "Pharmacology", "relevance": 0.937697, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical industry", "relevance": 0.733514, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_industry"}, {"text": "Drug development", "relevance": 0.707983, "dbpedia_resource": "http://dbpedia.org/resource/Drug_development"}, {"text": "New Drug Application", "relevance": 0.638234, "dbpedia_resource": "http://dbpedia.org/resource/New_Drug_Application"}, {"text": "Drug discovery", "relevance": 0.635588, "dbpedia_resource": "http://dbpedia.org/resource/Drug_discovery"}, {"text": "Clinical trial", "relevance": 0.617865, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"}, {"text": "Cancer", "relevance": 0.510251, "dbpedia_resource": "http://dbpedia.org/resource/Cancer"}, {"text": "Clinical research", "relevance": 0.473618, "dbpedia_resource": "http://dbpedia.org/resource/Clinical_research"}, {"text": "Urinary bladder", "relevance": 0.465705, "dbpedia_resource": "http://dbpedia.org/resource/Urinary_bladder"}, {"text": "Executive officer", "relevance": 0.461311, "dbpedia_resource": "http://dbpedia.org/resource/Executive_officer"}, {"text": "Chief executive officer", "relevance": 0.455796, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executive_officer"}, {"text": "Therapy", "relevance": 0.422214, "dbpedia_resource": "http://dbpedia.org/resource/Therapy"}, {"text": "Chief executives", "relevance": 0.406218, "dbpedia_resource": "http://dbpedia.org/resource/Chief_executives"}, {"text": "Drug design", "relevance": 0.386983, "dbpedia_resource": "http://dbpedia.org/resource/Drug_design"}, {"text": "Corporate governance", "relevance": 0.385892, "dbpedia_resource": "http://dbpedia.org/resource/Corporate_governance"}, {"text": "Latin honors", "relevance": 0.377249, "dbpedia_resource": "http://dbpedia.org/resource/Latin_honors"}, {"text": "Food and Drug Administration", "relevance": 0.370279, "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"}, {"text": "Management occupations", "relevance": 0.363682, "dbpedia_resource": "http://dbpedia.org/resource/Management_occupations"}, {"text": "Pharmaceutical drug", "relevance": 0.354434, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Business and financial operations occupations", "relevance": 0.342883, "dbpedia_resource": "http://dbpedia.org/resource/Business_and_financial_operations_occupations"}, {"text": "Pre-clinical development", "relevance": 0.338471, "dbpedia_resource": "http://dbpedia.org/resource/Pre-clinical_development"}, {"text": "Oncology", "relevance": 0.333924, "dbpedia_resource": "http://dbpedia.org/resource/Oncology"}, {"text": "Urology", "relevance": 0.329106, "dbpedia_resource": "http://dbpedia.org/resource/Urology"}, {"text": "Physician", "relevance": 0.322667, "dbpedia_resource": "http://dbpedia.org/resource/Physician"}, {"text": "New chemical entity", "relevance": 0.321124, "dbpedia_resource": "http://dbpedia.org/resource/New_chemical_entity"}, {"text": "Specialty", "relevance": 0.317022, "dbpedia_resource": "http://dbpedia.org/resource/Specialty_(medicine)"}, {"text": "Cancer staging", "relevance": 0.314971, "dbpedia_resource": "http://dbpedia.org/resource/Cancer_staging"}, {"text": "Doctor of Medicine", "relevance": 0.314092, "dbpedia_resource": "http://dbpedia.org/resource/Doctor_of_Medicine"}, {"text": "Bladder cancer", "relevance": 0.312243, "dbpedia_resource": "http://dbpedia.org/resource/Bladder_cancer"}], "categories": [{"score": 0.979849, "label": "/science/medicine/oncology"}, {"score": 0.930775, "label": "/health and fitness/disease/cancer"}, {"score": 0.824112, "label": "/health and fitness/therapy"}], "relations": [{"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.767675, "arguments": [{"text": "Chief Medical Officer", "location": [73, 94], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "New", "location": [69, 72], "entities": [{"type": "Organization", "text": "New Drug Application", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.799571, "arguments": [{"text": "Kerstein", "location": [1098, 1106], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "joins", "location": [1107, 1112], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}, {"type": "affectedBy", "sentence": "About David Kerstein, M.D. Dr. Kerstein joins Anchiano Therapeutics from Takeda Pharmaceuticals International Co., a global research and development-driven pharmaceutical company, where he served as Senior Medical Director of Oncology Clinical Research.", "score": 0.446124, "arguments": [{"text": "Anchiano Therapeutics", "location": [1113, 1134], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}, {"text": "joins", "location": [1107, 1112], "entities": [{"type": "EventPersonnel", "text": "joins"}]}]}, {"type": "hasAttribute", "sentence": "At Takeda, he was the lung cancer clinical portfolio strategy lead and global clinical lead for brigatinib.", "score": 0.820063, "arguments": [{"text": "he", "location": [1332, 1334], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "lung cancer", "location": [1343, 1354], "entities": [{"type": "HealthCondition", "text": "lung cancer"}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for iitial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.709676, "arguments": [{"text": "Senior Medical Director of Clinical Research", "location": [1483, 1527], "entities": [{"type": "Person", "text": "Senior Medical Director of Clinical Research"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1531, 1558], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for iitial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.385757, "arguments": [{"text": "where", "location": [1560, 1565], "entities": [{"type": "Organization", "text": "where"}]}, {"text": "ARIAD Pharmaceuticals, Inc.", "location": [1531, 1558], "entities": [{"type": "Organization", "text": "ARIAD Pharmaceuticals, Inc.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "employedBy", "sentence": "Prior to that, Dr. Kerstein was Medical Director then Senior Medical Director of Clinical Research at ARIAD Pharmaceuticals, Inc., where he was the medical lead for the brigatinib clinical development program and the medical lead for iitial New Drug Application submission and Marketing Authorization Application submission for brigatinib.", "score": 0.708832, "arguments": [{"text": "he", "location": [1566, 1568], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "where", "location": [1560, 1565], "entities": [{"type": "Organization", "text": "where"}]}]}, {"type": "partOf", "sentence": "Dr. Kerstein began his career as a Clinical Research Associate at NormaTec, a medical device company.", "score": 0.539604, "arguments": [{"text": "Clinical Research Associate", "location": [1966, 1993], "entities": [{"type": "Organization", "text": "Clinical Research Associate"}]}, {"text": "NormaTec", "location": [1997, 2005], "entities": [{"type": "Organization", "text": "NormaTec"}]}]}, {"type": "partOf", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.963007, "arguments": [{"text": "School of Medicine", "location": [2076, 2094], "entities": [{"type": "Organization", "text": "School of Medicine", "disambiguation": {"subtype": ["Educational"]}}]}, {"text": "Tufts University", "location": [2059, 2075], "entities": [{"type": "Organization", "text": "Tufts University", "disambiguation": {"subtype": ["Educational"]}}]}]}, {"type": "awardedTo", "sentence": "He received his M.D. from Tufts University School of Medicine and his B.S. in Biology, Summa Cum Laude, from Tufts University.", "score": 0.805927, "arguments": [{"text": "B.S.", "location": [2103, 2107], "entities": [{"type": "Degree", "text": "B.S."}]}, {"text": "his", "location": [2099, 2102], "entities": [{"type": "Person", "text": "David Kerstein"}]}]}, {"type": "basedIn", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.638138, "arguments": [{"text": "offices", "location": [2338, 2345], "entities": [{"type": "Organization", "text": "offices"}]}, {"text": "Cambridge", "location": [2349, 2358], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}]}, {"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.57588, "arguments": [{"text": "Chief Medical Officer", "location": [188, 209], "entities": [{"type": "Person", "text": "CAMBRIDGE"}]}, {"text": "New", "location": [184, 187], "entities": [{"type": "Organization", "text": "New Drug Application", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.984425, "arguments": [{"text": "Cambridge", "location": [2349, 2358], "entities": [{"type": "GeopoliticalEntity", "text": "Cambridge"}]}, {"text": "MA", "location": [2360, 2362], "entities": [{"type": "GeopoliticalEntity", "text": "Mass."}]}]}, {"type": "locatedAt", "sentence": "About Anchiano Therapeutics Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, with offices in Cambridge, MA, and Jerusalem, Israel.", "score": 0.977234, "arguments": [{"text": "Jerusalem", "location": [2368, 2377], "entities": [{"type": "GeopoliticalEntity", "text": "Jerusalem"}]}, {"text": "Israel", "location": [2379, 2385], "entities": [{"type": "GeopoliticalEntity", "text": "Israel"}]}]}, {"type": "employedBy", "sentence": "The Company's most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer.", "score": 0.305363, "arguments": [{"text": "candidate", "location": [2423, 2432], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [2391, 2398], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "employedBy", "sentence": "These risks and uncertainties include, but are not limited to: a lack of history of commercial sales; no anticipated earning operating income over the coming years; a dependence on the success of inodiftagene, the development of which will require significant additional clinical testing before regulatory approval can be sought and commercial sales launched; some scientific or technological difficulties that may be encountered and impede R&D activities; a need to raise substantial additional funds to complete R&D activities; the raising of additional capital may dilute holdings of our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or products; and an ability to obtain and maintain intellectual property protection for product candidates, including pursuant to licensed patents Company Contact: President and Chief Executive Officerinfo@anchiano.com", "score": 0.792256, "arguments": [{"text": "shareholders", "location": [3672, 3684], "entities": [{"type": "Person", "text": "shareholders"}]}, {"text": "our", "location": [3659, 3662], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "hasAttribute", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.87179, "arguments": [{"text": "Anchiano Therapeutics Ltd.", "location": [262, 288], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Ltd."}]}, {"text": "ANCN", "location": [296, 300], "entities": [{"type": "Ticker", "text": "ANCN"}]}]}, {"type": "timeOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.963358, "arguments": [{"text": "today", "location": [423, 428], "entities": [{"type": "Date", "text": "today"}]}, {"text": "announced", "location": [429, 438], "entities": [{"type": "EventCommunication", "text": "announced"}]}]}, {"type": "affectedBy", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.477451, "arguments": [{"text": "David Kerstein", "location": [458, 472], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "appointment", "location": [443, 454], "entities": [{"type": "EventPersonnel", "text": "appointment"}]}]}, {"type": "managerOf", "sentence": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer [November 26, 2018] Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (TASE: ANCN), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced the appointment of David Kerstein, M.D., as the Company's new Chief Medical Officer.", "score": 0.545681, "arguments": [{"text": "Chief Medical Officer", "location": [501, 522], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "Company", "location": [487, 494], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "agentOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.894571, "arguments": [{"text": "Frank Haluska", "location": [779, 792], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "said", "location": [774, 778], "entities": [{"type": "EventCommunication", "text": "said"}]}]}, {"type": "managerOf", "sentence": "\"We are thrilled to have David, a skilled medical lead and accomplished clinical drug strategist, join our team at Anchiano,\" said Frank Haluska, President and Chief Executive Officer of Anchiano Therapeutics.", "score": 0.752093, "arguments": [{"text": "Chief Executive Officer", "location": [808, 831], "entities": [{"type": "Person", "text": "Frank Haluska"}]}, {"text": "Anchiano Therapeutics", "location": [835, 856], "entities": [{"type": "Organization", "text": "Anchiano Therapeutics Announces Appointment"}]}]}, {"type": "agentOf", "sentence": "\" \"I am eager to contribute to Anchiano's mission to develop a DNA-based cancer therapy for the treatment of malignancies in the urinary bladder,\" said Dr. Kerstein.", "score": 0.898861, "arguments": [{"text": "Dr.", "location": [1053, 1056], "entities": [{"type": "Person", "text": "David Kerstein"}]}, {"text": "said", "location": [1048, 1052], "entities": [{"type": "EventCommunication", "text": "said"}]}]}], "keywords": [{"text": "Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.716923, "count": 3}, {"text": "Appointment of Dr. David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.675746, "count": 2}, {"text": "clinical-stage biopharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.659529, "count": 2}, {"text": "New Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.632607, "count": 1}, {"text": "development of novel therapies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593115, "count": 2}, {"text": "clinical drug development programs", "sentiment": {"score": 0.770762, "label": "positive"}, "relevance": 0.574976, "count": 1}, {"text": "significant additional clinical testing", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.565469, "count": 1}, {"text": "lack of history of commercial sales", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.562326, "count": 1}, {"text": "New Chief Medical Officer CAMBRIDGE", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.555321, "count": 1}, {"text": "R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.553788, "count": 1}, {"text": "advanced product candidate", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.553778, "count": 1}, {"text": "Anchiano Therapeutics Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.553099, "count": 1}, {"text": "actual performance", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.550886, "count": 1}, {"text": "regulatory approval", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.548793, "count": 1}, {"text": "skilled medical lead", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.548356, "count": 1}, {"text": "future events", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.547347, "count": 1}, {"text": "press release", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.544947, "count": 1}, {"text": "Company\u2019s new Chief Medical Officer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.542608, "count": 1}, {"text": "pharmaceutical company", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.541095, "count": 1}, {"text": "cancer therapy", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.539227, "count": 1}, {"text": "management\u2019s good faith belief", "sentiment": {"score": 0.661592, "label": "positive"}, "relevance": 0.53416, "count": 1}, {"text": "urinary bladder", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.533959, "count": 1}, {"text": "lung cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530509, "count": 1}, {"text": "substantial additional funds", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.529888, "count": 1}, {"text": "Chief Executive Officer of Anchiano Therapeutics", "sentiment": {"score": 0.845002, "label": "positive"}, "relevance": 0.529624, "count": 1}, {"text": "clinical development", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528687, "count": 1}, {"text": "clinical drug strategist", "sentiment": {"score": 0.951621, "label": "positive"}, "relevance": 0.528535, "count": 1}, {"text": "Medical Director", "sentiment": {"score": 0.470745, "label": "positive"}, "relevance": 0.52686, "count": 1}, {"text": "Takeda Pharmaceuticals International Co.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524894, "count": 1}, {"text": "appointment of David Kerstein", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524746, "count": 1}, {"text": "global research", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523083, "count": 1}, {"text": "ARIAD Pharmaceuticals", "sentiment": {"score": 0.470745, "label": "positive"}, "relevance": 0.522864, "count": 1}, {"text": "raising of additional capital", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.522585, "count": 1}, {"text": "Statements", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.521667, "count": 5}, {"text": "complete R&D activities", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.520064, "count": 1}, {"text": "clinical portfolio strategy lead", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518793, "count": 1}, {"text": "Dr. Kerstein", "sentiment": {"score": 0.643607, "label": "positive"}, "relevance": 0.517661, "count": 4}, {"text": "Tufts University", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517614, "count": 1}, {"text": "intellectual property protection", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.517138, "count": 1}, {"text": "Boston Biomedical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515612, "count": 1}, {"text": "risks", "sentiment": {"score": 0.337119, "mixed": "1", "label": "positive"}, "relevance": 0.514602, "count": 3}, {"text": "cancer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513806, "count": 2}, {"text": "uncertainties", "sentiment": {"score": 0.570817, "label": "positive"}, "relevance": 0.513681, "count": 3}, {"text": "technological difficulties", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.513125, "count": 1}, {"text": "Anchiano Therapeutics Anchiano Therapeutics", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51257, "count": 1}, {"text": "inodiftagene vixteplasmid", "sentiment": {"score": -0.782227, "label": "negative"}, "relevance": 0.512544, "count": 1}, {"text": "Tufts University School of Medicine", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510221, "count": 1}, {"text": "Anchiano\u2019s mission", "sentiment": {"score": -0.744703, "label": "negative"}, "relevance": 0.509353, "count": 1}, {"text": "development", "sentiment": {"score": -0.556767, "mixed": "1", "label": "negative"}, "relevance": 0.507482, "count": 3}, {"text": "products", "sentiment": {"score": 0.361598, "label": "positive"}, "relevance": 0.507436, "count": 1}]}, "extracted_metadata": {"sha1": "b374aa18818ad18d73ed20a1fa40afcd9f8aba69", "filename": "1543375888479.zip-99110a2842bc2f34197325ddb4ed9021.xml", "file_type": "json"}, "external_links": ["https://www.globenewswire.com/Tracker?data=q3OUTH-SpvKNYFAGYEXBpG9s_jvGxQuHF1a70sg_rqb6ydEDpoNvVBYbhB0APsvFMzEujK3mQjie069OmmyGYg=="], "title": "Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer", "forum_title": "TMCnet.com RSS Service: Medical Devices"}, {"id": "zXjya4RQhKw_plBBgUN5tappPAmE-D-ZS33XNvIGR8QProdAdu2bqzT2JEsP21Um", "result_metadata": {"score": 35.569614}, "author": "www.4-traders.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical", "relevance": 0.33, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [], "concepts": [{"text": "Takeda Pharmaceutical Company", "relevance": 0.91136, "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}], "categories": [{"score": 0.93119, "label": "/business and industrial/pharmaceutical industry"}], "relations": [], "keywords": [{"text": "Takeda Pharmaceutical", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.950288, "count": 1}, {"text": "Shire", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.937512, "count": 1}, {"text": "Form", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.812132, "count": 1}]}, "crawl_date": "2018-11-27T21:50:06Z", "url": "http://www.4-traders.com/SHIRE-9590198/news/Shire-Form-8-3-Takeda-Pharmaceutical-27669567/", "host": "4-traders.com", "text": "(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Takeda Pharmaceutical Co Ltd (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: n/a (e) Date position held/dealing undertaken: For an opening", "country": "FR", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T00:00:00+01:00", "enriched_text": {"entities": [{"count": 6, "sentiment": {"score": 0, "label": "neutral"}, "text": "UBS Asset Management", "relevance": 0.747522, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.460261, "label": "positive"}, "text": "UBS La Maison de Gestion", "relevance": 0.411149, "type": "Facility"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UBS AG", "relevance": 0.381523, "type": "Company", "disambiguation": {"subtype": [], "name": "UBS", "dbpedia_resource": "http://dbpedia.org/resource/UBS"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Shire plc", "relevance": 0.361448, "type": "Company", "disambiguation": {"subtype": [], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeda Pharmaceutical Co Ltd", "relevance": 0.309341, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "fund manager", "relevance": 0.278923, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "trustee", "relevance": 0.272287, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Mr James Mortimer", "relevance": 0.267345, "type": "Person", "disambiguation": {"subtype": [], "name": "James Mortimer", "dbpedia_resource": "http://dbpedia.org/resource/James_Mortimer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Takeover Panel", "relevance": 0.261577, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0.389935, "label": "positive"}, "text": "Hong Kong", "relevance": 0.260891, "type": "Location", "disambiguation": {"subtype": ["HumanLanguage", "AdministrativeDivision", "Country", "GovernmentalJurisdiction", "BodyOfWater", "Cuisine", "City"], "name": "Hong Kong", "dbpedia_resource": "http://dbpedia.org/resource/Hong_Kong"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Singapore) Ltd", "relevance": 0.258633, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Australia) Ltd", "relevance": 0.256343, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Switzerland", "relevance": 0.254267, "type": "Location", "disambiguation": {"subtype": ["Country"], "name": "Switzerland", "dbpedia_resource": "http://dbpedia.org/resource/Switzerland"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Regulatory Information Service", "relevance": 0.244687, "type": "JobTitle"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Taiwan) Ltd", "relevance": 0.221175, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "UK) Ltd", "relevance": 0.217857, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "monitoring@disclosure.org.uk", "relevance": 0.217857, "type": "EmailAddress"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1%", "relevance": 0.217857, "type": "Quantity"}], "sentiment": {"document": {"score": 0.44913, "label": "positive"}}, "semantic_roles": [{"subject": {"text": "PUBLIC OPENING POSITION", "keywords": [{"text": "PUBLIC OPENING POSITION"}]}, "sentence": " PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY", "object": {"text": "DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "DISCLOSURE/DEALING", "tense": "present"}, "text": "DISCLOSURE/DEALING", "normalized": "DISCLOSURE/DEALING"}}, {"subject": {"text": "a separate form", "keywords": [{"text": "separate form"}]}, "sentence": " Use a separate form for each offeror/offeree", "object": {"text": "for each offeror/offeree", "keywords": [{"text": "offeror/offeree"}]}, "action": {"verb": {"text": "Use", "tense": "present"}, "text": "Use", "normalized": "Use"}}, {"subject": {"text": "an exempt fund manager", "keywords": [{"text": "exempt fund manager"}], "entities": [{"type": "JobTitle", "text": "fund manager"}]}, "sentence": " (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:", "object": {"text": "identity of offeror/offeree", "keywords": [{"text": "identity"}, {"text": "offeror/offeree"}]}, "action": {"verb": {"text": "specify", "tense": "present"}, "text": "specify", "normalized": "specify"}}, {"subject": {"text": "(f) In addition to the company in 1(c) above,", "keywords": [{"text": "addition"}, {"text": "company"}]}, "sentence": " (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?", "object": {"text": "the discloser making disclosures", "keywords": [{"text": "disclosures"}, {"text": "discloser"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "it"}, "sentence": " If it is a cash offer or possible cash offer, state 'N/A'", "object": {"text": "a cash offer or possible cash offer", "keywords": [{"text": "possible cash offer"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.", "object": {"text": "in 1"}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "sentence": " (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)", "object": {"text": "following the dealing", "keywords": [{"text": "dealing"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relates", "normalized": "relate"}}, {"subject": {"text": "options) and agreements to purchase/sell", "keywords": [{"text": "agreements"}, {"text": "options"}]}, "sentence": " (3) Stock-settled derivatives (including options) and agreements to purchase/sell:", "object": {"text": "Stock-settled derivatives", "keywords": [{"text": "Stock-settled derivatives"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "All interests and all short positions", "keywords": [{"text": "short positions"}, {"text": "interests"}]}, "sentence": " All interests and all short positions should be disclosed.", "object": {"text": "disclosed"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "traded options), or agreements to purchase or sell relevant securities", "keywords": [{"text": "relevant securities"}, {"text": "agreements"}, {"text": "options"}]}, "sentence": " Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).", "object": {"text": "any open stock-settled derivative positions", "keywords": [{"text": "stock-settled derivative positions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "directors' and other employee options", "keywords": [{"text": "employee options"}, {"text": "directors"}]}, "sentence": " (b) Rights to subscribe for new securities (including directors' and other employee options)", "object": {"text": "new securities", "keywords": [{"text": "new securities"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "nature of the rights concerned and relevant percentages", "keywords": [{"text": "relevant percentages"}, {"text": "nature"}, {"text": "rights"}]}, "sentence": " Details, including nature of the rights concerned and relevant percentages:", "object": {"text": "Details", "keywords": [{"text": "Details"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "THE PERSON", "keywords": [{"text": "PERSON"}]}, "sentence": " 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE", "object": {"text": "THE DISCLOSURE", "keywords": [{"text": "DISCLOSURE"}]}, "action": {"verb": {"text": "MAKING", "tense": "present"}, "text": "MAKING", "normalized": "MAKING"}}, {"subject": {"text": "offeree", "keywords": [{"text": "offeree"}]}, "sentence": " Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.", "object": {"text": "in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate)", "keywords": [{"text": "copy table"}]}, "action": {"verb": {"text": "name", "tense": "past"}, "text": "named", "normalized": "name"}}, {"subject": {"text": "The currency of all prices and other monetary amounts", "keywords": [{"text": "monetary amounts"}, {"text": "currency"}, {"text": "prices"}]}, "sentence": " The currency of all prices and other monetary amounts should be stated.", "object": {"text": "stated"}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "options", "keywords": [{"text": "options"}]}, "sentence": " (c) Stock-settled derivative transactions (including options)", "object": {"text": "(c) Stock-settled derivative transactions", "keywords": [{"text": "Stock-settled derivative transactions"}]}, "action": {"verb": {"text": "include", "tense": "present"}, "text": "including", "normalized": "include"}}, {"subject": {"text": "paid/", "keywords": [{"text": "paid/"}]}, "sentence": " Option money paid/ received per unit", "object": {"text": "Option money", "keywords": [{"text": "Option money"}]}, "action": {"verb": {"text": "receive", "tense": "past"}, "text": "received", "normalized": "receive"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "the disclosure and any party", "keywords": [{"text": "disclosure"}, {"text": "party"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "any person", "keywords": [{"text": "person"}]}, "sentence": " Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:", "object": {"text": "with a party", "keywords": [{"text": "party"}]}, "action": {"verb": {"text": "act", "tense": "present"}, "text": "acting", "normalized": "act"}}, {"subject": {"text": "understandings", "keywords": [{"text": "understandings"}]}, "sentence": " (b) Agreements, arrangements or understandings relating to options or derivatives", "object": {"text": "to options or derivatives", "keywords": [{"text": "derivatives"}, {"text": "options"}]}, "action": {"verb": {"text": "relate", "tense": "present"}, "text": "relating", "normalized": "relate"}}, {"subject": {"text": "the person", "keywords": [{"text": "person"}]}, "sentence": " Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:", "object": {"text": "the disclosure", "keywords": [{"text": "disclosure"}]}, "action": {"verb": {"text": "make", "tense": "present"}, "text": "making", "normalized": "make"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to a Regulatory Information Service", "keywords": [{"text": "Regulatory Information Service"}], "entities": [{"type": "JobTitle", "text": "Regulatory Information Service"}]}, "action": {"verb": {"text": "make", "tense": "future"}, "text": "must be made", "normalized": "must be make"}}, {"subject": {"text": "Public disclosures", "keywords": [{"text": "Public disclosures"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "emailed to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "Public disclosures under Rule 8 of the Code", "keywords": [{"text": "Rule"}, {"text": "Public"}, {"text": "Code"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "to the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "email", "tense": "future"}, "text": "must also be emailed", "normalized": "must also be email"}}, {"subject": {"text": "the Takeover Panel", "keywords": [{"text": "Takeover Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "object": {"text": "@disclosure.org.uk", "entities": [{"type": "TwitterHandle", "text": "@disclosure"}]}, "action": {"verb": {"text": "monitor", "tense": "future"}, "text": "monitoring", "normalized": "monitor"}}, {"subject": {"text": "The Panel's Market Surveillance Unit", "keywords": [{"text": "Market Surveillance Unit"}, {"text": "Panel"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "sentence": " The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "object": {"text": "available for consultation", "keywords": [{"text": "consultation"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "viewed on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "be", "tense": "future"}, "text": "be", "normalized": "be"}}, {"subject": {"text": "The Code", "keywords": [{"text": "Code"}]}, "sentence": " The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "object": {"text": "on the Panel's website at www.thetakeoverpanel.org.uk", "keywords": [{"text": "Panel"}, {"text": "www.thetakeoverpanel.org.uk"}], "entities": [{"type": "JobTitle", "text": "Takeover Panel"}]}, "action": {"verb": {"text": "view", "tense": "future"}, "text": "can be viewed", "normalized": "can be view"}}, {"subject": {"text": "UBS", "keywords": [{"text": "UBS"}], "entities": [{"type": "Company", "text": "UBS Asset Management"}]}, "sentence": " UBS Asset Management (Americas) Inc.", "object": {"text": "Management", "keywords": [{"text": "Management"}]}, "action": {"verb": {"text": "Asset", "tense": "present"}, "text": "Asset", "normalized": "Asset"}}, {"subject": {"text": "UBS", "keywords": [{"text": "UBS"}], "entities": [{"type": "Company", "text": "UBS Asset Management"}]}, "sentence": " UBS Asset Management (Taiwan) Ltd", "object": {"text": "Management", "keywords": [{"text": "Management"}]}, "action": {"verb": {"text": "Asset", "tense": "present"}, "text": "Asset", "normalized": "Asset"}}, {"subject": {"text": "Shire plc", "keywords": [{"text": "Shire plc"}], "entities": [{"type": "Company", "text": "Shire plc", "disambiguation": {"subtype": ["Company"], "name": "Shire plc", "dbpedia_resource": "http://dbpedia.org/resource/Shire_plc"}}]}, "sentence": " Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "object": {"text": "this content", "keywords": [{"text": "content"}]}, "action": {"verb": {"text": "publish", "tense": "past"}, "text": "published", "normalized": "publish"}}, {"subject": {"text": "by Public", "keywords": [{"text": "Public"}]}, "sentence": " Distributed by Public, unedited and unaltered, on 27 November 2018 17:00:06 UTC", "object": {"text": "06 UTC", "keywords": [{"text": "UTC"}]}, "action": {"verb": {"text": "Distributed", "tense": "past"}, "text": "Distributed", "normalized": "Distributed"}}], "concepts": [{"text": "Option", "relevance": 0.97322, "dbpedia_resource": "http://dbpedia.org/resource/Option_(finance)"}, {"text": "Stock", "relevance": 0.672099, "dbpedia_resource": "http://dbpedia.org/resource/Stock"}, {"text": "Call option", "relevance": 0.506097, "dbpedia_resource": "http://dbpedia.org/resource/Call_option"}, {"text": "Strike price", "relevance": 0.489015, "dbpedia_resource": "http://dbpedia.org/resource/Strike_price"}, {"text": "Offer and acceptance", "relevance": 0.468191, "dbpedia_resource": "http://dbpedia.org/resource/Offer_and_acceptance"}, {"text": "Contract", "relevance": 0.443117, "dbpedia_resource": "http://dbpedia.org/resource/Contract"}, {"text": "Put option", "relevance": 0.411364, "dbpedia_resource": "http://dbpedia.org/resource/Put_option"}, {"text": "Stock market", "relevance": 0.408742, "dbpedia_resource": "http://dbpedia.org/resource/Stock_market"}, {"text": "Bond", "relevance": 0.395856, "dbpedia_resource": "http://dbpedia.org/resource/Bond_(finance)"}, {"text": "Unit type", "relevance": 0.389499, "dbpedia_resource": "http://dbpedia.org/resource/Unit_type"}, {"text": "Grammatical number", "relevance": 0.388737, "dbpedia_resource": "http://dbpedia.org/resource/Grammatical_number"}, {"text": "UBS AG", "relevance": 0.38104, "dbpedia_resource": "http://dbpedia.org/resource/UBS_AG"}, {"text": "Balance sheet", "relevance": 0.380723, "dbpedia_resource": "http://dbpedia.org/resource/Balance_sheet"}, {"text": "Security", "relevance": 0.379921, "dbpedia_resource": "http://dbpedia.org/resource/Security"}, {"text": "Option contract", "relevance": 0.364042, "dbpedia_resource": "http://dbpedia.org/resource/Option_contract"}], "categories": [{"score": 0.930388, "label": "/real estate/buying and selling homes"}, {"score": 0.889402, "label": "/finance/financial news"}, {"score": 0.742819, "label": "/finance/investing"}], "relations": [{"type": "agentOf", "sentence": "JPY TOTAL PURCHASE 3,200 TOTAL SALE 42,800 (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit (d) Other dealings (including subscribing for new securities)", "score": 0.726237, "arguments": [{"text": "i", "location": [3284, 3285], "entities": [{"type": "Person", "text": "Cash"}]}, {"text": "Writing", "location": [3287, 3294], "entities": [{"type": "EventCommunication", "text": "Writing"}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.853891, "arguments": [{"text": "UBS La Maison", "location": [5835, 5848], "entities": [{"type": "Organization", "text": "UBS La Maison"}]}, {"text": "Ltd", "location": [5831, 5834], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.347201, "arguments": [{"text": "UBS La Maison", "location": [5835, 5848], "entities": [{"type": "Organization", "text": "UBS La Maison"}]}, {"text": "Shire plc", "location": [5911, 5920], "entities": [{"type": "Organization", "text": "Shire plc\n2", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.892896, "arguments": [{"text": "Shire plc", "location": [5911, 5920], "entities": [{"type": "Organization", "text": "Shire plc\n2", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "published", "location": [5921, 5930], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "timeOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.589486, "arguments": [{"text": "November 2018", "location": [5950, 5963], "entities": [{"type": "Date", "text": "November 2018"}]}, {"text": "published", "location": [5921, 5930], "entities": [{"type": "EventCommunication", "text": "published"}]}]}, {"type": "participantIn", "sentence": "OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included.", "score": 0.346909, "arguments": [{"text": "person", "location": [4258, 4264], "entities": [{"type": "Person", "text": "person"}]}, {"text": "concert", "location": [4275, 4282], "entities": [{"type": "EventPerformance", "text": "concert"}]}]}, {"type": "employedBy", "sentence": "NO Date of disclosure: 27/11/2018 Contact name: Mr James Mortimer Telephone number: +44 20 7901 5828 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk .", "score": 0.771737, "arguments": [{"text": "Rule 8", "location": [5156, 5162], "entities": [{"type": "Person", "text": "Rule 8"}]}, {"text": "Code", "location": [5170, 5174], "entities": [{"type": "Organization", "text": "Takeover Code"}]}]}, {"type": "partOf", "sentence": "The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.", "score": 0.799125, "arguments": [{"text": "Market Surveillance Unit", "location": [5317, 5341], "entities": [{"type": "Organization", "text": "Market Surveillance Unit", "disambiguation": {"subtype": ["Government"]}}]}, {"text": "Panel", "location": [5309, 5314], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}]}, {"type": "hasAttribute", "sentence": "The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .", "score": 0.680057, "arguments": [{"text": "Panel", "location": [5484, 5489], "entities": [{"type": "Organization", "text": "Takeover Panel"}]}, {"text": "www.thetakeoverpanel.org.uk", "location": [5503, 5530], "entities": [{"type": "Web", "text": "www.thetakeoverpanel.org.uk"}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.759194, "arguments": [{"text": "UBS Asset Management", "location": [5693, 5713], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Ltd", "location": [5689, 5692], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.706849, "arguments": [{"text": "UBS Asset Management", "location": [5771, 5791], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Ltd", "location": [5767, 5770], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "partOf", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.652445, "arguments": [{"text": "UBS Asset Management", "location": [5805, 5825], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Ltd", "location": [5801, 5804], "entities": [{"type": "Organization", "text": "Takeda Pharmaceutical Co Ltd", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "basedIn", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.448075, "arguments": [{"text": "UBS Asset Management", "location": [5693, 5713], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Hong Kong", "location": [5715, 5724], "entities": [{"type": "GeopoliticalEntity", "text": "Hong Kong"}]}]}, {"type": "locatedAt", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.510206, "arguments": [{"text": "UBS Asset Management", "location": [5734, 5754], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Singapore", "location": [5756, 5765], "entities": [{"type": "GeopoliticalEntity", "text": "Singapore", "disambiguation": {"subtype": ["Country"]}}]}]}, {"type": "locatedAt", "sentence": "* this report is on behalf of: UBS AG (UBS Asset Management operating in Switzerland) UBS Asset Management (Americas) Inc. UBS Asset Management (Australia) Ltd UBS Asset Management (Hong Kong) Limited UBS Asset Management (Singapore) Ltd UBS Asset Management (Taiwan) Ltd UBS Asset Management (UK) Ltd UBS La Maison de Gestion Attachments Original document Permalink Disclaimer Shire plc published this content on 27 November 2018 and is solely responsible for the information contained herein.", "score": 0.534413, "arguments": [{"text": "UBS Asset Management", "location": [5771, 5791], "entities": [{"type": "Organization", "text": "UBS Asset Management *"}]}, {"text": "Taiwan", "location": [5793, 5799], "entities": [{"type": "GeopoliticalEntity", "text": "Taiwan", "disambiguation": {"subtype": ["Country"]}}]}]}], "keywords": [{"text": "UBS Asset Management", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.920328, "count": 3}, {"text": "UBS AG", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.850166, "count": 1}, {"text": "Exercise price", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.675284, "count": 1}, {"text": "RELEVANT SECURITIES", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.6607, "count": 5}, {"text": "PUBLIC OPENING POSITION DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.644338, "count": 1}, {"text": "Details of any open stock", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.610968, "count": 1}, {"text": "class of relevant securities of the offeror", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.567172, "count": 2}, {"text": "Full name of discloser", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.561763, "count": 1}, {"text": "cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.559453, "count": 1}, {"text": "Takeover Code", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.553554, "count": 1}, {"text": "Name of offeror", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548248, "count": 1}, {"text": "short positions", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.54385, "count": 3}, {"text": "DEALING DISCLOSURE", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.540064, "count": 1}, {"text": "additional class of relevant security", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.534569, "count": 2}, {"text": "Takeover Panel", "sentiment": {"score": -0.57699, "label": "negative"}, "relevance": 0.534545, "count": 1}, {"text": "possible cash offer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530399, "count": 1}, {"text": "voting rights", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.529456, "count": 1}, {"text": "exempt fund manager", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529063, "count": 1}, {"text": "Shire plc", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.525951, "count": 1}, {"text": "copy table", "sentiment": {"score": 0.781083, "label": "positive"}, "relevance": 0.522531, "count": 2}, {"text": "voting rights of any relevant securities", "sentiment": {"score": 0.857384, "label": "positive"}, "relevance": 0.521521, "count": 1}, {"text": "Panel's Market Surveillance Unit", "sentiment": {"score": -0.531215, "label": "negative"}, "relevance": 0.518409, "count": 1}, {"text": "Hong Kong", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517855, "count": 1}, {"text": "naming of nominee", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.517099, "count": 1}, {"text": "option arrangement", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.517074, "count": 1}, {"text": "PERSON", "sentiment": {"score": 0.569891, "label": "positive"}, "relevance": 0.515682, "count": 6}, {"text": "offer", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.515273, "count": 3}, {"text": "options", "sentiment": {"score": 0.380708, "mixed": "1", "label": "positive"}, "relevance": 0.514896, "count": 4}, {"text": "rights", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.514228, "count": 2}, {"text": "agreements", "sentiment": {"score": 0.467804, "label": "positive"}, "relevance": 0.514071, "count": 3}, {"text": "opening position disclosure", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513585, "count": 1}, {"text": "Irrevocable commitments", "sentiment": {"score": 0.853519, "label": "positive"}, "relevance": 0.513532, "count": 1}, {"text": "Date position", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.513288, "count": 1}, {"text": "Details", "sentiment": {"score": 0.763796, "label": "positive"}, "relevance": 0.512011, "count": 1}, {"text": "Owner", "sentiment": {"score": -0.860723, "label": "negative"}, "relevance": 0.511472, "count": 1}, {"text": "Regulatory Information Service", "sentiment": {"score": -0.57699, "label": "negative"}, "relevance": 0.511374, "count": 1}, {"text": "Public disclosures", "sentiment": {"score": -0.57699, "label": "negative"}, "relevance": 0.510584, "count": 1}, {"text": "POSITIONS OF THE PERSON", "sentiment": {"score": 0.895689, "label": "positive"}, "relevance": 0.51055, "count": 1}, {"text": "Supplemental Form", "sentiment": {"score": 0.688082, "label": "positive"}, "relevance": 0.510492, "count": 2}, {"text": "trust", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510149, "count": 1}, {"text": "INTERESTS", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.509896, "count": 3}, {"text": "Stock", "sentiment": {"score": -0.737533, "label": "negative"}, "relevance": 0.509807, "count": 2}, {"text": "currency of all prices", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509481, "count": 1}, {"text": "Rule", "sentiment": {"score": -0.57699, "label": "negative"}, "relevance": 0.509046, "count": 1}, {"text": "derivatives", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508948, "count": 2}, {"text": "state", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50886, "count": 1}, {"text": "FORM", "sentiment": {"score": 0.494736, "label": "positive"}, "relevance": 0.508739, "count": 2}, {"text": "Code", "sentiment": {"score": -0.329166, "mixed": "1", "label": "negative"}, "relevance": 0.508243, "count": 3}, {"text": "Purchases", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508124, "count": 1}, {"text": "Open Positions", "sentiment": {"score": 0.593322, "mixed": "1", "label": "positive"}, "relevance": 0.507883, "count": 2}]}, "extracted_metadata": {"sha1": "e623ee0d9279f78e8f21db5677a6c818f315bbc2", "filename": "1543355406412.zip-d0ac8211543a11da4b375055fc7325b1.xml", "file_type": "json"}, "external_links": ["http://www.publicnow.com/view/11E50390E1ED08962C9016F9B8C8305744BB0B69", "http://otp.investis.com/clients/uk/shire/rns1/regulatory-story.aspx?cid=1027&newsid=1210356"], "title": "Shire : Form 8.3 - Takeda Pharmaceutical", "forum_title": "F100 Stock Quote | FTSE 100 Index Stock Price () | Autre: F100 | MarketScreener"}, {"id": "8phr0aBnrzRdPHMW9Dx5zSgLZYJdDqw7sDVSWsKKUcv4-xAAxb2-uN_m1_oZg2El", "result_metadata": {"score": 35.196884}, "author": "Reportlinker", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.70228, "label": "negative"}, "text": "GERD", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": "The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027", "object": {"text": "at a CAGR of 1.12%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}], "concepts": [{"text": "Years in the future", "relevance": 0.842933, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Trade", "relevance": 0.772153, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}], "categories": [{"score": 0.801654, "label": "/health and fitness"}, {"score": 0.703212, "label": "/health and fitness/drugs"}, {"score": 0.69663, "label": "/technology and computing/operating systems"}], "relations": [], "keywords": [{"text": "global GERD drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997422, "count": 1}, {"text": "devices market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27244, "count": 1}, {"text": "CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.006855, "count": 1}]}, "crawl_date": "2018-11-28T00:07:00Z", "url": "https://www.prnewswire.com/news-releases/the-global-gerd-drug-and-devices-market-has-been-predicted-to-grow-at-a-cagr-of-1-12-between-2019-and-2027--300756204.html", "host": "prnewswire.com", "text": "Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T23:06:00-06:00", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.695673, "label": "negative"}, "text": "GERD", "relevance": 0.915242, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.374062, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.325553, "label": "negative"}, "text": "TAKEDA PHARMACEUTICALS", "relevance": 0.363916, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.35176, "type": "Organization", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"count": 1, "sentiment": {"score": -0.501076, "label": "negative"}, "text": "IRONWOOD PHARMACEUTICALS", "relevance": 0.315002, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EISAI INC", "relevance": 0.305516, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Scientific Corporation", "relevance": 0.297117, "type": "Company", "disambiguation": {"subtype": [], "name": "Boston Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.29302, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.273431, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": -0.317572, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.263761, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.374397, "label": "negative"}, "text": "Ironwood Pharmaceuticals, Inc.", "relevance": 0.258105, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RAQUALIA PHARMA INC.", "relevance": 0.253029, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PFIZER", "relevance": 0.251739, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.24702, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.244347, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cempra Inc.", "relevance": 0.235651, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.682633, "label": "negative"}, "text": "NEW YORK", "relevance": 0.231966, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0.402725, "label": "positive"}, "text": "Reportlinker", "relevance": 0.230954, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.493582, "label": "positive"}, "text": "JOHNSON", "relevance": 0.22662, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.223839, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ABBOTT LABORATORIES.", "relevance": 0.220237, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.216167, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "DAEWOONG CO. LTD.", "relevance": 0.203145, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.20073, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.532507, "label": "negative"}, "text": "Europe", "relevance": 0.199948, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.51678, "label": "positive"}, "text": "BAUSCH HEALTH", "relevance": 0.198551, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glaxosmithkline", "relevance": 0.197322, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "RaQualia Pharma Inc.", "relevance": 0.189547, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.17842, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.175768, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.339071, "label": "positive"}, "text": "Ausch Health", "relevance": 0.162674, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.364755, "label": "positive"}, "text": "Melinta", "relevance": 0.161595, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daewoong Co. Ltd.", "relevance": 0.161473, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Inc.", "relevance": 0.161311, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.161311, "type": "Quantity"}], "sentiment": {"document": {"score": -0.393745, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "NEW YORK KEY INSIGHTS Gastro-esophageal reflux disease (GERD)", "keywords": [{"text": "INSIGHTS Gastro-esophageal reflux"}, {"text": "GERD"}], "entities": [{"type": "Location", "text": "NEW YORK", "disambiguation": {"subtype": ["City"]}}, {"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": "NEW YORK KEY INSIGHTS Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing", "keywords": [{"text": "chronic digestive disorder"}, {"text": "complications"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the esophagus.The market", "keywords": [{"text": "esophagus.The market"}]}, "sentence": "NEW YORK KEY INSIGHTS Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "the drugs and devices required for its optimized cure and accurate diagnosis respectively", "keywords": [{"text": "optimized cure"}, {"text": "accurate diagnosis"}, {"text": "drugs"}, {"text": "devices"}]}, "action": {"verb": {"text": "produce", "tense": "present"}, "text": "producing and distributing", "normalized": "produce and distribute"}}, {"subject": {"text": "https://www.reportlinker.com/p05626023 The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " Read the full report: https://www.reportlinker.com/p05626023 The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027.", "object": {"text": "at a CAGR of 1.12% between 2019 and 2027", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}, {"subject": {"text": "MARKET", "keywords": [{"text": "MARKET"}]}, "sentence": " MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "The causes", "keywords": [{"text": "causes"}]}, "action": {"verb": {"text": "INSIGHTS", "tense": "present"}, "text": "INSIGHTS", "normalized": "INSIGHTS"}}, {"subject": {"text": "MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market", "keywords": [{"text": "GERD drug"}, {"text": "devices market"}, {"text": "causes"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents", "keywords": [{"text": "GERD disorders"}, {"text": "self-medication"}, {"text": "prominence"}, {"text": "trend"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "other drugs for its cure", "keywords": [{"text": "drugs"}, {"text": "cure"}]}, "sentence": " MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the majorly hampering the GERD Drug and devices market", "keywords": [{"text": "GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is segmented by dosage form and by administration of the drugs.", "object": {"text": "segmented by dosage form and by administration of the drugs", "keywords": [{"text": "dosage form"}, {"text": "drugs"}, {"text": "administration"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "REGIONAL INSIGHTS The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "REGIONAL INSIGHTS"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "REGIONAL INSIGHTS The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "REGIONAL INSIGHTS"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "action": {"verb": {"text": "spread", "tense": "past"}, "text": "is spread", "normalized": "be spread"}}, {"subject": {"text": "the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "proclaimed as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Latin America"}, {"text": "Middle East"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "proclaim", "tense": "past"}, "text": "has been proclaimed", "normalized": "have be proclaim"}}, {"subject": {"text": "The rise in the incidence of GERD in North American countries", "keywords": [{"text": "North American countries"}, {"text": "GERD"}, {"text": "incidence"}, {"text": "rise"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "responsible for the increase", "keywords": [{"text": "increase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "acid reducing and neutralizing drugs", "keywords": [{"text": "acid"}, {"text": "drugs"}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "is proliferating", "normalized": "be proliferate"}}, {"subject": {"text": "COMPETITIVE INSIGHTS Product launch", "keywords": [{"text": "INSIGHTS Product launch"}]}, "sentence": " COMPETITIVE INSIGHTS Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "primary strategy"}, {"text": "competitive edge"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the various market companies of the global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " COMPETITIVE INSIGHTS Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy", "keywords": [{"text": "primary strategy"}]}, "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "adopted", "normalized": "adopt"}}, {"subject": {"text": "Reportlinker", "keywords": [{"text": "Reportlinker"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "the latest industry data", "keywords": [{"text": "latest industry data"}]}, "action": {"verb": {"text": "organize", "tense": "present"}, "text": "organizes", "normalized": "organize"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research you need", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}], "concepts": [{"text": "Gastroesophageal reflux disease", "relevance": 0.946635, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "North America", "relevance": 0.945384, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacology", "relevance": 0.880327, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.753433, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Boston Scientific", "relevance": 0.722141, "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}, {"text": "Abbott Laboratories", "relevance": 0.709396, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}, {"text": "Drug", "relevance": 0.682103, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Pharmaceutical drug", "relevance": 0.649901, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Lansoprazole", "relevance": 0.645647, "dbpedia_resource": "http://dbpedia.org/resource/Lansoprazole"}, {"text": "Asthma", "relevance": 0.60331, "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}, {"text": "Ribavirin", "relevance": 0.585177, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Multinational companies", "relevance": 0.575745, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Valeant Pharmaceuticals International", "relevance": 0.57439, "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals_International"}, {"text": "Americas", "relevance": 0.569729, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Guidant", "relevance": 0.565544, "dbpedia_resource": "http://dbpedia.org/resource/Guidant"}, {"text": "Omeprazole", "relevance": 0.558727, "dbpedia_resource": "http://dbpedia.org/resource/Omeprazole"}, {"text": "Cough", "relevance": 0.552311, "dbpedia_resource": "http://dbpedia.org/resource/Cough"}, {"text": "United States", "relevance": 0.551592, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Esomeprazole", "relevance": 0.55099, "dbpedia_resource": "http://dbpedia.org/resource/Esomeprazole"}, {"text": "Johnson & Johnson", "relevance": 0.529405, "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}, {"text": "Latin America", "relevance": 0.528351, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}], "categories": [{"score": 0.971463, "label": "/health and fitness/disease/gerd and acid reflux"}, {"score": 0.833079, "label": "/health and fitness/drugs"}, {"score": 0.79767, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "locatedAt", "sentence": "The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "score": 0.800802, "arguments": [{"text": "countries", "location": [1238, 1247], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "North American", "location": [1223, 1237], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.382199, "arguments": [{"text": "Abbott Laboratories", "location": [1624, 1643], "entities": [{"type": "Organization", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1595, 1604], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.644268, "arguments": [{"text": "AstraZeneca", "location": [1645, 1656], "entities": [{"type": "Organization", "text": "AstraZeneca", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1595, 1604], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOf", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.467352, "arguments": [{"text": "Melinta", "location": [1783, 1790], "entities": [{"type": "Organization", "text": "MELINTA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merged", "location": [1771, 1777], "entities": [{"type": "Organization", "text": "CEMPRA INC.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Companies mentioned 1.", "score": 0.852976, "arguments": [{"text": "Companies", "location": [1999, 2008], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "mentioned", "location": [2009, 2018], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "basedIn", "sentence": "BOSTON SCIENTIFIC CORPORATION 5.", "score": 0.883816, "arguments": [{"text": "SCIENTIFIC CORPORATION 5", "location": [2140, 2164], "entities": [{"type": "Organization", "text": "SCIENTIFIC CORPORATION 5"}]}, {"text": "BOSTON", "location": [2133, 2139], "entities": [{"type": "GeopoliticalEntity", "text": "BOSTON"}]}]}, {"type": "hasAttribute", "sentence": "IRONWOOD PHARMACEUTICALS, INC. 10.", "score": 0.192369, "arguments": [{"text": "PHARMACEUTICALS, INC.", "location": [2265, 2286], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS, INC."}]}, {"text": "10", "location": [2287, 2289], "entities": [{"type": "Age", "text": "10"}]}]}, {"type": "hasAttribute", "sentence": "RAQUALIA PHARMA INC. 15.", "score": 0.178778, "arguments": [{"text": "INC.", "location": [2381, 2385], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS INTERNATIONAL, INC."}]}, {"text": "15", "location": [2386, 2388], "entities": [{"type": "Age", "text": "15"}]}]}], "keywords": [{"text": "Formerly Valeant Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63504, "count": 1}, {"text": "devices market", "sentiment": {"score": -0.564902, "mixed": "1", "label": "negative"}, "relevance": 0.626502, "count": 5}, {"text": "North America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.613345, "count": 1}, {"text": "global GERD drug", "sentiment": {"score": -0.846018, "label": "negative"}, "relevance": 0.61277, "count": 2}, {"text": "Cempra Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.61179, "count": 2}, {"text": "NEW YORK", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.591594, "count": 1}, {"text": "Reportlinker ReportLinker", "sentiment": {"score": 0.831414, "label": "positive"}, "relevance": 0.584513, "count": 1}, {"text": "MARKET INSIGHTS", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.580362, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578226, "count": 2}, {"text": "Takeda Pharmaceuticals Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573156, "count": 1}, {"text": "Daewoong Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568191, "count": 2}, {"text": "market", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.567737, "count": 3}, {"text": "Eisai Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563231, "count": 1}, {"text": "full report", "sentiment": {"score": 0.28387, "mixed": "1", "label": "positive"}, "relevance": 0.557096, "count": 2}, {"text": "proton pump inhibitors", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.55424, "count": 1}, {"text": "adverse effect", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.554189, "count": 1}, {"text": "COMPETITIVE INSIGHTS Product launch", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.553537, "count": 1}, {"text": "largest market", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.552013, "count": 1}, {"text": "Ironwood Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548474, "count": 2}, {"text": "GERD", "sentiment": {"score": -0.940139, "label": "negative"}, "relevance": 0.548456, "count": 2}, {"text": "Latin America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.548451, "count": 1}, {"text": "RaQualia Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.54799, "count": 2}, {"text": "GERD drug", "sentiment": {"score": -0.617996, "mixed": "1", "label": "negative"}, "relevance": 0.547727, "count": 3}, {"text": "Middle East", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.544922, "count": 1}, {"text": "chronic digestive disorder", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.53966, "count": 1}, {"text": "competitive edge", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.539484, "count": 1}, {"text": "drugs", "sentiment": {"score": -0.721786, "label": "negative"}, "relevance": 0.538082, "count": 3}, {"text": "increasing occurrence of GERD disorders", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.536641, "count": 1}, {"text": "Boston Scientific Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.53255, "count": 1}, {"text": "growing trend of self-medication", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.531596, "count": 1}, {"text": "Ausch Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530365, "count": 1}, {"text": "devices", "sentiment": {"score": -0.362833, "mixed": "1", "label": "negative"}, "relevance": 0.528202, "count": 2}, {"text": "market research", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.525719, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.523897, "count": 1}, {"text": "American region", "sentiment": {"score": 0.467953, "mixed": "1", "label": "positive"}, "relevance": 0.520843, "count": 2}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519141, "count": 4}, {"text": "accurate diagnosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515636, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514125, "count": 2}, {"text": "REGIONAL INSIGHTS", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.513474, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.512547, "count": 2}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511049, "count": 2}, {"text": "Novartis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510729, "count": 2}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509913, "count": 2}, {"text": "Glaxosmithkline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509331, "count": 2}, {"text": "prominence", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.508441, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.508337, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.507672, "count": 7}, {"text": "Europe", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.507599, "count": 1}, {"text": "complications", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.507483, "count": 1}, {"text": "demand", "sentiment": {"score": -0.503707, "label": "negative"}, "relevance": 0.507078, "count": 1}]}, "extracted_metadata": {"sha1": "c164ebf5d37a9d364e56a6816d183af504a9daf6", "filename": "1543363620788.zip-94f1b98ddeaa25f0f482b36eb6141d6d.xml", "file_type": "json"}, "external_links": ["https://www.reportlinker.com/", "https://www.reportlinker.com/p05626023"], "title": "The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027", "forum_title": "Latest Health, Healthcare News and Press Releases | PR Newswire"}, {"id": "ruLJNsXAQetTdRAVPB_YGEQ033htYKQzk9P3PROc1u2PKUyR3Jv1kpHWcUIEdu5e", "result_metadata": {"score": 34.753174}, "author": "Reportlinker", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.70228, "label": "negative"}, "text": "GERD", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": "The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027", "object": {"text": "at a CAGR of 1.12%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}], "concepts": [{"text": "Years in the future", "relevance": 0.842933, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Trade", "relevance": 0.772153, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}], "categories": [{"score": 0.801654, "label": "/health and fitness"}, {"score": 0.703212, "label": "/health and fitness/drugs"}, {"score": 0.69663, "label": "/technology and computing/operating systems"}], "relations": [], "keywords": [{"text": "global GERD drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997422, "count": 1}, {"text": "devices market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27244, "count": 1}, {"text": "CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.006855, "count": 1}]}, "crawl_date": "2018-11-27T23:13:42Z", "url": "https://www.prnewswire.com:443/news-releases/the-global-gerd-drug-and-devices-market-has-been-predicted-to-grow-at-a-cagr-of-1-12-between-2019-and-2027--300756204.html", "host": "prnewswire.com", "text": "Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T23:06:00Z", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.69347, "label": "negative"}, "text": "GERD", "relevance": 0.911181, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.37273, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.325553, "label": "negative"}, "text": "TAKEDA PHARMACEUTICALS", "relevance": 0.362563, "type": "Company", "disambiguation": {"subtype": [], "name": "Takeda Pharmaceutical Company", "dbpedia_resource": "http://dbpedia.org/resource/Takeda_Pharmaceutical_Company"}}, {"count": 5, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.351731, "type": "Organization", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"count": 1, "sentiment": {"score": -0.501076, "label": "negative"}, "text": "IRONWOOD PHARMACEUTICALS", "relevance": 0.313826, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EISAI INC", "relevance": 0.304372, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Scientific Corporation", "relevance": 0.296496, "type": "Company", "disambiguation": {"subtype": [], "name": "Boston Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.291752, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.272997, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": -0.317572, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.263388, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.374397, "label": "negative"}, "text": "Ironwood Pharmaceuticals, Inc.", "relevance": 0.25709, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RAQUALIA PHARMA INC.", "relevance": 0.252567, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PFIZER", "relevance": 0.251351, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.246206, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.243789, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cempra Inc.", "relevance": 0.235469, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEW YORK", "relevance": 0.23189, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 3, "sentiment": {"score": 0.402725, "label": "positive"}, "text": "Reportlinker", "relevance": 0.230773, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.493582, "label": "positive"}, "text": "JOHNSON", "relevance": 0.226181, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.223344, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "ABBOTT LABORATORIES.", "relevance": 0.219917, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.215927, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "DAEWOONG CO. LTD.", "relevance": 0.202997, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.200499, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.532507, "label": "negative"}, "text": "Europe", "relevance": 0.199788, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0.51678, "label": "positive"}, "text": "BAUSCH HEALTH", "relevance": 0.198258, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glaxosmithkline", "relevance": 0.196971, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "RaQualia Pharma Inc.", "relevance": 0.189161, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.178141, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.175458, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.339071, "label": "positive"}, "text": "Ausch Health", "relevance": 0.162473, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.364755, "label": "positive"}, "text": "Melinta", "relevance": 0.161444, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daewoong Co. Ltd.", "relevance": 0.161323, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Inc.", "relevance": 0.161162, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.161162, "type": "Quantity"}], "sentiment": {"document": {"score": -0.394026, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "NEW YORK , Nov. 27, KEY INSIGHTS Gastro-esophageal reflux disease (GERD)", "keywords": [{"text": "INSIGHTS Gastro-esophageal reflux"}, {"text": "NEW YORK"}, {"text": "GERD"}], "entities": [{"type": "Location", "text": "NEW YORK", "disambiguation": {"subtype": ["City"]}}, {"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": "NEW YORK , Nov. 27, KEY INSIGHTS Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing", "keywords": [{"text": "chronic digestive disorder"}, {"text": "complications"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the esophagus.The market", "keywords": [{"text": "esophagus.The market"}]}, "sentence": "NEW YORK , Nov. 27, KEY INSIGHTS Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "the drugs and devices required for its optimized cure and accurate diagnosis respectively", "keywords": [{"text": "optimized cure"}, {"text": "accurate diagnosis"}, {"text": "drugs"}, {"text": "devices"}]}, "action": {"verb": {"text": "produce", "tense": "present"}, "text": "producing and distributing", "normalized": "produce and distribute"}}, {"subject": {"text": "https://www.reportlinker.com/p05626023 The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " Read the full report: https://www.reportlinker.com/p05626023 The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027.", "object": {"text": "at a CAGR of 1.12% between 2019 and 2027", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}, {"subject": {"text": "MARKET", "keywords": [{"text": "MARKET"}]}, "sentence": " MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "The causes", "keywords": [{"text": "causes"}]}, "action": {"verb": {"text": "INSIGHTS", "tense": "present"}, "text": "INSIGHTS", "normalized": "INSIGHTS"}}, {"subject": {"text": "MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market", "keywords": [{"text": "GERD drug"}, {"text": "devices market"}, {"text": "causes"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents", "keywords": [{"text": "GERD disorders"}, {"text": "self-medication"}, {"text": "prominence"}, {"text": "trend"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "other drugs for its cure", "keywords": [{"text": "drugs"}, {"text": "cure"}]}, "sentence": " MARKET INSIGHTS The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the majorly hampering the GERD Drug and devices market", "keywords": [{"text": "GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is segmented by dosage form and by administration of the drugs.", "object": {"text": "segmented by dosage form and by administration of the drugs", "keywords": [{"text": "dosage form"}, {"text": "drugs"}, {"text": "administration"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "REGIONAL INSIGHTS The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "REGIONAL INSIGHTS"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "REGIONAL INSIGHTS The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "REGIONAL INSIGHTS"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "action": {"verb": {"text": "spread", "tense": "past"}, "text": "is spread", "normalized": "be spread"}}, {"subject": {"text": "the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "proclaimed as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Latin America"}, {"text": "Middle East"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " REGIONAL INSIGHTS The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "proclaim", "tense": "past"}, "text": "has been proclaimed", "normalized": "have be proclaim"}}, {"subject": {"text": "The rise in the incidence of GERD in North American countries", "keywords": [{"text": "North American countries"}, {"text": "GERD"}, {"text": "incidence"}, {"text": "rise"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "responsible for the increase", "keywords": [{"text": "increase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "acid reducing and neutralizing drugs", "keywords": [{"text": "acid"}, {"text": "drugs"}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "is proliferating", "normalized": "be proliferate"}}, {"subject": {"text": "COMPETITIVE INSIGHTS Product launch", "keywords": [{"text": "INSIGHTS Product launch"}]}, "sentence": " COMPETITIVE INSIGHTS Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "primary strategy"}, {"text": "competitive edge"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the various market companies of the global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " COMPETITIVE INSIGHTS Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy", "keywords": [{"text": "primary strategy"}]}, "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "adopted", "normalized": "adopt"}}, {"subject": {"text": "Reportlinker", "keywords": [{"text": "Reportlinker"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "the latest industry data", "keywords": [{"text": "latest industry data"}]}, "action": {"verb": {"text": "organize", "tense": "present"}, "text": "organizes", "normalized": "organize"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research you need", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}], "concepts": [{"text": "Gastroesophageal reflux disease", "relevance": 0.988708, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "North America", "relevance": 0.986946, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacology", "relevance": 0.919694, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.786029, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Boston Scientific", "relevance": 0.753713, "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}, {"text": "Abbott Laboratories", "relevance": 0.740455, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}, {"text": "Drug", "relevance": 0.713747, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Pharmaceutical drug", "relevance": 0.678678, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Lansoprazole", "relevance": 0.673582, "dbpedia_resource": "http://dbpedia.org/resource/Lansoprazole"}, {"text": "Asthma", "relevance": 0.631511, "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}, {"text": "Ribavirin", "relevance": 0.613038, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Valeant Pharmaceuticals International", "relevance": 0.600815, "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals_International"}, {"text": "Multinational companies", "relevance": 0.598059, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Americas", "relevance": 0.590813, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Guidant", "relevance": 0.589026, "dbpedia_resource": "http://dbpedia.org/resource/Guidant"}, {"text": "Omeprazole", "relevance": 0.583288, "dbpedia_resource": "http://dbpedia.org/resource/Omeprazole"}, {"text": "Cough", "relevance": 0.578578, "dbpedia_resource": "http://dbpedia.org/resource/Cough"}, {"text": "Esomeprazole", "relevance": 0.573564, "dbpedia_resource": "http://dbpedia.org/resource/Esomeprazole"}, {"text": "United States", "relevance": 0.57199, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Johnson & Johnson", "relevance": 0.551462, "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}, {"text": "Latin America", "relevance": 0.550152, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}], "categories": [{"score": 0.971464, "label": "/health and fitness/disease/gerd and acid reflux"}, {"score": 0.833094, "label": "/health and fitness/drugs"}, {"score": 0.797689, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "locatedAt", "sentence": "The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "score": 0.800802, "arguments": [{"text": "countries", "location": [1249, 1258], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "North American", "location": [1234, 1248], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.382199, "arguments": [{"text": "Abbott Laboratories", "location": [1635, 1654], "entities": [{"type": "Organization", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1606, 1615], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.644268, "arguments": [{"text": "AstraZeneca", "location": [1656, 1667], "entities": [{"type": "Organization", "text": "AstraZeneca", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1606, 1615], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOf", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.467352, "arguments": [{"text": "Melinta", "location": [1794, 1801], "entities": [{"type": "Organization", "text": "MELINTA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merged", "location": [1782, 1788], "entities": [{"type": "Organization", "text": "CEMPRA INC.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Companies mentioned 1.", "score": 0.852976, "arguments": [{"text": "Companies", "location": [2010, 2019], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "mentioned", "location": [2020, 2029], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "basedIn", "sentence": "BOSTON SCIENTIFIC CORPORATION 5.", "score": 0.883816, "arguments": [{"text": "SCIENTIFIC CORPORATION 5", "location": [2151, 2175], "entities": [{"type": "Organization", "text": "SCIENTIFIC CORPORATION 5"}]}, {"text": "BOSTON", "location": [2144, 2150], "entities": [{"type": "GeopoliticalEntity", "text": "BOSTON"}]}]}, {"type": "hasAttribute", "sentence": "IRONWOOD PHARMACEUTICALS, INC. 10.", "score": 0.192369, "arguments": [{"text": "PHARMACEUTICALS, INC.", "location": [2276, 2297], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS, INC."}]}, {"text": "10", "location": [2298, 2300], "entities": [{"type": "Age", "text": "10"}]}]}, {"type": "hasAttribute", "sentence": "RAQUALIA PHARMA INC. 15.", "score": 0.178778, "arguments": [{"text": "INC.", "location": [2392, 2396], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS INTERNATIONAL, INC."}]}, {"text": "15", "location": [2397, 2399], "entities": [{"type": "Age", "text": "15"}]}]}], "keywords": [{"text": "Formerly Valeant Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.63467, "count": 1}, {"text": "devices market", "sentiment": {"score": -0.564902, "mixed": "1", "label": "negative"}, "relevance": 0.624183, "count": 5}, {"text": "North America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.612443, "count": 1}, {"text": "Cempra Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.611655, "count": 2}, {"text": "global GERD drug", "sentiment": {"score": -0.846018, "label": "negative"}, "relevance": 0.611588, "count": 2}, {"text": "NEW YORK", "sentiment": {"score": -0.989754, "label": "negative"}, "relevance": 0.601715, "count": 1}, {"text": "Reportlinker ReportLinker", "sentiment": {"score": 0.831414, "label": "positive"}, "relevance": 0.584169, "count": 1}, {"text": "MARKET INSIGHTS", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.579138, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577782, "count": 2}, {"text": "Takeda Pharmaceuticals Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.573057, "count": 1}, {"text": "Daewoong Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.568395, "count": 2}, {"text": "market", "sentiment": {"score": -0.989754, "label": "negative"}, "relevance": 0.566448, "count": 3}, {"text": "Eisai Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.563418, "count": 1}, {"text": "full report", "sentiment": {"score": 0.28387, "mixed": "1", "label": "positive"}, "relevance": 0.556983, "count": 2}, {"text": "adverse effect", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.553792, "count": 1}, {"text": "proton pump inhibitors", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.553766, "count": 1}, {"text": "COMPETITIVE INSIGHTS Product launch", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.551456, "count": 1}, {"text": "largest market", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.551146, "count": 1}, {"text": "Ironwood Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548706, "count": 2}, {"text": "RaQualia Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.548221, "count": 2}, {"text": "Latin America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.54811, "count": 1}, {"text": "GERD", "sentiment": {"score": -0.940786, "label": "negative"}, "relevance": 0.547913, "count": 2}, {"text": "GERD drug", "sentiment": {"score": -0.617996, "mixed": "1", "label": "negative"}, "relevance": 0.547372, "count": 3}, {"text": "Middle East", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.544579, "count": 1}, {"text": "chronic digestive disorder", "sentiment": {"score": -0.989754, "label": "negative"}, "relevance": 0.539835, "count": 1}, {"text": "competitive edge", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.537708, "count": 1}, {"text": "drugs", "sentiment": {"score": -0.721786, "label": "negative"}, "relevance": 0.537502, "count": 3}, {"text": "increasing occurrence of GERD disorders", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.536756, "count": 1}, {"text": "Boston Scientific Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.533013, "count": 1}, {"text": "growing trend of self-medication", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.53195, "count": 1}, {"text": "Ausch Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.530796, "count": 1}, {"text": "devices", "sentiment": {"score": -0.362833, "mixed": "1", "label": "negative"}, "relevance": 0.527782, "count": 2}, {"text": "market research", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.525264, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.524345, "count": 1}, {"text": "American region", "sentiment": {"score": 0.467953, "mixed": "1", "label": "positive"}, "relevance": 0.521025, "count": 2}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519024, "count": 4}, {"text": "accurate diagnosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.515562, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.514, "count": 2}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51247, "count": 2}, {"text": "REGIONAL INSIGHTS", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.511755, "count": 1}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510977, "count": 2}, {"text": "Novartis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51066, "count": 2}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509855, "count": 2}, {"text": "Glaxosmithkline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509273, "count": 2}, {"text": "prominence", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.508382, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.508278, "count": 1}, {"text": "Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508215, "count": 7}, {"text": "Europe", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.507549, "count": 1}, {"text": "complications", "sentiment": {"score": -0.989754, "label": "negative"}, "relevance": 0.507407, "count": 1}, {"text": "Reportlinker finds", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.507217, "count": 1}]}, "extracted_metadata": {"sha1": "9074a17a1bf0bdf382fae432115acb6ac2e50516", "filename": "1543360422674.zip-47d74b0aa469c33067c1b4fa473e166e.xml", "file_type": "json"}, "external_links": ["https://www.reportlinker.com/", "https://www.reportlinker.com/p05626023"], "title": "The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027", "forum_title": "PR Newswire:"}, {"id": "MTb9RNHTIUfy3-89JUywCfnpnrnwHUmiO8xlvccUqCidI925u48IryUjL43zqxsX", "result_metadata": {"score": 34.641144}, "author": "PRESS RELEASE PR Newswire", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.70228, "label": "negative"}, "text": "GERD", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.33, "type": "Quantity"}], "sentiment": {"document": {"score": 0, "label": "neutral"}}, "semantic_roles": [{"subject": {"text": "The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": "The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027", "object": {"text": "at a CAGR of 1.12%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}], "concepts": [{"text": "Years in the future", "relevance": 0.842933, "dbpedia_resource": "http://dbpedia.org/resource/Years_in_the_future"}, {"text": "Trade", "relevance": 0.772153, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}], "categories": [{"score": 0.801654, "label": "/health and fitness"}, {"score": 0.703212, "label": "/health and fitness/drugs"}, {"score": 0.69663, "label": "/technology and computing/operating systems"}], "relations": [], "keywords": [{"text": "global GERD drug", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.997422, "count": 1}, {"text": "devices market", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.27244, "count": 1}, {"text": "CAGR", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.006855, "count": 1}]}, "crawl_date": "2018-11-28T00:31:14Z", "url": "https://markets.businessinsider.com/news/stocks/the-global-gerd-drug-and-devices-market-has-been-predicted-to-grow-at-a-cagr-of-1-12-between-2019-and-2027-1027760987", "host": "markets.businessinsider.com", "text": "Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co.", "main_image_url": "https://c212.net/c/img/favicon.png?sn=SP84512&amp;sd=2018-11-27", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T06:06:00-06:00", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.719266, "label": "negative"}, "text": "GERD", "relevance": 0.893857, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.395758, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.607879, "label": "negative"}, "text": "TAKEDA PHARMACEUTICALS COMPANY", "relevance": 0.351229, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RAQUALIA PHARMA INC", "relevance": 0.329898, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.532059, "label": "negative"}, "text": "IRONWOOD PHARMACEUTICALS", "relevance": 0.318591, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EISAI INC", "relevance": 0.302565, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Scientific Corporation", "relevance": 0.294221, "type": "Company", "disambiguation": {"subtype": [], "name": "Boston Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.286893, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glaxosmithkline", "relevance": 0.275068, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.271946, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.269652, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 2, "sentiment": {"score": -0.302533, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.264305, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.374397, "label": "negative"}, "text": "Ironwood Pharmaceuticals, Inc.", "relevance": 0.252856, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.450649, "label": "positive"}, "text": "ASTRAZENECA", "relevance": 0.248133, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 3, "sentiment": {"score": 0.634187, "label": "positive"}, "text": "Reportlinker", "relevance": 0.245768, "type": "Person"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.242646, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PFIZER", "relevance": 0.235889, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEW YORK", "relevance": 0.235178, "type": "Location", "disambiguation": {"subtype": ["City"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.220895, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0.472818, "label": "positive"}, "text": "DAEWOONG CO. LTD", "relevance": 0.214441, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.214035, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0.474688, "label": "positive"}, "text": "CEMPRA INC.", "relevance": 0.203411, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.198614, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.55264, "label": "negative"}, "text": "Europe", "relevance": 0.198078, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.193816, "type": "Organization", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "RaQualia Pharma Inc.", "relevance": 0.186537, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.176135, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.173102, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.339071, "label": "positive"}, "text": "Ausch Health", "relevance": 0.160482, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cempra Inc.", "relevance": 0.159712, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.364755, "label": "positive"}, "text": "Melinta", "relevance": 0.159508, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daewoong Co. Ltd.", "relevance": 0.159386, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Inc.", "relevance": 0.159224, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.159224, "type": "Quantity"}], "sentiment": {"document": {"score": -0.394103, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Gastro-esophageal reflux disease (GERD)", "keywords": [{"text": "Gastro-esophageal reflux disease"}, {"text": "GERD"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing", "keywords": [{"text": "chronic digestive disorder"}, {"text": "complications"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the esophagus.The market", "keywords": [{"text": "esophagus.The market"}]}, "sentence": " Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "the drugs and devices required for its optimized cure and accurate diagnosis respectively", "keywords": [{"text": "optimized cure"}, {"text": "accurate diagnosis"}, {"text": "drugs"}, {"text": "devices"}]}, "action": {"verb": {"text": "produce", "tense": "present"}, "text": "producing and distributing", "normalized": "produce and distribute"}}, {"subject": {"text": "The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027.", "object": {"text": "at a CAGR of 1.12%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}, {"subject": {"text": "The causes", "keywords": [{"text": "causes"}]}, "sentence": " The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the GERD drug and devices market", "keywords": [{"text": "GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "The causes primarily responsible for driving the GERD drug and devices market", "keywords": [{"text": "GERD drug"}, {"text": "devices market"}, {"text": "causes"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents", "keywords": [{"text": "GERD disorders"}, {"text": "self-medication"}, {"text": "prominence"}, {"text": "trend"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "other drugs for its cure", "keywords": [{"text": "drugs"}, {"text": "cure"}]}, "sentence": " The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the majorly hampering the GERD Drug and devices market", "keywords": [{"text": "GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is segmented by dosage form and by administration of the drugs.", "object": {"text": "segmented by dosage form and by administration of the drugs", "keywords": [{"text": "dosage form"}, {"text": "drugs"}, {"text": "administration"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "action": {"verb": {"text": "spread", "tense": "past"}, "text": "is spread", "normalized": "be spread"}}, {"subject": {"text": "the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "proclaimed as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "global GERD Drug"}, {"text": "Africa.The North American"}, {"text": "devices market"}, {"text": "Middle East"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "proclaim", "tense": "past"}, "text": "has been proclaimed", "normalized": "have be proclaim"}}, {"subject": {"text": "The rise in the incidence of GERD in North American countries", "keywords": [{"text": "North American countries"}, {"text": "GERD"}, {"text": "incidence"}, {"text": "rise"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "responsible for the increase", "keywords": [{"text": "increase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "acid reducing and neutralizing drugs", "keywords": [{"text": "acid"}, {"text": "drugs"}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "is proliferating", "normalized": "be proliferate"}}, {"subject": {"text": "Product launch", "keywords": [{"text": "Product launch"}]}, "sentence": " Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "primary strategy"}, {"text": "competitive edge"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the various market companies of the global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy", "keywords": [{"text": "primary strategy"}]}, "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "adopted", "normalized": "adopt"}}, {"subject": {"text": "ReportLinker", "keywords": [{"text": "ReportLinker"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "sentence": " ReportLinker is an award-winning market research solution.", "object": {"text": "an award-winning market research solution", "keywords": [{"text": "award-winning market research"}, {"text": "solution"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Reportlinker", "keywords": [{"text": "Reportlinker"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "the latest industry data", "keywords": [{"text": "latest industry data"}]}, "action": {"verb": {"text": "organize", "tense": "present"}, "text": "organizes", "normalized": "organize"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research you need", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}], "concepts": [{"text": "Gastroesophageal reflux disease", "relevance": 0.984365, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "North America", "relevance": 0.981853, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacology", "relevance": 0.915977, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.781221, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Boston Scientific", "relevance": 0.749606, "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}, {"text": "Abbott Laboratories", "relevance": 0.736624, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}, {"text": "Drug", "relevance": 0.712511, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Pharmaceutical drug", "relevance": 0.675469, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Lansoprazole", "relevance": 0.669521, "dbpedia_resource": "http://dbpedia.org/resource/Lansoprazole"}, {"text": "Asthma", "relevance": 0.630731, "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}, {"text": "Ribavirin", "relevance": 0.613031, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Valeant Pharmaceuticals International", "relevance": 0.599429, "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals_International"}, {"text": "Multinational companies", "relevance": 0.590569, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Guidant", "relevance": 0.584072, "dbpedia_resource": "http://dbpedia.org/resource/Guidant"}, {"text": "Americas", "relevance": 0.582036, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Omeprazole", "relevance": 0.580355, "dbpedia_resource": "http://dbpedia.org/resource/Omeprazole"}, {"text": "Cough", "relevance": 0.578531, "dbpedia_resource": "http://dbpedia.org/resource/Cough"}, {"text": "Esomeprazole", "relevance": 0.568241, "dbpedia_resource": "http://dbpedia.org/resource/Esomeprazole"}, {"text": "United States", "relevance": 0.563445, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Johnson & Johnson", "relevance": 0.546894, "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}, {"text": "Latin America", "relevance": 0.545281, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}, {"text": "Companies listed on the New York Stock Exchange", "relevance": 0.523718, "dbpedia_resource": "http://dbpedia.org/resource/Companies_listed_on_the_New_York_Stock_Exchange"}], "categories": [{"score": 0.971466, "label": "/health and fitness/disease/gerd and acid reflux"}, {"score": 0.833122, "label": "/health and fitness/drugs"}, {"score": 0.797725, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "locatedAt", "sentence": "The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "score": 0.800802, "arguments": [{"text": "countries", "location": [1270, 1279], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "North American", "location": [1255, 1269], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.382199, "arguments": [{"text": "Abbott Laboratories", "location": [1656, 1675], "entities": [{"type": "Organization", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1627, 1636], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.644268, "arguments": [{"text": "AstraZeneca", "location": [1677, 1688], "entities": [{"type": "Organization", "text": "AstraZeneca", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1627, 1636], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOf", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.467352, "arguments": [{"text": "Melinta", "location": [1815, 1822], "entities": [{"type": "Organization", "text": "MELINTA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merged", "location": [1803, 1809], "entities": [{"type": "Organization", "text": "CEMPRA INC.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Companies mentioned 1.", "score": 0.852976, "arguments": [{"text": "Companies", "location": [2031, 2040], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "mentioned", "location": [2041, 2050], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "basedIn", "sentence": "BOSTON SCIENTIFIC CORPORATION 5.", "score": 0.883816, "arguments": [{"text": "SCIENTIFIC CORPORATION\n5", "location": [2172, 2196], "entities": [{"type": "Organization", "text": "SCIENTIFIC CORPORATION\n5"}]}, {"text": "BOSTON", "location": [2165, 2171], "entities": [{"type": "GeopoliticalEntity", "text": "BOSTON"}]}]}, {"type": "hasAttribute", "sentence": "IRONWOOD PHARMACEUTICALS, INC. 10.", "score": 0.192369, "arguments": [{"text": "PHARMACEUTICALS, INC.", "location": [2297, 2318], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS, INC."}]}, {"text": "10", "location": [2319, 2321], "entities": [{"type": "Age", "text": "10"}]}]}, {"type": "hasAttribute", "sentence": "RAQUALIA PHARMA INC. 15.", "score": 0.178778, "arguments": [{"text": "INC.", "location": [2413, 2417], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS INTERNATIONAL, INC."}]}, {"text": "15", "location": [2418, 2420], "entities": [{"type": "Age", "text": "15"}]}]}], "keywords": [{"text": "global GERD drug", "sentiment": {"score": -0.846018, "label": "negative"}, "relevance": 0.639538, "count": 2}, {"text": "North America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.637658, "count": 1}, {"text": "devices market", "sentiment": {"score": -0.564902, "mixed": "1", "label": "negative"}, "relevance": 0.6294, "count": 5}, {"text": "Reportlinker finds", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.596236, "count": 1}, {"text": "Cempra Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.593722, "count": 2}, {"text": "Formerly Valeant Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.591759, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.577852, "count": 2}, {"text": "market", "sentiment": {"score": -0.989704, "label": "negative"}, "relevance": 0.56667, "count": 3}, {"text": "Daewoong Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566069, "count": 2}, {"text": "chronic digestive disorder", "sentiment": {"score": -0.989704, "label": "negative"}, "relevance": 0.565921, "count": 1}, {"text": "GERD drug", "sentiment": {"score": -0.617996, "mixed": "1", "label": "negative"}, "relevance": 0.56586, "count": 3}, {"text": "proton pump inhibitors", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.565442, "count": 1}, {"text": "adverse effect", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.565428, "count": 1}, {"text": "MARKET INSIGHTS", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.561667, "count": 1}, {"text": "increasing occurrence of GERD disorders", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.561121, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.5586, "count": 1}, {"text": "growing trend of self-medication", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.55809, "count": 1}, {"text": "GERD", "sentiment": {"score": -0.940791, "label": "negative"}, "relevance": 0.556941, "count": 2}, {"text": "largest market", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.554859, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.554393, "count": 1}, {"text": "Eisai Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552031, "count": 1}, {"text": "American region", "sentiment": {"score": 0.467953, "mixed": "1", "label": "positive"}, "relevance": 0.541428, "count": 2}, {"text": "drugs", "sentiment": {"score": -0.721786, "label": "negative"}, "relevance": 0.540301, "count": 3}, {"text": "Boston Scientific Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.539788, "count": 1}, {"text": "RaQualia Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529295, "count": 2}, {"text": "devices", "sentiment": {"score": -0.362833, "mixed": "1", "label": "negative"}, "relevance": 0.529146, "count": 2}, {"text": "Ausch Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.527845, "count": 1}, {"text": "Ironwood Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526735, "count": 2}, {"text": "market research", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.525976, "count": 1}, {"text": "primary strategy", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.523095, "count": 1}, {"text": "Expiry of patents", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.521268, "count": 1}, {"text": "competitive edge", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.520023, "count": 1}, {"text": "accurate diagnosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518878, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518349, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518008, "count": 4}, {"text": "Takeda Pharmaceuticals Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517062, "count": 1}, {"text": "Asia-Pacific", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.513493, "count": 1}, {"text": "American countries", "sentiment": {"score": -0.503707, "label": "negative"}, "relevance": 0.513415, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511682, "count": 2}, {"text": "NEW YORK", "sentiment": {"score": -0.989704, "label": "negative"}, "relevance": 0.511117, "count": 1}, {"text": "prominence", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.51047, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.510298, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510244, "count": 2}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509712, "count": 2}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509579, "count": 2}, {"text": "Novartis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509382, "count": 2}, {"text": "complications", "sentiment": {"score": -0.989704, "label": "negative"}, "relevance": 0.509305, "count": 1}, {"text": "Europe", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.509226, "count": 1}, {"text": "Glaxosmithkline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508562, "count": 2}, {"text": "cure", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.508527, "count": 2}]}, "extracted_metadata": {"sha1": "a2b2297684234f1a882cf0e4d9e37fd48740b470", "filename": "1543365074721.zip-e08f0b03c0fc256319e2b624ff575930.xml", "file_type": "json"}, "external_links": ["https://www.reportlinker.com/", "https://www.reportlinker.com/p05626023"], "title": "The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027", "forum_title": "Stock Market News | Financial &amp; Business News | Markets Insider"}, {"id": "xOg6Z6JVea8McTs_8bH4_TShRYpSIp5PJXoQRsftJXNWS-HO4RfIepV9yX2HMNSJ", "result_metadata": {"score": 34.58784}, "author": "mylubbocktv.com", "enriched_title": {"entities": [{"count": 1, "sentiment": {"score": -0.853933, "label": "negative"}, "text": "GERD", "relevance": 0.33, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}], "sentiment": {"document": {"score": -0.896925, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": "The global GERD drug and devices market has been predicted to gr", "object": {"text": "predicted to gr"}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}], "concepts": [{"text": "Trade", "relevance": 0.838718, "dbpedia_resource": "http://dbpedia.org/resource/Trade"}, {"text": "Capitalism", "relevance": 0.751422, "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"}], "categories": [{"score": 0.799177, "label": "/health and fitness"}, {"score": 0.700341, "label": "/technology and computing/hardware/computer peripherals"}, {"score": 0.6977, "label": "/technology and computing/operating systems"}], "relations": [], "keywords": [{"text": "global GERD drug", "sentiment": {"score": -0.896925, "label": "negative"}, "relevance": 0.998638, "count": 1}, {"text": "devices market", "sentiment": {"score": -0.896925, "label": "negative"}, "relevance": 0.207172, "count": 1}, {"text": "gr", "sentiment": {"score": -0.896925, "label": "negative"}, "relevance": 0.005192, "count": 1}]}, "crawl_date": "2018-11-28T02:59:26Z", "url": "http://www.mylubbocktv.com/story/39548998/the-global-gerd-drug-and-devices-market-has-been-predicted-to-grow-at-a-cagr-of-112-between-2019-and-2027", "host": "mylubbocktv.com", "text": "Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co.", "country": "US", "source_type": "mainstream", "language": "en", "publication_date": "2018-11-27T00:00:00-05:00", "enriched_text": {"entities": [{"count": 9, "sentiment": {"score": -0.719266, "label": "negative"}, "text": "GERD", "relevance": 0.901657, "type": "HealthCondition", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Valeant Pharmaceuticals International", "relevance": 0.398508, "type": "Company", "disambiguation": {"subtype": [], "name": "Valeant Pharmaceuticals", "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals"}}, {"count": 1, "sentiment": {"score": -0.607879, "label": "negative"}, "text": "TAKEDA PHARMACEUTICALS COMPANY", "relevance": 0.35393, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "RAQUALIA PHARMA INC", "relevance": 0.332627, "type": "Company"}, {"count": 1, "sentiment": {"score": -0.532059, "label": "negative"}, "text": "IRONWOOD PHARMACEUTICALS", "relevance": 0.320934, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "EISAI INC", "relevance": 0.304793, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Boston Scientific Corporation", "relevance": 0.29541, "type": "Company", "disambiguation": {"subtype": [], "name": "Boston Scientific", "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "Takeda Pharmaceuticals Company Limited", "relevance": 0.289323, "type": "Company"}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Glaxosmithkline", "relevance": 0.275935, "type": "Company", "disambiguation": {"subtype": [], "name": "GlaxoSmithKline", "dbpedia_resource": "http://dbpedia.org/resource/GlaxoSmithKline"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Novartis", "relevance": 0.27278, "type": "Company", "disambiguation": {"subtype": [], "name": "Novartis", "dbpedia_resource": "http://dbpedia.org/resource/Novartis"}}, {"count": 2, "sentiment": {"score": 0, "label": "neutral"}, "text": "Abbott Laboratories", "relevance": 0.270794, "type": "Company", "disambiguation": {"subtype": ["VentureFundedCompany"], "name": "Abbott Laboratories", "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}}, {"count": 2, "sentiment": {"score": -0.302533, "label": "negative"}, "text": "Merck & Co. Inc.", "relevance": 0.265023, "type": "Company", "disambiguation": {"subtype": [], "name": "Merck & Co.", "dbpedia_resource": "http://dbpedia.org/resource/Merck_&_Co."}}, {"count": 1, "sentiment": {"score": -0.374397, "label": "negative"}, "text": "Ironwood Pharmaceuticals, Inc.", "relevance": 0.254791, "type": "Company"}, {"count": 3, "sentiment": {"score": 0.634187, "label": "positive"}, "text": "Reportlinker", "relevance": 0.254043, "type": "Person"}, {"count": 1, "sentiment": {"score": 0.450649, "label": "positive"}, "text": "ASTRAZENECA", "relevance": 0.248947, "type": "Company", "disambiguation": {"subtype": [], "name": "AstraZeneca", "dbpedia_resource": "http://dbpedia.org/resource/AstraZeneca"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Johnson & Johnson", "relevance": 0.244196, "type": "Company", "disambiguation": {"subtype": ["AwardPresentingOrganization", "CompanyShareholder"], "name": "Johnson & Johnson", "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "PFIZER", "relevance": 0.236602, "type": "Company", "disambiguation": {"subtype": [], "name": "Pfizer", "dbpedia_resource": "http://dbpedia.org/resource/Pfizer"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "NEW YORK", "relevance": 0.226787, "type": "Organization"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "North America", "relevance": 0.221809, "type": "Location", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"count": 1, "sentiment": {"score": 0.472818, "label": "positive"}, "text": "DAEWOONG CO. LTD", "relevance": 0.214961, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Middle East", "relevance": 0.21446, "type": "Location", "disambiguation": {"subtype": ["Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}, {"count": 1, "sentiment": {"score": 0.474688, "label": "positive"}, "text": "CEMPRA INC.", "relevance": 0.203693, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Asia-Pacific", "relevance": 0.199018, "type": "Location", "disambiguation": {"subtype": ["Country"]}}, {"count": 1, "sentiment": {"score": -0.55264, "label": "negative"}, "text": "Europe", "relevance": 0.198348, "type": "Location", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"count": 1, "sentiment": {"score": -0.335957, "label": "negative"}, "text": "RaQualia Pharma Inc.", "relevance": 0.187262, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Inc.", "relevance": 0.185565, "type": "Organization", "disambiguation": {"subtype": ["Magazine"], "name": "Inc. (magazine)", "dbpedia_resource": "http://dbpedia.org/resource/Inc._(magazine)"}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Latin America", "relevance": 0.176634, "type": "Location", "disambiguation": {"subtype": ["Continent"]}}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Pfizer, Inc.", "relevance": 0.173679, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.339071, "label": "positive"}, "text": "Ausch Health", "relevance": 0.160843, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Cempra Inc.", "relevance": 0.159982, "type": "Company"}, {"count": 1, "sentiment": {"score": 0.364755, "label": "positive"}, "text": "Melinta", "relevance": 0.159776, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Daewoong Co. Ltd.", "relevance": 0.159652, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "Eisai Inc.", "relevance": 0.159487, "type": "Company"}, {"count": 1, "sentiment": {"score": 0, "label": "neutral"}, "text": "1.12%", "relevance": 0.159487, "type": "Quantity"}], "sentiment": {"document": {"score": -0.393745, "label": "negative"}}, "semantic_roles": [{"subject": {"text": "Gastro-esophageal reflux disease (GERD)", "keywords": [{"text": "Gastro-esophageal reflux disease"}, {"text": "GERD"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing", "keywords": [{"text": "chronic digestive disorder"}, {"text": "complications"}, {"text": "market"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "the esophagus.The market", "keywords": [{"text": "esophagus.The market"}]}, "sentence": " Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively.", "object": {"text": "the drugs and devices required for its optimized cure and accurate diagnosis respectively", "keywords": [{"text": "optimized cure"}, {"text": "accurate diagnosis"}, {"text": "drugs"}, {"text": "devices"}]}, "action": {"verb": {"text": "produce", "tense": "present"}, "text": "producing and distributing", "normalized": "produce and distribute"}}, {"subject": {"text": "The global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The global GERD drug and devices market has been predicted to grow at a CAGR of 1.12% between 2019 and 2027.", "object": {"text": "at a CAGR of 1.12%", "keywords": [{"text": "CAGR"}], "entities": [{"type": "Quantity", "text": "1.12"}]}, "action": {"verb": {"text": "grow", "tense": "future"}, "text": "has been predicted to grow", "normalized": "have be predict to grow"}}, {"subject": {"text": "The causes", "keywords": [{"text": "causes"}]}, "sentence": " The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the GERD drug and devices market", "keywords": [{"text": "GERD drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "drive", "tense": "present"}, "text": "driving", "normalized": "drive"}}, {"subject": {"text": "The causes primarily responsible for driving the GERD drug and devices market", "keywords": [{"text": "GERD drug"}, {"text": "devices market"}, {"text": "causes"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents", "keywords": [{"text": "GERD disorders"}, {"text": "self-medication"}, {"text": "prominence"}, {"text": "trend"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "other drugs for its cure", "keywords": [{"text": "drugs"}, {"text": "cure"}]}, "sentence": " The causes primarily responsible for driving the GERD drug and devices market are the growing trend of self-medication for the increasing occurrence of GERD disorders and the prominence in awareness about GERD.Expiry of patents and the adverse effect of using proton pump inhibitors and other drugs for its cure are the majorly hampering the GERD Drug and devices market.", "object": {"text": "the majorly hampering the GERD Drug and devices market", "keywords": [{"text": "GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "are", "normalized": "be"}}, {"subject": {"text": "The market", "keywords": [{"text": "market"}]}, "sentence": " The market is segmented by dosage form and by administration of the drugs.", "object": {"text": "segmented by dosage form and by administration of the drugs", "keywords": [{"text": "dosage form"}, {"text": "drugs"}, {"text": "administration"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "Latin America"}, {"text": "Asia-Pacific"}], "entities": [{"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "The global GERD Drug and devices market", "keywords": [{"text": "global GERD Drug"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "action": {"verb": {"text": "spread", "tense": "past"}, "text": "is spread", "normalized": "be spread"}}, {"subject": {"text": "the Middle East and Africa.The North American region", "keywords": [{"text": "Africa.The North American"}, {"text": "Middle East"}, {"text": "region"}], "entities": [{"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "proclaimed as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "past"}, "text": "been", "normalized": "be"}}, {"subject": {"text": "The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region", "keywords": [{"text": "global GERD Drug"}, {"text": "Africa.The North American"}, {"text": "devices market"}, {"text": "Middle East"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}, {"type": "Location", "text": "Europe", "disambiguation": {"subtype": ["MusicalGroup", "BroadcastArtist", "FilmMusicContributor", "Lyricist", "MusicalArtist", "RecordProducer", "Continent"], "name": "Europe", "dbpedia_resource": "http://dbpedia.org/resource/Europe"}}, {"type": "Location", "text": "Asia-Pacific", "disambiguation": {"subtype": ["Country"]}}, {"type": "Location", "text": "North America", "disambiguation": {"subtype": ["Continent"], "name": "North America", "dbpedia_resource": "http://dbpedia.org/resource/North_America"}}, {"type": "Location", "text": "Latin America", "disambiguation": {"subtype": ["Continent"]}}, {"type": "Location", "text": "Middle East", "disambiguation": {"subtype": ["Region", "Region"], "name": "Middle East", "dbpedia_resource": "http://dbpedia.org/resource/Middle_East"}}]}, "sentence": " The global GERD Drug and devices market is spread over Europe , Asia-Pacific , North America , Latin America and the Middle East and Africa.The North American region has been proclaimed as the largest market for GERD drug and devices.", "object": {"text": "as the largest market for GERD drug and devices", "keywords": [{"text": "GERD drug"}, {"text": "largest market"}, {"text": "devices"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "proclaim", "tense": "past"}, "text": "has been proclaimed", "normalized": "have be proclaim"}}, {"subject": {"text": "The rise in the incidence of GERD in North American countries", "keywords": [{"text": "North American countries"}, {"text": "GERD"}, {"text": "incidence"}, {"text": "rise"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "responsible for the increase", "keywords": [{"text": "increase"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "acid reducing and neutralizing drugs", "keywords": [{"text": "acid"}, {"text": "drugs"}]}, "sentence": " The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "object": {"text": "the market growth", "keywords": [{"text": "market growth"}]}, "action": {"verb": {"text": "proliferate", "tense": "present"}, "text": "is proliferating", "normalized": "be proliferate"}}, {"subject": {"text": "Product launch", "keywords": [{"text": "Product launch"}]}, "sentence": " Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "primary strategy"}, {"text": "competitive edge"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "by the various market companies of the global GERD drug and devices market", "keywords": [{"text": "global GERD drug"}, {"text": "various market companies"}, {"text": "devices market"}], "entities": [{"type": "HealthCondition", "text": "GERD", "disambiguation": {"subtype": ["DiseaseOrMedicalCondition", "DiseaseCause", "RiskFactor", "Symptom", "Disease"], "name": "Gastroesophageal reflux disease", "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}}]}, "sentence": " Product launch is a primary strategy adopted by the various market companies of the global GERD drug and devices market to gain a competitive edge.", "object": {"text": "a primary strategy", "keywords": [{"text": "primary strategy"}]}, "action": {"verb": {"text": "adopt", "tense": "past"}, "text": "adopted", "normalized": "adopt"}}, {"subject": {"text": "ReportLinker", "keywords": [{"text": "ReportLinker"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "sentence": " ReportLinker is an award-winning market research solution.", "object": {"text": "an award-winning market research solution", "keywords": [{"text": "award-winning market research"}, {"text": "solution"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "action": {"verb": {"text": "be", "tense": "present"}, "text": "is", "normalized": "be"}}, {"subject": {"text": "Reportlinker", "keywords": [{"text": "Reportlinker"}], "entities": [{"type": "Person", "text": "Reportlinker"}]}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "the latest industry data", "keywords": [{"text": "latest industry data"}]}, "action": {"verb": {"text": "organize", "tense": "present"}, "text": "organizes", "normalized": "organize"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research you need", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "get", "tense": "present"}, "text": "get", "normalized": "get"}}, {"subject": {"text": "you"}, "sentence": " Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.", "object": {"text": "all the market research", "keywords": [{"text": "market research"}]}, "action": {"verb": {"text": "need", "tense": "present"}, "text": "need", "normalized": "need"}}], "concepts": [{"text": "Gastroesophageal reflux disease", "relevance": 0.94522, "dbpedia_resource": "http://dbpedia.org/resource/Gastroesophageal_reflux_disease"}, {"text": "North America", "relevance": 0.943721, "dbpedia_resource": "http://dbpedia.org/resource/North_America"}, {"text": "Pharmacology", "relevance": 0.879115, "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"}, {"text": "Pharmaceutical companies of the United States", "relevance": 0.751867, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_companies_of_the_United_States"}, {"text": "Boston Scientific", "relevance": 0.720802, "dbpedia_resource": "http://dbpedia.org/resource/Boston_Scientific"}, {"text": "Abbott Laboratories", "relevance": 0.708147, "dbpedia_resource": "http://dbpedia.org/resource/Abbott_Laboratories"}, {"text": "Drug", "relevance": 0.6817, "dbpedia_resource": "http://dbpedia.org/resource/Drug"}, {"text": "Pharmaceutical drug", "relevance": 0.648856, "dbpedia_resource": "http://dbpedia.org/resource/Pharmaceutical_drug"}, {"text": "Lansoprazole", "relevance": 0.644324, "dbpedia_resource": "http://dbpedia.org/resource/Lansoprazole"}, {"text": "Asthma", "relevance": 0.603056, "dbpedia_resource": "http://dbpedia.org/resource/Asthma"}, {"text": "Ribavirin", "relevance": 0.585175, "dbpedia_resource": "http://dbpedia.org/resource/Ribavirin"}, {"text": "Valeant Pharmaceuticals International", "relevance": 0.573941, "dbpedia_resource": "http://dbpedia.org/resource/Valeant_Pharmaceuticals_International"}, {"text": "Multinational companies", "relevance": 0.573304, "dbpedia_resource": "http://dbpedia.org/resource/Multinational_companies"}, {"text": "Americas", "relevance": 0.566865, "dbpedia_resource": "http://dbpedia.org/resource/Americas"}, {"text": "Guidant", "relevance": 0.563929, "dbpedia_resource": "http://dbpedia.org/resource/Guidant"}, {"text": "Omeprazole", "relevance": 0.557772, "dbpedia_resource": "http://dbpedia.org/resource/Omeprazole"}, {"text": "Cough", "relevance": 0.552295, "dbpedia_resource": "http://dbpedia.org/resource/Cough"}, {"text": "Esomeprazole", "relevance": 0.549256, "dbpedia_resource": "http://dbpedia.org/resource/Esomeprazole"}, {"text": "United States", "relevance": 0.548803, "dbpedia_resource": "http://dbpedia.org/resource/United_States"}, {"text": "Johnson & Johnson", "relevance": 0.527916, "dbpedia_resource": "http://dbpedia.org/resource/Johnson_&_Johnson"}, {"text": "Latin America", "relevance": 0.526761, "dbpedia_resource": "http://dbpedia.org/resource/Latin_America"}], "categories": [{"score": 0.971463, "label": "/health and fitness/disease/gerd and acid reflux"}, {"score": 0.833079, "label": "/health and fitness/drugs"}, {"score": 0.79767, "label": "/business and industrial/pharmaceutical industry"}], "relations": [{"type": "locatedAt", "sentence": "The rise in the incidence of GERD in North American countries is responsible for the increase in demand for acid reducing and neutralizing drugs, which is proliferating the market growth in the North American region.", "score": 0.800802, "arguments": [{"text": "countries", "location": [1251, 1260], "entities": [{"type": "GeopoliticalEntity", "text": "countries", "disambiguation": {"subtype": ["Area"]}}]}, {"text": "North American", "location": [1236, 1250], "entities": [{"type": "GeopoliticalEntity", "text": "North American region"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.382199, "arguments": [{"text": "Abbott Laboratories", "location": [1637, 1656], "entities": [{"type": "Organization", "text": "Abbott Laboratories", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1608, 1617], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOfMany", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.644268, "arguments": [{"text": "AstraZeneca", "location": [1658, 1669], "entities": [{"type": "Organization", "text": "AstraZeneca", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "companies", "location": [1608, 1617], "entities": [{"type": "Organization", "text": "Companies"}]}]}, {"type": "partOf", "sentence": "Some of the pioneering companies in this market are Abbott Laboratories, AstraZeneca, Ausch Health (Formerly Valeant Pharmaceuticals International, Inc.), Boston Scientific Corporation, Cempra Inc. (Merged with Melinta), Daewoong Co. Ltd., Eisai Inc., Glaxosmithkline, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co. Inc., Novartis, Pfizer, Inc., RaQualia Pharma Inc. and Takeda Pharmaceuticals Company Limited.", "score": 0.467352, "arguments": [{"text": "Melinta", "location": [1796, 1803], "entities": [{"type": "Organization", "text": "MELINTA", "disambiguation": {"subtype": ["Commercial"]}}]}, {"text": "Merged", "location": [1784, 1790], "entities": [{"type": "Organization", "text": "CEMPRA INC.", "disambiguation": {"subtype": ["Commercial"]}}]}]}, {"type": "agentOf", "sentence": "Companies mentioned 1.", "score": 0.852976, "arguments": [{"text": "Companies", "location": [2012, 2021], "entities": [{"type": "Organization", "text": "Companies"}]}, {"text": "mentioned", "location": [2022, 2031], "entities": [{"type": "EventCommunication", "text": "mentioned"}]}]}, {"type": "basedIn", "sentence": "BOSTON SCIENTIFIC CORPORATION 5.", "score": 0.883816, "arguments": [{"text": "SCIENTIFIC CORPORATION\n5", "location": [2153, 2177], "entities": [{"type": "Organization", "text": "SCIENTIFIC CORPORATION\n5"}]}, {"text": "BOSTON", "location": [2146, 2152], "entities": [{"type": "GeopoliticalEntity", "text": "BOSTON"}]}]}, {"type": "hasAttribute", "sentence": "IRONWOOD PHARMACEUTICALS, INC. 10.", "score": 0.192369, "arguments": [{"text": "PHARMACEUTICALS, INC.", "location": [2278, 2299], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS, INC."}]}, {"text": "10", "location": [2300, 2302], "entities": [{"type": "Age", "text": "10"}]}]}, {"type": "hasAttribute", "sentence": "RAQUALIA PHARMA INC. 15.", "score": 0.178778, "arguments": [{"text": "INC.", "location": [2394, 2398], "entities": [{"type": "Organization", "text": "PHARMACEUTICALS INTERNATIONAL, INC."}]}, {"text": "15", "location": [2399, 2401], "entities": [{"type": "Age", "text": "15"}]}]}], "keywords": [{"text": "global GERD drug", "sentiment": {"score": -0.846018, "label": "negative"}, "relevance": 0.640748, "count": 2}, {"text": "North America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.638786, "count": 1}, {"text": "devices market", "sentiment": {"score": -0.564902, "mixed": "1", "label": "negative"}, "relevance": 0.630618, "count": 5}, {"text": "Cempra Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.594494, "count": 2}, {"text": "Formerly Valeant Pharmaceuticals International", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.592515, "count": 1}, {"text": "Abbott Laboratories", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.578497, "count": 2}, {"text": "market", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.567298, "count": 3}, {"text": "Daewoong Co. Ltd", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.566617, "count": 2}, {"text": "chronic digestive disorder", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.566493, "count": 1}, {"text": "GERD drug", "sentiment": {"score": -0.617996, "mixed": "1", "label": "negative"}, "relevance": 0.566468, "count": 3}, {"text": "proton pump inhibitors", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.566004, "count": 1}, {"text": "adverse effect", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.565984, "count": 1}, {"text": "MARKET INSIGHTS", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.562301, "count": 1}, {"text": "increasing occurrence of GERD disorders", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.561659, "count": 1}, {"text": "Latin America", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.559097, "count": 1}, {"text": "growing trend of self-medication", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.558588, "count": 1}, {"text": "GERD", "sentiment": {"score": -0.940139, "label": "negative"}, "relevance": 0.557441, "count": 2}, {"text": "largest market", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.555364, "count": 1}, {"text": "Middle East", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.554857, "count": 1}, {"text": "Eisai Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.552466, "count": 1}, {"text": "American region", "sentiment": {"score": 0.467953, "mixed": "1", "label": "positive"}, "relevance": 0.541806, "count": 2}, {"text": "drugs", "sentiment": {"score": -0.721786, "label": "negative"}, "relevance": 0.540669, "count": 3}, {"text": "Boston Scientific Corporation", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.540119, "count": 1}, {"text": "Reportlinker finds", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.536852, "count": 1}, {"text": "RaQualia Pharma Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.529543, "count": 2}, {"text": "devices", "sentiment": {"score": -0.362833, "mixed": "1", "label": "negative"}, "relevance": 0.529413, "count": 2}, {"text": "Ausch Health", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.528077, "count": 1}, {"text": "Ironwood Pharmaceuticals", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.526959, "count": 2}, {"text": "market research", "sentiment": {"score": 0.4462, "label": "positive"}, "relevance": 0.526219, "count": 1}, {"text": "primary strategy", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.523316, "count": 1}, {"text": "Expiry of patents", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.521453, "count": 1}, {"text": "competitive edge", "sentiment": {"score": 0.865177, "label": "positive"}, "relevance": 0.520388, "count": 1}, {"text": "accurate diagnosis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.519036, "count": 1}, {"text": "Co. Inc.", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.518502, "count": 1}, {"text": "Johnson", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.51816, "count": 4}, {"text": "Takeda Pharmaceuticals Company Limited", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.517211, "count": 1}, {"text": "Asia-Pacific", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.513611, "count": 1}, {"text": "American countries", "sentiment": {"score": -0.503707, "label": "negative"}, "relevance": 0.513543, "count": 1}, {"text": "Merck", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.511781, "count": 2}, {"text": "prominence", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.510559, "count": 1}, {"text": "awareness", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.510386, "count": 1}, {"text": "companies", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.510333, "count": 2}, {"text": "AstraZeneca", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509794, "count": 2}, {"text": "Pfizer", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.50966, "count": 2}, {"text": "Novartis", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.509461, "count": 2}, {"text": "complications", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.509387, "count": 1}, {"text": "Europe", "sentiment": {"score": 0.36591, "label": "positive"}, "relevance": 0.509304, "count": 1}, {"text": "Glaxosmithkline", "sentiment": {"score": 0, "label": "neutral"}, "relevance": 0.508634, "count": 2}, {"text": "cure", "sentiment": {"score": -0.881019, "label": "negative"}, "relevance": 0.508602, "count": 2}, {"text": "esophagus", "sentiment": {"score": -0.988618, "label": "negative"}, "relevance": 0.508509, "count": 1}]}, "extracted_metadata": {"sha1": "e39063687a34d41ae9a78b1ac9e9aea4dd1f05d3", "filename": "1543373966863.zip-61a0d0ac9305bc002ce27fb6f53d03fb.xml", "file_type": "json"}, "external_links": ["https://www.reportlinker.com/", "https://www.reportlinker.com/p05626023"], "title": "The global GERD drug and devices market has been predicted to gr", "forum_title": "Health Care"}]}